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PREFACE 
Preface 
The completion of the Supplements to the Fourth Edition of the European Guidelines for quality 
assurance in breast cancer screening and diagnosis is a further milestone towards high quality cancer 
screening and diagnosis.   
Cancers may be cured, or the prospects of cure greatly increased, if they are detected early. Well 
organized, nationwide screening programmes therefore have a huge potential to reduce cancer 
mortality. There have been considerable achievements in cancer screening, as a result of coordinated 
work at EU level to support Member States in the implementation of national cancer screening 
programmes.  
This publication is a good illustration of the role the EU can play to improve the health of its citizens. 
The Supplements to the Fourth Edition of the European Guidelines for quality assurance in breast 
cancer screening and diagnosis take into account recent developments and will improve quality 
assurance before the publication of the next edition. They will help to give women a better chance of 
receiving timely treatment as a result of early diagnosis of breast cancer. 
Cancer has been a priority issue for EU public health policy for more than 25 years and will remain 
high on the European agenda. At this juncture, I would like to thank all partners and contributors 
involved in this project for their valuable contribution to this publication which moves us an important 
step further down the road towards the common goal to improve public health throughout the 
European Union. 
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Acting Director,  
Public Health, DG Health and Consumers, 
European Commission 
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FOREWORD 
Foreword 
The fourth edition of the European guidelines for quality assurance in breast cancer screening and 
diagnosis was published by the European Commission in 2006. The present supplements to the fourth 
edition have been produced by the same groups of experts originally established under the Europe 
Against Cancer programme that have developed and updated the guidelines since the early 1990s. 
Over the years, the scope and the depth of the multidisciplinary guidelines have expanded, and 
recommendations and protocols have been updated to keep pace with developments in the field. 
Many of the experts who contributed to the early editions of the guidelines are no longer active or 
have moved on to other endeavours, and in presenting the current supplements we wish to thank and 
pay tribute to the dedication of all current and previous contributors. 
The present supplements are appearing at a time of transition. The European Parliament has called 
for European Union (EU)-wide accreditation of breast centres to ensure that all women in the EU have 
access to high-quality breast services. The European Commission has allocated funding to develop 
and pilot a voluntary accreditation scheme and to prepare the new, fifth edition of the guidelines that 
will be needed for the accreditation project. The Joint Research Centre of the European Commission 
has been commissioned to coordinate these key efforts. 
The present supplements lay a cornerstone for a new, completely revised fifth edition of the 
guidelines. Their availability should not delay the important efforts at the European level to produce 
the fifth edition. The editors would also like to point out that for the foreseeable future dedicated, 
sustainable support is also required for the pan-European exchange of experience and collaboration in 
training, monitoring and evaluation, and other areas of quality assurance initiated in the European 
Breast Cancer Screening Network established under the former Europe Against Cancer programme. 
Such collaborative efforts will be essential to ensure that in the future breast screening and diagnostic 
services fulfilling the European standards are available to all women in the EU. 
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EXECUTIVE SUMMARY 
For women in Europe, breast cancer is currently the most common cancer and the most common 
cause of cancer-induced death. According to the most recently available estimates from cancer 
registry data, more than 330 000 new cases and nearly 90 000 deaths due to the disease were 
reported in the 27 Member States of the European Union (EU) in 2008 (Ferlay et al., 2010). Nine out 
of 10 of those deaths were in women aged 50 years or older, making breast cancer a leading cause of 
age-related mortality in women. As pointed out in the fourth edition of the European guidelines for 
quality assurance in breast cancer screening and diagnosis, published in 2006 (Perry et al., 2006; see 
also Perry et al., 2008), systematic early detection through screening, effective diagnostic pathways 
and optimal treatment can significantly lower current breast cancer mortality rates and reduce the 
burden of disease in the population. For these benefits to be obtained, high-quality services are 
essential. These may be achieved through the underlying basic principles of training, specialization, 
volume levels, multidisciplinary teamwork, the use of set targets and performance indicators and 
audit. Ethically, these principles should be regarded as applying equally to symptomatic diagnostic 
services and screening. 
Since the fourth edition was published, the importance of continued efforts at the European level to 
implement and improve breast, cervical and colorectal cancer screening programmes in the EU 
Member States has been confirmed by resolutions of the European Parliament (European Parliament, 
2006; European Parliament, 2008a; European Parliament, 2008b) and conclusions of the Council of 
the EU (Council of the European Union, 2008; Council of the European Union, 2010). A new European 
Partnership for Action Against Cancer (www.epaac.eu) has been established by the European 
Commission, and a third set of comprehensive European quality assurance guidelines, which deals 
with colorectal cancer screening, has been developed by experts and published by the European 
Commission (Segnan et al., 2010). These efforts underline the current consensus on the importance 
of continuously updating the comprehensive evidence-based standards and recommendations for best 
practice provided in the European guidelines. 
A full revision of the European guidelines for quality assurance in breast cancer screening and 
diagnosis is now under way, and the new, fifth edition is planned for publication in the coming years. 
In the meantime, these supplements to the current, fourth edition have been developed to address 
those fields that the editors felt warranted an update of the standards, protocols and best practice 
recommendations. At a meeting of the editorial board in November 2009 in London, it was agreed 
that the supplements would be prepared by the same groups of experts engaged in the development 
of the fourth edition and according to the same methodology. The authors and editors welcome 
comments and feedback on these documents. 
Digital mammography update 
The first supplement (Digital mammography update) responds to the rapid technological development 
that has accompanied a wide increase in the use of digital imaging in mammography screening and 
diagnosis since the fourth edition was published. It has been prepared largely by the experts in the 
European Reference Organisation for Quality Assured Breast Screening and Diagnostic Services 
(EUREF) Physico-Technical Steering Group, who have been recruited from European medical physics 
quality assurance teams experienced in guideline development and in implementation of population-
based mammography screening programmes. Part 1 of the first supplement (Acceptance and 
constancy testing; van Engen et al., 2013a) updates the digital mammography part of the European 
protocol for the quality control of the physical and technical aspects of mammography screening (van 
Engen et al., 2006) in the fourth edition (Perry et al., 2006). The authors indicate the changes 
compared with the version of the digital mammography protocol in the fourth edition, and in some 
sections further guidance and clarification is provided. It is therefore essential to consult the original 
text and the supplement together. 
Only a few aspects of the updates to the digital mammography protocol can be highlighted here. Of 
prime importance are the changes to the system requirements that any mammography equipment 
must fulfil. They include, in addition to other elements, a fully automatic exposure control (AEC). A 
(XURSHDQJXLGHOLQHVIRUqualityassuranceLQEUHDVWFDQFHUVFUHHQLQJDQGGLDJQRVLVFourtheditionSupplements XV 
EXECUTIVE SUMMARY 
system with solely manual exposure control (in which the user has to define anode material, filter, 
tube voltage and dose) is not acceptable; neither is a system with semi-automated exposure control 
(that adapts dose according to breast transparency, but still requires the user to define anode 
material, filter and tube voltage). For quality control purposes it should be possible to output 
unprocessed images in DICOM format from the acquisition workstation or computed radiography (CR) 
reader. 
Part 2 of the first supplement (European type testing; van Engen et al., 2013b) adds a new dimension 
to the quality assurance philosophy anchored in the fourth edition, namely type testing of digital 
imaging systems. The need for a European type testing protocol based on the most recent version of 
the European guidelines became apparent during the preparation of the digital mammography update 
dealing with acceptance and constancy testing. Equipment users and manufacturers pointed out that 
an additional European protocol would facilitate avoidance of potential quality problems before 
equipment is delivered to users. The editorial board of the fourth edition of the guidelines therefore 
requested that the experts in the EUREF Physico-Technical Steering Group also develop a procedure 
and protocol suitable for standardizing type testing for mammography systems at the European level. 
The standards and procedures presented in Part 2 of the first supplement take into account the 
updates to the digital mammography physico-technical protocol that are reported in Part 1. The 
European type testing protocol currently aims to verify whether imaging systems of a given type or 
brand are fundamentally capable of fulfilling the acceptance criteria of the European physico-technical 
protocol. Furthermore, guidelines are provided on best practice in controlling dose and (clinical) image 
quality. After a successful type test, individual mammography units of the same type or brand still 
need to undergo an acceptance test before clinical use. Passing the type test merely guarantees that 
the system is in principle capable of meeting the requirements of the European physico-technical 
protocol; the type test report may also provide suggestions for optimal use, or may specify conditions 
to be avoided in practice. 
The chapter on the physico-technical aspects of quality control in the fourth edition was originally 
developed for acceptance and constancy testing and not for type testing. Therefore, some differences 
exist between Part 1 and Part 2 of the first supplement; these differences are reported in Part 2 of the 
supplement. The new European protocol for type testing (Part 2) has been developed for digital 
mammography (direct radiography and computed radiography) systems. In the future, the protocol 
may be expanded to include type testing of image-processing algorithms, workstations and film 
digitizers. 
The preparation of the new and revised standards, protocols and recommendations in the first 
supplement was coordinated by the EUREF office based at the National Expert and Training Centre for 
Breast Cancer Screening in Nijmegen, The Netherlands. It involved extensive planning, empirical 
measurements and numerous scientific studies in the work package on digital mammography in the 
project ‘European Cooperation on Development and Implementation of Cancer Screening and 
Prevention Guidelines (ECCG)’, in which key quality assurance centres in Belgium, France, Germany, 
Italy, The Netherlands and the United Kingdom collaborated. Experience in the practical application of 
the new and further developed standards was gathered in site visits and training courses attended by 
medical physicists and technicians from several EU Member States, including those that acceded to 
the EU in 2004 and 2007. This experience fed into the final formulation of the digital mammography 
supplements. The highly effective professional and scientific cooperation in the project was facilitated 
by the collaborative platform provided by participation of most of the authors in the EUREF Physico-
Technical Steering Group. 
Pathology update 
The second supplement (Pathology update; Wells et al., 2013) deals with several topics in the quality 
assurance of pathology in breast cancer screening and diagnosis in which problems and practical 
solutions as well as new techniques and other advances have emerged in recent years. The authors 
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felt that these topics warranted urgent attention pending a full revision of the pathology chapter. They 
include the classification of early forms of neoplastic changes in the breast and the differential 
diagnosis of columnar cell lesions (CCLs), atypical ductal hyperplasia (ADH) and ductal carcinoma in 
situ (DCIS). Other sections provide an update on the classification of invasive carcinoma and on the 
diagnosis and differential diagnosis of microinvasive carcinoma. Special attention is paid to the 
assessment of the axilla, and the updated guidance on axillary dissection and preoperative staging 
takes into account problems and pitfalls as well as the most recent revision of the TNM system (Sobin 
et al., 2009). The supplement also includes comprehensive practical recommendations on examination 
techniques and interpretation of sentinel node biopsy specimens. Best practice in the use of frozen 
sections, an update on vacuum-assisted needle core biopsy (VANCB) and recommendations on 
pathological reporting of post-chemotherapy specimens are also provided. 
The supplement with updates on pathology has been prepared by the European Working Group on 
Breast Screening Pathology, which also prepared the chapter on pathology in the fourth edition (Wells 
et al., 2006) and in previous editions of the guidelines. The group consists of 38 breast pathologists in 
23 EU Member States, Switzerland and Turkey and has been led by the editor of the chapter on 
pathology in the guidelines. All of the pathologists in the group are leaders in the field of breast 
pathology in their countries. The recommendations in the supplement have been drafted by selected 
members of the group and have been discussed and agreed upon at twice-yearly meetings held in 
Hungary, Switzerland, Italy, France, The Netherlands and Finland since the fourth edition was 
published. 
Implementation of population-based cancer screening programmes 
In Annex 1, the supplements volume also includes recommendations on implementation of 
population-based cancer screening programmes that are relevant not only to breast cancer screening 
but also to cervical and colorectal cancer screening. The Annex consists of a brief statement (von 
Karsa et al., 2013) and a longer article (Lynge et al., 2012) summarizing the results of a pan-
European workshop organized by the European Science Advisory Network for Health (EuSANH, 
www.EuSANH.eu) in Stockholm in February 2011. At the meeting, a multidisciplinary group of 
scientists and professionals experienced in implementation and quality assurance of cancer screening 
programmes and in development of scientific advice on health policy reviewed the available evidence. 
The conclusions and comprehensive recommendations that emerged identify the major determinants 
of successful implementation of population-based cancer screening programmes. 
The authors emphasize that any policy decision in Europe to implement a cancer screening 
programme should take into account EU recommendations and guidelines based on the available 
evidence and the experience in Europe in implementing population-based cancer screening 
programmes. Key references in this regard are the Recommendation on Cancer Screening of 2 
December 2003 of the Council of the EU (Council of the European Union, 2003), the European 
guidelines for quality assurance in breast, cervical and colorectal cancer screening (Perry et al., 2006; 
Arbyn et al., 2008; Segnan et al., 2010; see also Perry et al., 2008 and Arbyn et al., 2010) and recent 
reports dealing with the implementation of cancer screening programmes in the EU (von Karsa et al., 
2008; Commission of the European Communities, 2008; Anttila et al., 2009). 
The experience in Europe shows that quality-assured implementation of population-based cancer 
screening programmes generally involves a very long process, extending over 10 or more years and 
beginning with planning followed by feasibility testing, piloting and gradual rollout of the programme 
across a country. Successful completion of the quality-assured process requires engagement of civil 
society, including societal debate; effective cancer registration; good governance providing long-term 
political commitment; adequate and sustainable resources and competent oversight; autonomous 
programme management with coordination of numerous stakeholders and activities; organizational 
development and control of resources (dedicated budget and staff); as well as international 
collaboration in quality assurance. In a fully established programme, the proportion of the expenditure 
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devoted to quality assurance should be no less than 10–20%, depending on the scale of the 
programme. This investment is cost-effective and will save lives. 
Computerized information systems and accessible registries are necessary for the management of 
effective and efficient screening services (e.g. for call and re-call systems and fail-safe procedures in 
follow-up of participants with abnormal test results). They are also needed to monitor and evaluate 
the performance and the outcome of the screening programme, e.g. through linkage of individual data 
on cancer occurrence and morbidity, screening history, diagnosis and treatment. 
Once the political decision has been taken to establish a population-based cancer screening 
programme, a competent programme coordinator should receive the mandate to manage and thereby 
adequately assure quality throughout the process of programme implementation. This is necessary to 
fulfil the European principles and guidelines and relevant national standards and regulations. The 
coordinator should be provided with sufficient organizational and financial resources to effectively 
manage the screening programme and take further decisions as necessary. 
The same conclusions apply to efforts at the European level to support the EU Member States in 
implementing the Council Recommendation on cancer screening. Their success in making evidence-
based screening programmes recommended by the EU available to all citizens who may benefit will 
depend on the availability of comprehensive, evidence-based guidelines that are updated 
continuously. Successful implementation of the guidelines across the EU will likewise require 
engagement of civil society and the availability of an autonomous coordination under competent 
oversight, with adequate, sustainable resources and long-term political support. 
 
References 
Anttila A, Ronco G, Working Group on the Registration and Monitoring of Cervical Cancer Screening 
Programmes in the European Union; within the European Network for Information on Cancer 
(EUNICE) (2009). Description of the national situation of cervical cancer screening in the member 
states of the European Union. Eur. J. Cancer, 45:2685–2708.  
http://www.ejcancer.info/article/S0959-8049(09)00576-0/abstract 
Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener H, Herbert A, von Karsa L 
(2010). European guidelines for quality assurance in cervical cancer screening, second edition – 
summary document. Ann. Oncol., 21:448–458. 
Arbyn M, Anttila A, Jordan J, Schenck U, Ronco G, Segnan N, Wiener H, Herbert A, Daniel J, von Karsa 
L (eds.) (2008). European guidelines for quality assurance in cervical cancer screening. Second 
edition. European Commission, Office for Official Publications of the European Communities, 
Luxembourg.  
http://bookshop.europa.eu/is-bin/INTERSHOP.enfinity/WFS/EU-Bookshop-Site/en_GB/-
/EUR/ViewPublication-Start?PublicationKey=ND7007117 
Commission of the European Communities (2008). Report from the Commission to the Council, the 
European Parliament, the European Economic and Social committee and the Committee of the 
Regions – Implementation of the Council Recommendation of 2 December 2003 on cancer screening 
(2003/878/EC) Brussels, Report no. COM(2008) 882 final.  
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2008:0882:FIN:EN:PDF 
Council of the European Union (2003). Council Recommendation of 2 December 2003 on cancer 
screening (2003/878/EC). Off. J. Eur. Union L 327:34–38.  
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:327:0034:0038:EN:PDF 
Council of the European Union (2008). Council Conclusions on reducing the burden of cancer. 2876th 
Employment, Social Policy, Health and Consumer Affairs Council meeting. Luxembourg, 10 June 2008. 
(XURSHDQJXLGHOLQHVIRUqualityassuranceLQEUHDVWFDQFHUVFUHHQLQJDQGGLDJQRVLVFourtheditionSupplementsXVIII 
EXECUTIVE SUMMARY 
Brussels, Belgium, Press Office of the Council of the European Union. 10414/08 (Presse 166), 
http://www.consilium.europa.eu/ueDocs/cms_Data/docs/pressData/en/lsa/101031.pdf 
Council of the European Union (2010). Council Conclusions on Action Against Cancer, 3032nd Council 
meeting. General affairs. Press release 236, 13420/1/10 REV 1, Brussels, Belgium, 13 September 
2010, Press Office of the Council of the European Union.  
http://www.consilium.europa.eu/press/press-releases/latest-press-
releases/newsroomrelated?lang=en&bid=72&grp=17287&id=1851 
European Parliament (2006). European Parliament Resolution on Breast Cancer in the Enlarged 
European Union. P6_TA(2006)0449. 
European Parliament (2008a). European Parliament resolution of 10 April on combating cancer in the 
enlarged European Union. P6_TA-PROV(2008)0121. 
European Parliament (2008b). European Parliament resolution of 9 October 2008 on ‘Together for 
Health: A Strategic Approach for the EU 2008-2013’. P6_TA(2008)0477. 
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010). GLOBOCAN 2008, Cancer 
Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet] International Agency for 
Research on Cancer, Lyon, France. http://globocan.iarc.fr/ 
Lynge E, Törnberg S, von Karsa L, Segnan N, van Delden JJM (2012). Determinants of successful 
implementation of population-based cancer screening programmes. Eur. J. Cancer, 48:743–748. 
Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L (2008). European guidelines for 
quality assurance in breast cancer screening and diagnosis, Fourth edition – Summary document. Ann 
Oncol., 19:614–622. 
Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L, Puthaar E (eds.) (2006). 
European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition. 
European Commission, Office for Official Publications of the European Communities, Luxembourg. 
Segnan N, Patnick J, von Karsa L (eds.) (2010). European guidelines for quality assurance in colorectal 
cancer screening and diagnosis. First edition. European Commission, Office for Official Publications of 
the European Union, Luxembourg. 
Sobin LH, Gospodarowicz MK, Wittekind C (eds.) (2009). TNM Classification of Malignant Tumours, 7th 
edition. Wiley-Blackwell. 
van Engen RE, Bosmans H, Dance DR, Heid P, Lazzari B, Marshall N, Schopphoven S, Thijssen M, 
Young KC (2013a). Digital mammography update. European protocol for the quality control of the 
physical and technical aspects of mammography screening. S1, Part 1: Acceptance and constancy 
testing. In: European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth 
edition, Supplements. Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L (eds.). 
European Commission, Office for Official Publications of the European Union, Luxembourg, pp. 1–54. 
van Engen RE, Bosmans H, Heid P, Lazzari B, Schopphoven S, Thijssen M, Young KC (2013b). Digital 
mammography update. European protocol for the quality control of the physical and technical aspects 
of mammography screening. S1, Part 2: European type testing. In: European guidelines for quality 
assurance in breast cancer screening and diagnosis. Fourth edition, Supplements. Perry N, Broeders 
M, de Wolf C, Törnberg S, Holland R, von Karsa L (eds.). European Commission, Office for Official 
Publications of the European Union, Luxembourg, pp. 55–71. 
van Engen RE, Young KC, Bosmans H, Thijssen M (2006). European protocol for the quality control of 
the physical and technical aspects of mammography screening. Chapter 2b: Digital mammography. 
In: European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition. 
Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L (eds.). European Commission, 
Office for Official Publications of the European Communities, Luxembourg, pp. 105–165. 
von Karsa L, Anttila A, Primic Žakelj M, de Wolf C, Bielska-Lasota M, Törnberg S, Segnan N (2013). 
Stockholm statement on successful implementation of population-based cancer screening 
(XURSHDQJXLGHOLQHVIRUqualityassuranceLQEUHDVWFDQFHUVFUHHQLQJDQGGLDJQRVLVFourtheditionSupplements XIX 
EXECUTIVE SUMMARY 
programmes. Annex 1a. In: European guidelines for quality assurance in breast cancer screening and 
diagnosis. Fourth edition, Supplements. Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von 
Karsa L (eds.). European Commission, Office for Official Publications of the European Union, 
Luxembourg, pp. 123–128. 
von Karsa L, Anttila A, Ronco G, Ponti A, Malila N, Arbyn M, Segnan N, Castillo-Beltran M, Boniol M, 
Ferlay J, Hery C, Sauvaget C, Voti L, Autier P (2008). Cancer screening in the European Union, Report 
on the implementation of the Council Recommendation on cancer screening – First Report. European 
Commission, Office for Official Publications of the European Communities, Luxembourg.  
http://ec.europa.eu/health/ph_determinants/genetics/documents/cancer_screening.pdf 
Wells CA, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, Boecker W, Borisch B, Bussolati G, 
Connolly CE, Cserni G, Decker T, Dervan P, Drijkoningen M, Ellis IO, Elston CW, Eusebi V, Faverly DR, 
Heikkilä P, Holland R, Kerner H, Kulka J, Jacquemier J, Lacerda M, Martinez-Penuela J, de Miguel C,  
Nordgren H, Peterse JL, Rank F, Regitnig P, Reiner A, Sapino A, Sigal-Zafrani B, Tanous AM, 
Thorstenson S, Zozaya E (2006). Chapter 6: Quality assurance guidelines for pathology. In: European 
guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition. Perry N, 
Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L (eds.). European Commission, Office for 
Official Publications of the European Union, Luxembourg, pp. 219–311. 
Wells CA, Amendoeira I, Bellocq JP, Bianchi S, Boecker W, Borisch B, Bruun Rasmussen B, Callagy GM, 
Chmielik E, Cordoba A, Cserni G, Decker T, DeGaetano J, Drijkoningen M, Ellis IO, Faverly DR, 
)RVFKLQL03)UNRYLü-Grazio S, Grabau D, Heikkilä P, Iacovou E, Jacquemier J, Kaya H, Kulka J, 
Lacerda M, Liepniece-Karele I, Martinez-Penuela J, Quinn CM, Rank Fg, Regitnig P, Reiner A, Sapino A, 
Tot T, Van Diest PJ, Varga Z, Wesseling J, Zolota V, Zozaya-Alvarez E (2013). S2: Pathology update. 
Quality assurance guidelines for pathology. In: European guidelines for quality assurance in breast 
cancer screening and diagnosis. Fourth edition, Supplements. Perry N, Broeders M, de Wolf C, 
Törnberg S, Holland R, von Karsa L (eds.). European Commission, Office for Official Publications of the 
European Union, Luxembourg, pp. 73–120. 
 
(XURSHDQJXLGHOLQHVIRUqualityassuranceLQEUHDVWFDQFHUVFUHHQLQJDQGGLDJQRVLVFourtheditionSupplementsXX 
European guidel ines for 
quality assurance in 
breast cancer screening 
and diagnosis 
Fourth Edition 
Supplement 
 
 
 
 
 
 
 
 
 
Part  1  
 
Acceptance and constancy testing 
 
 
Part  2  
 
European type testing 
 
 
 
 
 
 
 
 
(XURSHDQJXLGHOLQHVIRUqualityassuranceLQEUHDVWFDQFHUVFUHHQLQJDQGGLDJQRVLVFourtheditionSupplements2 
SUPPLEMENT 1 – DIGITAL MAMMOGRAPHY UPDATE 
 
Introduction 
The aim of the European Reference Organisation for Quality Assured Breast Screening and Diagnostic 
Services (EUREF) is to improve the quality of mammography in Europe and to disseminate knowledge 
on high-quality breast imaging. Within this context, EUREF has produced the European guidelines for 
quality assurance in breast cancer screening and diagnosis (Perry et al., 2001; de Wolf & Perry, 1996). 
The current version of these guidelines is the fourth edition, published by the European Commission in 
2006 (Perry et al., 2006). It includes in Chapter 2 the European protocol for the quality control of the 
physical and technical aspects of mammography screening, an internationally recognized standard 
that is widely used in Europe and worldwide (van Engen et al., 2006a; van Engen et al., 2006b). In 
Part 2b of this protocol, the requirements for digital mammography imaging systems are defined and 
standards and protocols relevant to acceptance and constancy testing of equipment are described 
(van Engen et al., 2006b). Due to the rapid developments in imaging technology in recent years and 
further experience with digital mammography systems, some updating and extension of the scope of 
the protocol is warranted and is supplied here in the form of a supplement (S1: Digital mammography 
update). 
Part 1 of the supplement (Acceptance and constancy testing; van Engen et al., 2013a) deals with 
relevant aspects of acceptance and constancy testing of digital mammography equipment that are 
addressed in Chapter 2b in the fourth edition. During the preparation of these aspects, equipment 
users and manufacturers expressed the need for type testing of digital imaging equipment based on 
the fourth edition. The availability of an additional protocol for type testing enables manufacturers to 
avoid potential quality problems before equipment is delivered to the user. The editorial board of the 
fourth edition therefore requested that the experts in the EUREF Physico-Technical Steering Group 
also develop a procedure and protocol suitable for standardizing type testing for mammography 
systems at the European level. The developed standards are presented in Part 2 of the supplement 
(European type testing; van Engen et al., 2013b); they take into account the updates presented in 
Part 1 of the supplement. 
The type testing described in Part 2 of this supplement aims to verify whether imaging systems of a 
given type or brand are fundamentally capable of fulfilling the acceptance criteria of the European 
physico-technical protocol, and to provide guidelines for best practice in controlling dose and (clinical) 
image quality. After a successful type test, individual mammography units of the same type or brand 
still need to undergo an acceptance test before clinical use. Passing the type test merely guarantees 
that the system is in principle capable of meeting the requirements of the European physico-technical 
protocol; the type test report may also provide suggestions for optimal use or specify conditions to be 
avoided in practice. 
The European protocol for type testing is currently developed for digital mammography (direct 
radiography [DR] and computed radiography [CR]) systems. In the future, the protocol may be 
expanded to include type testing of image processing algorithms, workstations and film digitizers. 
This supplement has been prepared by the experts in the EUREF Physico-Technical Steering Group 
who have been recruited from European medical physics quality assurance teams experienced in 
guideline development and in implementation of population-based mammography screening 
programmes. The authors welcome all comments and feedback on this document to improve the 
standards and protocols. Future updates of the current version will be made available on the web sites 
of the European Commission (http://ec.europa.eu/health/index_en.htm) and EUREF (www.euref.org). 
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2b.1 Introduction 
The European guidelines for quality assurance in breast cancer screening and diagnosis (Perry et al., 
2006) include as Chapter 2 the European protocol for the quality control of the physical and technical 
aspects of mammography screening. In Part 2b of this protocol, the requirements for digital mam-
mography imaging systems are defined (van Engen et al., 2006b). Due to the rapid developments in 
imaging technology in recent years and further experience with digital mammography systems, some 
updating of the protocol is required and is supplied here in the form of a supplement. 
The authors welcome all comments and feedback on this document to improve the protocol. Updates 
of the current version will be made available on the EUREF web site (www.euref.org). 
In this supplement, only the changes compared with the original version of the quality control protocol 
in the fourth edition are indicated. Items that are not mentioned in this supplement remain 
unchanged. In some sections, further guidance and clarification is provided. 
2b.1.2 System requirements 
A mammography unit should incorporate a fully automatic exposure control (AEC). A 
system with solely manual exposure control (in which the user has to define anode 
material, filter, tube voltage and dose) is not acceptable. Neither is a system with semi-
automated exposure control (in which the user has to define anode material, filter and 
tube voltage but adapts dose according to breast transparency). 
It should be possible to output unprocessed images in DICOM format from the acquisition 
workstation or CR reader for quality control purposes. 
In addition to the parts of the DICOM standard mentioned in the fourth edition, mammography 
equipment should fulfil the recommendations of the IHE Mammography Image profile (MAMMO) and 
the IHE Mammography Acquisition Workflow profile (MAWF). The equipment must be CE marked and 
must be sold as ‘usable for mammography purposes’. DICOM communication between X-ray unit and 
CR reader (complete transfer of exposure parameters) is recommended. 
The acceptable level is the minimum acceptable level; however, it is recommended that systems 
operate as far as possible at a standard equal to or better than the achievable level. Slow screen-film 
systems are capable of operating close to the achievable image quality level. Faster screen-film 
systems are capable of operating near the acceptable level. For the next edition of the guidelines, the 
acceptable and achievable levels will be reviewed. 
Section 2b.2.4.2, Modulation transfer function (MTF) and noise power spectrum (NPS), of the fourth 
edition has been moved to Appendix 7. This indicates that it is not recommended to perform these 
measurements on a routine basis for quality control (QC) purposes. In practice, however, linear 
system theory metrics are being used in system acceptance testing or in regular QC procedures. 
Appendix 7 represents an effort to harmonize the methods of determining linear system theory 
metrics in these cases. 
Printer 
This section applies when printed films are used for reading by either the first or the second reader (in 
current and subsequent screening rounds). 
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To obtain an optimal quality for reading hard-copy films on viewing boxes, requirements for printing 
mammographic images are: 
x The hard-copy film type must be suitable for mammography. 
x Printing two (or more) images on the same film is not recommended. 
x To be able to print images with sufficient resolution, the pixel pitch of the printer should be similar 
WRRUVPDOOHUWKDQWKHSL[HOSLWFKRIWKHLPDJHDQGPXVWDOZD\VEH 100 μm. 
x All images must be printed directly without any manipulation by the user (contrast, luminosity, 
etc.) at the (diagnosis) workstation. 
x Clinical information must be printed on each film: the name of the patient, laterality, date of 
exams, etc. 
After each film refill in the hard-copy printer, the printer must be calibrated (if this is not done 
automatically). After a period of inactivity of more than one day, a calibration must be done before 
printing any diagnostic film. 
Different film formats are available on the market. For mammography, only 2 sizes should be used: 
x 200 mm × 250 mm (8 × 10 inches) 
x 250 mm × 300 mm (10 × 12 inches). 
Other formats are not recommended (i.e. 260 mm × 360 mm). 
2b.1.5 Definition of terms 
AEC sensor area (DR systems) 
The area of a DR detector in which the exposure factors for an image are determined during or after a 
pre-exposure. For some AEC systems, the size and location of the AEC sensor area depends on the 
tissue (or test object) being imaged. 
Dark noise image 
An image acquired without exposure to the detector; cover the detector with a sufficiently thick metal 
plate, e.g. lead or stainless steel, and set the lowest possible tube loading. 
Detector surface 
The accessible area that is closest to the image receptor plane. Depending on removability, the 
detector may include e.g. breast support, covers, antiscatter grid. 
Linearized pixel value 
For images of systems with a non-linear response, the pixel values must be linearized before analysis 
using the response function of the system or the mathematical relationship provided by the 
manufacturer. Offset correction and linearization must be performed for noise evaluation and 
determination of linear system theory metrics. In principle, for some other tests (like the calculation of 
SDNR) the images need to be linearized. However, for those tests the images are acquired at almost 
the same dose so that the system can be supposed to be locally linear. 
Modulation transfer function (MTF) 
The MTF describes the response of a system to a sinusoidal input signal; see Appendix 7. 
Noise power spectrum (NPS) 
The NPS describes the variance of an image intensity divided among its frequency components; see 
Appendix 7. 
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Reference region of interest (ROI) 
The size of the reference ROI is 5 mm × 5 mm, instead of 20 mm × 20 mm as originally stated in the 
fourth edition. The centre of the reference ROI is positioned 60 mm from the chest wall edge and 
centred laterally. 
Standard image 
Image made by an exposure of a 45 mm thick polymethyl methacrylate (PMMA) block plus 8 mm 
spacers covering the whole image receptor. A standard compression of 100 N should be applied, and 
the exposure should be made in the standard clinical AEC mode. 
2b.2 Image acquisition 
2b.2.1.1.1 Focal spot size 
This measurement is omitted. Potential image quality problems are identified by image quality 
measurements. 
2b.2.1.1.2 Source-to-image distance 
This measurement is omitted. 
2b.2.1.1.3 Alignment of X-ray field/image area 
This measurement is optional. 
2b.2.1.1.4 Radiation leakage 
This measurement is omitted. 
2b.2.1.1.5  Tube output 
Tube output is measured only for calculating mean glandular doses and does not have to meet any 
limiting values. It must be known for all clinically used beam qualities. The number of different beam 
qualities can be substantial. The parametric approach as published by Robson (2001) allows the tube 
output to be estimated for any tube voltage in the range 25 kVp–32 kVp from a single measurement 
at 28 kVp that uses the same target/filter combination. 
This is a 2-step procedure. First, the value of A is calculated from equation (1), in which Output is the 
measured air kerma (mGy) at 28 kVp, (kV) is the measured tube voltage and the parameter n is 
target/filter beam-specific and can be obtained from Table 1.1: 
        (1) 
 
Second, the tube output at another tube voltage (kV) is obtained from the following equation: 
 
          (2) 


Output=A(kV)n 
log10(air kerma) = nlog10(kV) + log10(A) 
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Table 1.1:  Calculated values of the parameters n, a and b for a range of target/filter  
   combinations (Robson, 2001) 
 
Target/filter 
combination 
Measured 
filter 
thickness 
n a b 
Mo/30 μm Mo 36.1 μm 3.06 –0.000326 0.0273 
Mo/25 μm Rh 29.9 μm 3.24 –0.000624 0.0445 
Rh/25 μm Rh 29.9 μm 3.03 –0.000514 0.0425 
W/50 μm Rh 58.9 μm 1.96 –0.000539 0.0403 
Rh/1.0 mm Al 1.20 mm 4.39 –0.00113   0.0909 
Mo/1.0 mm Al 1.20 mm 4.23 –0.000775 0.0593 
 
2b.2.1.2.2 Half value layer 
Half value layer (HVL) is measured to calculate glandular dose. HVL does not have to meet any 
requirements. Typical values are given in Table A5.3 in the fourth edition. 
For patient dosimetry applications, HVLs of all clinically used beam qualities are required. The number 
of different beam qualities can be substantial. The parametric approach as published by Robson 
(2001) allows the HVL to be estimated for any tube voltage in the range 25 kVp–32 kVp from a single 
measurement at 28 kVp that uses the same target/filter combination. 
As with the tube output, this is a 2-step procedure based on parameters from Table 1.1. First, the 
value of c is calculated from the equation 
           (3) 
 
in which HVL is the measured HVL at 28 kVp, (kVp) is the measured tube voltage and the parameters 
a and b are target/filter beam-specific and can be obtained from Table 1.1. 
HVLs at other tube voltages can then be calculated from the same equation using a, b and c. 
2b.2.1.3.1 Exposure control steps 
If exposure control steps are available on a mammography system, then the control step should have 
known dose increments, e.g. 20% per step, and should be verified. 
2b.2.1.3.3 Short-term reproducibility 
The short-term reproducibility of the AEC system is calculated by the deviation of the linearized pixel 
value of 10 exposures in fully automatic mode of the standard test block. 
If it is noticed that the system switches between two spectra, release the compression paddle and 
compress again or use another PMMA thickness (add, e.g., 5 mm PMMA) to force the choice of one 
single spectrum, and repeat the measurement. 
Limiting value Deviations fURPWKHPHDQYDOXHRIH[SRVXUHV DFKLHYDEOH ±2%. 
Frequency Every 6 months. 
Equipment Standard test block. 
 
 
HVL=a(kVp)2+ b(kVp) + c
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2b.2.1.3.5 Breast thickness and composition compensation 
Spacers are used to adjust the height of the compression paddle equal to the height of the 
compression paddle of the breast thickness with equivalent attenuation as given in Table 1.2. Dance 
and colleagues have verified that this table is accurate to within 1 mm or 2 mm across the wide range 
of spectra encountered in digital mammography (Dance et al., 2009). 
The spacers should not cover the part of the detector in which exposure factors are determined (AEC 
sensor area). 
Table 1.2:  PMMA thickness and equivalent breast thickness in terms of attenuation and 
glandularity, accurate over a wide range of X-ray spectra (Dance et al., 2009) 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
Images should be acquired in fully automatic mode; however, on some systems it may be convenient 
to mimic the exposure of the fully automatic mode in manual mode. In this case, it should be realized 
that the pre-exposure image is not used for the actual image on some types of system. This should be 
taken into account when determining signal-difference-to-noise ratio (SDNR) in manual mode. It 
should also be known whether the pre-exposure is included in the displayed mAs value in fully 
automatic mode. 
The following method can be used to determine whether the tube load (mAs) of the exposure is 
included in the tube load indication (mAs) of the fully automatic exposure mode. Determine the 
relationship between tube load and pixel value (PV) in a reference ROI for a series of manual 
exposures over the clinical working range. Make an exposure in fully automatic mode. Record beam 
quality and mAs value. Verify whether the PV in the reference ROI of this image is compatible with the 
PV of a manual exposure with the same tube load (mAs). 
The dimensions of the aluminium object are 10 mm × 10 mm and 0.2 mm thick. The object is 
positioned as shown in Figures 1.1 and 1.2. The aluminium object is positioned between the two 
lowest 10 mm thick plates of PMMA. 
The ROI within the aluminium object is 5 mm × 5 mm in the middle of the object. The background 
ROIs are 4 ROIs of 5 mm × 5 mm, on all 4 sides of the aluminium object; see Figure 1.3. 
 
 
 
PMMA 
thickness 
(mm) 
Equivalent 
breast 
thickness 
(mm) 
Glandularity 
of equivalent 
breast 
(%) 
20 21 97 
30 32 67 
40 45 41 
45 53 29 
50 60 20 
60 75 9 
70 90 4 
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Figure 1.1: Set-up for the breast thickness and composition measurements, top view  
 and 3D view 


 
Figure 1.2: Set-up for the breast thickness and composition measurements, front view
 and side view 
 
 
 
Figure 1.3: Position of the ROIs for calculating SDNR 
 
 
 
 
 
 
 
 
 
 
 
 
10 mm 
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Calculate PV(background) and the standard deviation SD(background) according to: 
      
 (4) 
 
 
      (5) 
 
 
Calculate SDNR of the aluminium object: 
 
 
 
          (6) 
 
 
To apply the standards in the European protocol, the limiting values for SDNR have to be determined. 
Two methods are described here. The first is a simplified method using threshold gold thickness, and 
the second involves calculating the threshold contrast for the beam quality used. It is assumed in both 
methods that the exposure factors for the CDMAM phantom and the 50 mm of PMMA are the same. If 
for some reason they are not, then a small correction can be applied. 
Simplified method using threshold gold thickness 
The limiting values for SDNR are calculated using equations (7) and (8). These equations determine 
the SDNR values necessary to achieve the minimum and achievable threshold gold thickness in the 
image quality measurements for the 0.1 mm detail size at this thickness, i.e. 50 mm PMMA or 
equivalent. 
 
 SDNRminimum=
minimum
measured
measured Tg
TgSDNR u   (7) 
 
 SDNRachievable=
achievable
measured
measured Tg
TgSDNR u   (8) 

 
 
where Tgmeasured is the threshold gold thickness for the 0.1 mm detail size predicted for a human 
observer, and Tgminimum and Tgachievable are the limiting values for threshold gold thickness for the 
0.1 mm detail size in the European protocol. 
It is estimated that the maximum error in estimating the target SDNR by this method as compared 
with calculations based on threshold contrasts (see next paragraph) is 4%. Thus, for routine QC this 
simplified method may be acceptable. 
Method using threshold contrast 
A more accurate method of defining the limiting values for SDNR involves estimating the contrast of 
the gold discs for the beam quality used. Such a transformation from gold thickness to contrast is 
necessary because of the non-linear relationship between these two properties. A simple tool for cal-
SDNR
PV(signal) – PV(background) 
SD(signal)2 + SD(background)2  
2  
4
)SD(ROI
 und)SD(backgro
4
1 n¦ 
4
)PV(ROI
 und)PV(backgro
4
1 n¦ 
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culating the limiting values is provided on the EUREF web site, and the method used is described 
here. 
Limiting values for SDNR are calculated using equations (9) and (10). These equations determine the 
SDNR values necessary to achieve the minimum and achievable threshold gold thickness in the image 
quality measurements for the 0.1 mm detail size at this thickness, i.e. 50 mm PMMA or equivalent. 
 
 SDNRminimum=
minimum
measured
measured Tc
TcSDNR u   (9) 
 
 SDNRachievable=
achievable
measured
measured Tc
TcSDNR u   (10) 
where 
 (11) 
 
 
 (12) 
 
 
 (13) 
 
 
where Tcmeasured is the threshold contrast for the 0.1 mm detail size calculated from the measured 
threshold gold thickness, Tcminimum and Tcachievable are the threshold contrasts calculated from the 
limiting values for threshold gold thickness for the 0.1 mm detail size in the European protocol and μeff 
is the effective attenuation coefficient used to estimate the contrast of gold discs in the CDMAM 
phantom depending on the beam quality used. A look-up table of values for μeff is included in the 
software tool on the EUREF web site. 
The methods above determine the limiting values for SDNR for an attenuation equivalent to 50 mm 
PMMA. The European protocol adjusts SDNRminimum for other thicknesses of PMMA using equation (14) 
and Table 1.3. The SDNRachievable limit can be applied across other PMMA thicknesses. 
 
SDNRminimum=
minimum
measured
measured Tg
TgSDNR u ×z  (14) 
Table 1.3:  z-Factors to calculate SDNRminimum at different thicknesses of PMMA 
Thickness of PMMA 
(mm) z-factor 
20 1.15 
30 1.10 
40 1.05 
45 1.03 
50 1.00 
60 0.95 
70 0.90  
measuredeff1measured
TgeTc  P
minimumeff1minimum
TgeTc  P
achievableeff1achievable
TgeTc  P
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To evaluate the AEC performance, the measured SDNR should be plotted against the PMMA thickness 
and compared with the limiting SDNR values, as shown in Figure 1.4. In this case, the system failed to 
exceed the minimum acceptable SDNR at the 60 mm and 70 mm thicknesses of PMMA. 
Figure 1.4:  Example of an evaluation of measured SDNR against target SDNR 
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Note that in general a change to a higher SDNR will be associated with better image quality if all other 
factors are unchanged. However, if such a change is associated with a change in image sharpness, 
the opposite may be true and an investigation of sharpness and image quality should be undertaken. 
2b.2.1.3.6 Local dense area (only DR systems) 
Most systems measure the attenuation of the imaged object during a pre-exposure. The areas with 
highest attenuation in the clinically relevant part of the image should determine the exposure factors 
for imaging. It is required that the signal-to-noise ratio (SNR) in the images be adjusted to the 
(relatively large) regions with highest density. 
Put a 30 mm stack of PMMA plates on the bucky. Put spacers on top of the stack, such that the 
compression paddle is positioned at a height of 40 mm above the breast holder (compression force 
can be applied). The spacers should not cover the part of the detector in which exposure factors are 
determined (AEC sensor area). On the compression paddle, position a first, small PMMA plate, 
representing a relatively large area with higher density (20 mm × 40 mm, 2 mm thick), in the central 
part of the detector with its lower edge 50 mm from the chest wall side.1 (It must be ensured that this 
plate is within the AEC sensor area. If this is not the case, another position should be chosen.) See 
Figures 1.5 and 1.6. Make an exposure, and record the exposure factors. Add another small PMMA 
plate on top of the previous one, and repeat the procedure until 10 small plates have been added. 
Measure PV and standard deviation (SD) in the area of extra attenuation (20 mm × 40 mm PMMA 
plates) with a ROI of 5 mm × 5 mm. Calculate SNR for each image and the average SNR for all 
images. It should be checked whether the exposure of the images is increased with increasing 
thickness and whether the extra attenuation is detected. For this, the following value can be used as 
guidance: the SNR of each image should be within 20% of the average SNR (provisional). 
1 The small PMMA plates may also be positioned in a non-central region but must be positioned within the AEC sensor area. 
6'15PLQLPXPPP300$
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PP300$
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Guidance  The SNR of each image should be within 20% of the average SNR (provisional). 
Frequency Every 6 months, or after AEC software upgrades. 
Equipment Three 150 mm × 180 mm PMMA plates (10 mm thick), two spacers (10 mm 
 thick), ten 20 mm × 40 mm PMMA plates (2 mm thick). 
 
 
 
Figure 1.5:   Set-up for the local dense area measurement, top view and 3D view 
 


 
 
 
Figure 1.6:   Set-up for the local dense area measurement, side views 
 
 
2b.2.1.5 Antiscatter grid 
2b.2.1.5.1 Grid system factor 
This measurement is omitted. 
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2b.2.1.5.2 Grid imaging 
This measurement is omitted. 
2b.2.2.1.2 Noise evaluation 
The scope of this test is the analysis of different noise components to provide additional information 
on the performance of the imaging system and to optimize troubleshooting in case of potentially 
decreased image quality. The method described here is reported in greater detail elsewhere (Evans et 
al., 2002; Borasi et al., 2003; Young et al., 2006b) and particularly in Bouwman et al. (2009). 
General requirement: For systems with a non-linear response, the pixel data must be linearized before 
analysis. 
Noise in images can be subdivided into electronic noise, quantum noise and structure noise: 
 
       (15) 
 
SD =   standard deviation in reference ROI 
ke =   electronic noise coefficient 
kq =   quantum noise coefficient 
ks =   structure noise coefficient 
p =   average pixel value in reference ROI. 
 
Electronic noise is assumed to be independent of the exposure level and arises from several sources: 
dark noise, readout noise and amplifier noise. 
Quantum noise arises due to the variations in X-ray flux and (if present) secondary carrier flux. 
Structure noise is present due to spatially fixed variations of the gain of an imaging system. The flat-
fielding performed in DR systems will largely remove the effects of structure noise. Due to the limited 
number of images used for the flat-field mask and the associated noise in the mask, some structure 
noise will still be present. 
Remove the compression paddle and all other removable parts (e.g. covers and antiscatter grid) from 
the X-ray beam. Position a 2 mm thick aluminium plate as close as possible to the X-ray tube. 
Set the target/filter combination and the tube voltage that is chosen in fully automatic mode for a 
45 mm thick PMMA object plus 8 mm spacers. In manual mode, set the minimum mAs value. Image 
the aluminium plate. Increase the mAs value and image the plate again. Take a large number of 
images at different mAs values (e.g. 15 values for acceptance tests, 8 values for subsequent tests) 
over the whole range of available values with a typical spacing of approximately 40%. Then, take a 
dark noise image. 
It is optional to repeat the measurement for all target/filter combinations, with a clinically relevant 
tube voltage for each combination. 
It is optional to measure or calculate the dose on the detector surface from tube output measure-
ments for all spectra, to be able to use detector air kerma instead of PV in this evaluation. 
Analysis steps: 
1. Measure PV and SD in the reference ROI. 
2. Plot PV against detector dose to determine the response function. 
3. Plot SD² against PV (or detector dose). 

SD2=ke2 + kq2 * p   + ks2 * p2
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4. Fit the points using equation (15), and determine the noise coefficients. 
5. Determine the detector dose range for which quantum noise is the largest noise component. 
 
Option: The calculated noise components can be used to plot PV (or detector dose) against the 
percentage of the total relative noise for all noise components. In this graph, the magnitude (in %) of 
all noise components is visualized for the range of PVs (or detector doses). 
Limiting value Quantum noise should be the largest noise component for the pixel value 
 range (detector dose range) that is used clinically. 
Frequency Every 6 months. 
Equipment Aluminium plate (2 mm thick) covering the whole X-ray field (near the tube), 
 appropriate software tools. 
2b.2.2.3.1 Image receptor homogeneity 
In addition to the test described in the fourth edition, with an ROI size of 10 mm × 10 mm, another 
ROI, of dimensions 2 mm × 2 mm, is used to calculate variance in each ROI. Equation (16) is used to 
calculate variance. This parameter is sensitive to the occurrence of artefacts on the image and 
supports visual artefact analysis by indicating deviations automatically. 
         
 (16) 
 
 
More detailed information on the method described here is provided in van Engen et al. (2006a); see 
also Marshall (2006). 
 
Limiting value The average variance of each ROI should be compared with the average 
 variance of the neighbouring ROIs. If the variance in an ROI LV 30% higher 
 than the variance in neighbouring ROIs, the image should be investigated 
 visually for an artefact at this position. 
Frequency Weekly (it is recommended to perform this test before and after calibration); 
 optional: daily. 
Equipment Standard test block covering the complete detector, appropriate software 
 tools. 
2b.2.2.3.2 Detector element failure (DR systems) 
The method and limiting values of the fourth edition are used. The bad pixel map should be easily 
accessible for all users and should be provided e.g. as a table including number, size and location of 
the defective elements, clusters and lines. If uncorrected bad pixels are visible on the images, this 
should be taken into account when evaluating detector element failure. 
2b.2.2.4 Interplate sensitivity variations and plate uniformity (CR systems) 
In addition to the test in the fourth edition: Take an image receptor homogeneity image (see 
Section 2b.2.2.3.1), and inspect the variance map for all plates. It may be necessary to clean the 
plates, following the standard cleaning procedure given by the manufacturers, to determine whether 
some artefact can be removed. 
Limiting value No artefacts should be present. If the YDULDQFH LQ DQ 52, LV 10% higher 
 than the variance in neighbouring ROIs, the image should be investigated 
 visually for an artefact at this position. 

Var(X)=
i=1(xi – μ)2 
N  
N– 1
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Frequency Monthly. 
Equipment Standard test object covering the complete detector. 
2b.2.2.5 Influence of other sources of radiation 
This test is omitted. 
2b.2.2.6 Fading of latent image (CR systems) 
This test is omitted. 
2b.2.3 Dosimetry 
This section makes it possible to apply the existing dosimetric procedures to the wider range of 
target/filter combinations found in modern X-ray sets. Typically, these involve using beam qualities 
with higher HVL than provided for previously. In addition, more specific guidance is given for the 
configuration to be used in determining the incident air kerma. Other aspects of the previous guidance 
are repeated here so that all the required information is available within this document. 
2b.2.3.1 Dose to typical breasts simulated with PMMA 
The doses to a range of typical breasts should be assessed with blocks of PMMA as breast substitutes 
using the usual clinically selected exposure factors, including any automatic selection of tube voltage 
and target/filter combination. This method relies on the equivalence in attenuation between different 
thicknesses of PMMA and typical breasts (Dance et al., 2000), as listed in Table A5.1 in Appendix 5. It 
should be noted that because PMMA is denser than breast tissue, any automatic selection of tube 
voltage, target or filter may be slightly different from that for real breasts. This can be corrected by 
adding spacers (e.g. expanded polystyrene blocks) to the PMMA to make up a total thickness equal to 
that of the equivalent breast. Small pieces of more attenuating materials can also be used as spacers 
provided they are outside the sensitive area of the AEC. On systems that determine the exposure 
factors using transmission, spacers should not be necessary. 
Set the AEC to normally used clinical settings, and expose PMMA plates of 20 mm thickness. Record 
the exposure factors chosen by the AEC. Repeat this measurement for 30, 40, 45, 50, 60 and 70 mm 
PMMA thickness. (For routine testing it is sufficient to use only a 45 mm thickness of PMMA.) Calculate 
the average glandular dose (D) to a typical breast of thickness and composition equivalent to the 
thickness of PMMA by applying the following formula: 
D = Kgcs             (17) 
 
where K is the incident air kerma (without backscatter) calculated at the upper surface of the PMMA 
using the method described later in this section. The g-factor corresponds to a glandularity of 50%, is 
derived from the values calculated by Dance (1990), Dance et al. (2000) and Dance et al. (2009) and 
is shown in Table A5.1 for a range of HVLs. The c-factor corrects for the difference in composition of 
typical breasts from 50% glandularity (Dance et al., 2000; Dance et al., 2011) and is given in 
Table A5.2 for typical breasts for women in the age group 50–64. Note that the g-factors and c-
factors applied are those for the corresponding thickness of typical breast rather than the thickness of 
PMMA block used. Where necessary, interpolation may be made for different values of HVL. Typical 
values of HVL for various spectra are given in Table A5.3, but HVLs are normally measured at the 
same time as the measurements necessary to determine the incident air kerma. The s-factor shown in 
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Table A5.4a corrects for any difference due to the choice of X-ray spectrum (Dance et al., 2000; 
Dance et al., 2011). Note that for the W/Al target/filter combination, the s-factor varies with filter 
thickness and breast thickness (Tables A5.4b–e). 
Maximum average glandular dose 
Limiting value  A maximum average glandular dose is set per PMMA thickness, as shown in 
 Table 1.4. 
Frequency Every 6 months. 
Equipment Calibrated mammographic dosimeter, 20–70 mm thick blocks of PMMA. 
 
Table 1.4:   Dose levels for typical breasts simulated with PMMA 
Thickness 
of PMMA 
(mm) 
Equivalent 
breast 
thickness  
(mm) 
Maximum average glandular 
dose to equivalent breasts 
(mGy) 
Acceptable level Achievable 
level 
20 21  1.0  0.6 
30 32  1.5  1.0 
40 45  2.0  1.6 
45 53  2.5  2.0 
50 60  3.0  2.4 
60 75  4.5  3.6 
70 90  6.5  5.1 
 
 
Incident air kerma 
In the original publication by Dance (1990), the incident air kerma was calculated for a dosimeter in 
contact with and below a compression paddle. It follows that the determination of incident air kerma 
at the surface of PMMA test phantoms or breasts should be based on measurements made with this 
geometry to correctly include scatter from the paddle. The recommended geometry for the procedure 
is shown in Figures 1.7 and 1.8 and is described below. 
Calculate the incident air kerma for each of the beam qualities used in exposing the blocks of PMMA 
by making an exposure of the dosimeter positioned as in Figures 1.7 and 1.8 using a manually 
selected tube loading (e.g. 50 mAs). Estimate the incident air kerma at the upper surface of the PMMA 
by using the inverse square law and scaling to the appropriate value of tube loading (mAs). The HVL 
should also be estimated at the same time using multiple layers of aluminium, as described in the 
fourth edition. 
The chamber should be positioned on a line extending from the tube focus to a point on the mid-line 
of the breast support table 60 mm from the chest wall edge. If the chamber has backscatter 
correction, the recommended position is directly on the breast support with the paddle in contact. It 
would also be possible to make a measurement of air kerma with the dosimeter higher above the 
breast support and with the paddle in contact provided the appropriate inverse square law correction 
is made. This approach is recommended if the chamber does not have backscatter correction. The 
effect of scatter from the compression paddle on the measurement of incident air kerma is discussed 
in Dance et al. (2009), where it is shown that for the above geometry and a polycarbonate paddle 
2.4 mm thick, scattered photons contribute 7% of the total measured air kerma. 
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Figure 1.7:  Position of dosimeter to estimate incident air kerma for dose estimation, 
 top view and 3D view 
 
 
  
 
 
Figure 1.8:  Position of dosimeter to estimate incident air kerma for dose estimation,  
 front view and side view 
 
 
 
2b.2.3.2 Clinical breast doses 
It is also possible to measure the average glandular dose for a series of breast examinations on each 
mammography system. To do this, for each exposure the breast thickness under compression is 
measured and the exposure factors are recorded. From measurements of air kerma as described 
previously (Figures 1.7 and 1.8) at the tube voltage and target/filter combination used, the tube 
loading (mAs) may be used to estimate the incident air kerma and to determine the average glandular 
dose using equation (17). In this case, K is the incident air kerma calculated at the upper surface of 
the breast. For the appropriate breast thickness, g-factors should be interpolated from Table A5.5; 
c-factors for typical breast compositions for women in the age groups 50–64 and 40–49 are shown in 
Tables A5.6 and A5.7, respectively. Measurement of compressed breast thickness for this purpose is 
performed by the radiographer, by reading the displayed compressed thickness on the X-ray set. The 
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accuracy of the displayed thickness should be verified by applying a typical force (e.g. 100 N) to rigid 
material of known thickness. It may be necessary to apply correction factors if the displayed values 
are in error. An accuracy of  ±2 mm is required. Software for making such dose calculations has 
been published by the United Kingdom Breast Screening Programme (Young, 2001). 
2b.2.4.1 Threshold contrast visibility 
In threshold contrast visibility analysis, the pixel value (PV) and SNR are assumed to be relatively 
constant over the imaging fields. If low-frequency trends in PV are present, it may be necessary to 
correct for such a trend before analysis. 
Threshold contrast visibility is determined for cylindrical details with diameters in the range from 
0.1 mm to 1 mm. The details are imaged on a background object with an attenuation equivalent to 
50 mm of PMMA. The details must be positioned at a height of 20–25 mm above the breast support 
table. Use the exposure factors that are selected in fully automatic mode for 50 mm PMMA with 
10 mm thick spacers, as found when measuring breast thickness and composition compensation. 
Take at least 16 images of the details, and move the details slightly between the images to obtain 
images in which the relative positions of the details and the detector elements are different. The ‘for 
processing’ version of the images should be used for analysis. 
Automated threshold contrast measurement using CDMAM 
If the CDMAM phantom is used, it is recommended that automated computer reading be performed to 
determine the threshold gold thickness for each detail size. Software tools for doing this are 
downloadable from the EUREF web site (www.euref.org). This will involve downloading the latest 
version of CDCOM. Appendix 8 provides a description of how CDCOM works. 
Using the output of CDCOM, a detection matrix is constructed and for each diameter of cylindrical 
details a psychometric curve is fitted (Veldkamp et al., 2003): 
                      
25.0
1
0.75p(d) )(   CtCfe    (18) 
 
    C = logarithm of signal contrast; C  ORJíeíǋG) 
    Ct = signal contrast at the threshold of 62.5% 
   = fitting parameter 
     p(d) = the probability of detection of an object with size d. 
 
A threshold at 62.5% correct response is used to determine the threshold contrast. Results for which 
the psychometric curve is fitted with only a few data points are disregarded.2 To use the limiting 
values in the existing protocol (in the fourth edition), the resulting thresholds for each diameter have 
to be converted to human readout. 
A tool called ‘CDMAM analysis software tool’ uses the output from CDCOM for a set of images to 
determine threshold gold thicknesses for the different detail sizes. A software description and software 
manual for ‘CDMAM analysis software tool’ is also available for download from the EUREF web site 
(www.euref.org). Because the automated analysis is more successful at locating the gold discs than 
human observers are, ‘CDMAM analysis software tool’ also provides the threshold gold thickness 
expected for a typical observer. Two basic methods of converting from automated thresholds to those 
predicted for human observers have been used. In the original approach described by Young et al. 
2A typical range for which the psychometric curve can be fitted is 0.1 mm to 1.0 mm (CDMAM version 3.4). 
f
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(2006a), the thresholds are scaled up using a value for each detail diameter (referred to as the United 
Kingdom method). More recently, a formula such as that shown in equation (19) and described in 
Young et al. (2008) has been used, which scales the threshold gold thickness independent of diameter 
(referred to as the EU method). Both methods are currently implemented in ‘CDMAM analysis software 
tool’ to provide retrospective compatibility. However, it is recommended that the United Kingdom 
method be adopted. 
                         Tpredicted = a[Tauto]n   (19) 
 
  Tpredicted = predicted human threshold gold thickness 
  Tauto = computer readout of threshold gold thickness 
  a and n = fitted parameters with a = 1.441, n = 0.895. 
 
‘CDMAM analysis software tool’ also fits the resulting predicted threshold gold thicknesses with a third-
order polynomial function (Equation (20)) to obtain the contrast-detail curve. 
 
                (20) 
 
T = threshold gold thickness (μm) 
x = detail diameter (mm) 
a, b, c and d = coefficients adjusted to achieve 
 a least-squares fit; all DUH 0 
 
The values from the fitted curve should be checked against the limiting values for human readout of 
threshold gold thickness as published in the fourth edition. 
 
Limiting value See fourth edition. 
Frequency Every 6 months. 
Equipment CDMAM structure plate compliant with version 3.4 (or higher) and four 
10 ± 0.2 mm thick PMMA plates of the same size; appropriate software tools. 
 
Comments and tips 
The results of these measurements are related in a predictable manner to the exposure factors used 
for a given system in terms of radiation dose, all other things being equal. Therefore, it is important to 
record the exposure factors used and to calculate the corresponding radiation dose in terms of the 
mean glandular dose (MGD) to the standard breast simulated using a 50 mm thickness of PMMA, as 
described in the dosimetry section. Care should be taken when an exposure in fully automatic mode 
(from the thickness compensation measurement) is mimicked in manual mode. Account needs to be 
taken of whether the pre-exposure is included in the displayed mAs value in automatic mode. Once 
threshold gold thickness is known for one dose level, it is relatively straightforward to predict the 
results at other dose levels. 
Whereas automated analysis works quite consistently for a given phantom, the results vary more 
between phantoms. Several methods to reduce this problem are being explored and are expected to 
result in improved versions of CDCOM and/or a calibration procedure for phantoms. The type and 
serial number of the phantom used should be recorded. 
In threshold contrast visibility analysis, the PV and SNR are assumed to be relatively constant over the 
imaging fields. If large low-frequency trends in PV are present, it may be necessary to correct for such 
a trend before analysis e.g. by applying a flat-field correction to the images. However, this is rarely 
necessary because most manufacturers already apply such a correction to their unprocessed images. 

T=a+ 
b
x

+ 
c
x2
 d
x3
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If reasonable doubts exist about the automated readout of the phantom images, the images should 
be scored by human observers. 
2b.2.4.2 Modulation transfer function (MTF) and noise power spectrum (NPS) 
Moved to Appendix 7. 
2b.2.4.3 Exposure time 
The time for an exposure in all clinically used AEC modes is measured at 45 mm PMMA thickness. 
2b.2.4.4 Geometrical distortion and artefact evaluation 
Image the phantoms in fully automatic mode. Artefact evaluation should also be performed using the 
variance map mentioned in Section 2b.2.2.3.1. 
2b.3 Image processing 
It is not yet possible to perform objective quantitative measurements on image processing in the 
context of an acceptance test. Due to the importance of the subject, some guidance on the evaluation 
of image processing is given in this section. The method described here is reported in greater detail 
elsewhere (Van Ongeval et al., 2008; van Engen et al., 2013). 
An unprocessed image (DICOM: ‘for processing’) with a linear relationship between detector dose and 
PV, which is the output of most current DR systems, is not the most suitable image for radiologists to 
read. In this type of image, the PV is related to the number of X-ray quanta interacting in the 
detector. A radiologist, however, is interested in structures in the breast and the amount of radiation 
attenuated by these structures. This ‘attenuation image’ is obtained by transforming PVs 
logarithmically. For most CR systems the images are already scaled logarithmically by the hardware of 
the reader, so the unprocessed images have a non-linear relationship between image receptor dose 
and PV. 
In the next stage, the image is further processed to enhance the visibility of the clinically relevant 
information, yielding a processed image (DICOM: ‘for presentation’). 
Processing techniques that are applied to mammographic images include: 
x LUT and Bit operations 
x thickness equalization at the edge of the breast 
x sharpening of the image 
x noise reduction 
x contrast optimization. 
Objective evaluation of image processing algorithms is very difficult. Image characteristics, like PV 
distribution (histogram), shape, etc., are used in image processing algorithms. This means that 
phantoms whose characteristics differ from those of a breast cannot be used to evaluate image 
processing. The difference in characteristics causes the processing of phantom images to be different 
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from that of images of breasts. Artefacts may also be introduced because image processing algorithms 
presume a breast edge (skin line) that may not be present in technical test objects. 
Therefore, to date only subjective evaluation of image processing algorithms could be performed, by 
radiologists scoring mammograms. 
After installation of a system and the acceptance test, it is recommended to carefully evaluate a series 
of clinical images. If possible, clinical images taken with the new system should be compared with 
previous images of the breasts of the same woman taken with a diagnostically established modality. 
The following image characteristics may be taken into account when comparing images: 
1. the visualization of the skin line 
2. the visibility of vascular structures through dense parenchyma 
3. the visualization of vascular and fibrous structures and pectoral muscle 
4. the visualization of structures along the pectoral muscle 
5. the visualization of Cooper’s ligaments and vascular structures in the low- and high-PV areas of 
the image 
6. the outlines of microcalcifications 
7. the noise in the low- and high-PV areas of the image 
8. the contrast in the low- and high-PV areas of the image 
9. the appearance of glandular tissue 
10. the appearance of the background area (the area directly exposed to the X-ray field without any 
attenuation by the imaged object) 
11. the confidence of the radiologist with the representation of the image 
12. the presence of artefacts. 
It must be realized that large numbers of cases of different breast types, breast thicknesses and dose 
levels should be reviewed before conclusions about the quality of images can be drawn, because the 
visibility of structures may differ in individual cases, e.g. due to differences in positioning or variations 
in anatomical structures. 
2b.4 Image presentation 
2b.4.1  Monitors 
2b.4.1.1  Ambient light 
For LCD displays, the maximum ambient light value is increased to 20 lux. For CRT displays, the 
maximum ambient light level remains 10 lux. 
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2b.4.1.2–5 Constancy tests of monitor performance 
In the fourth edition, it is stipulated that the following parameters of a monitor should be evaluated 
daily: geometrical distortion (on CRT displays) (2b.4.1.2), contrast visibility (2b.4.1.3) and display 
artefacts (2b.4.1.5). It was recommended that these tests should be performed by using the TG18-QC 
test pattern of the American Association of Physicists in Medicine (AAPM). In this section, alternative 
test patterns are described that can be used to test contrast visibility, geometrical distortion and 
display artefacts as efficiently as with the AAPM test patterns (Jacobs et al., 2007). The complete 
procedure includes the use of a newly generated test pattern for every evaluation and a fill-in sheet 
for comparing the readings with the true values. This procedure overcomes inattentive scoring and 
allows adherence to the QC procedures to be verified easily. The software for generating and scoring 
the test patterns is downloadable from the EUREF web site (www.euref.org). 
The MoniQA pattern is divided into 4 equally sized rectangular segments with 4 uniform background 
values of different intensities. The values were chosen to be 0%, 33%, 66% and 100% of the 
maximum grey level. The position of these rectangles swaps randomly each time the pattern is 
generated, with one restriction: the rectangle with a grey level of 0% (Lmin) will always have a mutual 
border with the rectangle with a grey level of 100% (Lmax). This guarantees a black-to-white or white-
to-black transition between the patches with the maximum and the minimum grey level. This 
transition can be either horizontal or vertical. Figure 1.9 shows two examples of the variable pattern. 
 
Figure 1.9:  Two examples of the MoniQA pattern. These patterns include checks for 
contrast visibility, geometrical distortion, spatial resolution, global image 
quality and artefacts (reprinted with permission from Med. Phys.) 
 
 
 
Extra tests: 
i. Low-contrast characters 
In the centre of each rectangular segment there is a set of five characters that have a low contrast 
with the background PV (Figure 1.10a). Each time the pattern is generated, the characters are 
randomly chosen out of a subset of the Latin alphabet, i.e. ABCDEHJKLMPSTUZ. Each set of 
characters has PV differences of 7, 5, 3, 2 and 1 between background and character. The observer 
has to read as many characters as possible. It is suggested that the observer guess the identity of one 
character more than those seen with certainty. 
Score criteria: If characters are not discriminated from the background, points are subtracted from the 
initial score of 100 according to the PV difference between character and background. If the least 
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visible character is not identified correctly, 1 point is deducted. The next character has a value of 2 
points; the third character has a value of 3 points. For the fourth character, 5 points are deducted, 
and if the highest contrast character is not detectable, 7 points are deducted. 
ii. Gradient bar of patches with increasing PVs and low-contrast characters 
In the centre of the display, a gradient bar of 18 distinct greyscale steps is drawn, with PVs as used in 
the central rectangle of the AAPM TG18-LN patterns. This bar is horizontal or vertical but will never 
divide the rectangles with 0% and 100% of the maximum grey level. A randomly chosen character is 
placed on each step of the gradient. The bar is divided into 2 equally sized parts, a northern and a 
southern part or a western and an eastern part. In each part of the gradient bar, each character is 
unique. The characters are selected from the same subset of the Latin alphabet as used for the 
selection of the low-contrast characters. The greyscale value of each character is the same as the 
greyscale value of the preceding luminance patch (Figure 1.10b), with the whitest and darkest 
patches at the extremes. 
To evaluate this pattern, characters are to be read starting in the middle and then reading, according 
to the orientation of the bar, towards the west and east or north and south. If a luminance character 
is visible, it is concluded that the underlying patch can be clearly distinguished from the adjacent 
patch. In the AAPM TG18-QC and the DIN test patterns, the purpose of this gradient bar is to verify 
whether the different steps are distinguishable. This is most critical for the lowest and highest PVs. 
When evaluating the MoniQA pattern, only the two last visible characters have to be registered. 
Score criteria: 10 points are deducted for each incorrectly identified or invisible low-luminance patch, 
and this is done for both extremities of the gradient bar. If no character has been identified correctly, 
9 × 10 points are deducted. 
iii. The MoniQA pattern can be used to test geometrical distortion, whether all pixels of the test 
image are shown, high- and low-contrast spatial resolution and artefacts (black-to-white and 
white-to-black transition problems). Any imperfection lowers the score by 5 points, except a dead 
pixel, which lowers the score by 11 points. 
The MoniQA pattern is highly variable. There are 16 combinations of background positions, 4 positions 
for the resolution pattern inside each background field and 2 resolution types (high- and low-
contrast), which means the total number of possible configurations is 128. In addition, there is a very 
large number of combinations of characters for the low-contrast visibility checks. 
Limiting value Score obtained from MoniQA pattern should be  95. 
Frequency Daily; optional: weekly. 
Equipment MoniQA test pattern. 
2b.4.1.8 Luminance uniformity 
Limiting value of luminance deviation 
        CRT  LCD 
Test pattern TG18-UNL10    30%   30% 
Test pattern TG18-UNL80    30%   15% 
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Figure 1.10:  Examples of features of the MoniQA pattern: (a) example of a sequence of 
characters with a low-contrast luminance difference from the background; 
(b) gradient bar of patches with increasing pixel values and with randomly 
selected characters with a pixel value as in the adjacent patch; (c) grid 
pattern; (d) corner lines pattern; (e) resolution patterns: (left) high-contrast 
and (right) low-contrast; (f) horizontal and (g) vertical version of the 
hourglass object (all elements are shown with enhanced contrast for clarity) 
 
 
 
 
 
gridlines corner lines 
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2b.4.2  Printers 
General remark: For all test items in this section, each test pattern should be printed 3 times. If 
optical densities (ODs) are to be measured, the average OD from the 3 prints should be used for 
further analysis. 
The suggestions for QC made by AAPM Task Group 18 have been adapted slightly. The Task Group 18 
measurements are based on measuring OD of a printed test pattern. From a QC point of view, a 
standard viewing box has been defined (luminance of the viewing box without film: 4000 cd/m²; 
luminance contribution due to ambient illuminance reflecting on the printout: 1 cd/m²). The ODs of 
the test pattern should be such that the printout in combination with this virtual viewing box conforms 
to the greyscale standard display function (GSDF). The luminance of the viewing boxes is controlled 
by the tests described in the screen-film section of the fourth edition. 
x AAPM TG18 patterns must be in DICOM MG format. 
x AAPM test patterns must be printed from the acquisition workstation (or printing server) and, if 
applicable, from the diagnosis workstation. 
x AAPM test patterns must be printed for all film formats that are used. 
2b.4.2.5 Optical density range 
Print the TG18-PQC test pattern. Measure Dmin and Dmax on this image. 
Limiting value Dmin  0.25 OD, Dmax  3.60 OD. 
Frequency Every 6 months. 
Equipment Suitable densitometer, TG18-PQC test pattern. 
2b.4.3 Viewing boxes 
If mammograms are read on printed images, check the viewing boxes using the method and limiting 
values described in the fourth edition (page 82). 
2b.4.3.1 Ambient lighting level 
The artefacts and loss of image quality associated with reflections from the display surface depend on 
the level of ambient lighting. It is important to verify that the ambient lighting in the room is below 
the maximum limit. The conditions for the tests should be similar to those during normal use of the 
equipment. 
If mammograms are read on printed images, check ambient light using the method and limiting 
values described in the fourth edition (page 82). 
 
 
 
 
 
(XURSHDQJXLGHOLQHVIRUqualityassuranceLQEUHDVWFDQFHUVFUHHQLQJDQGGLDJQRVLVFourtheditionSupplements 33 
SUPPLEMENT 1 – DIGITAL MAMMOGRAPHY UPDATE – APPENDIX 5 
Appendix 5: Tables for determination of average glandular dose 
Most of the data in the following tables are from Dance (1990), Dance et al. (2000), Dance et al.. 
(2009) and Dance et al. (2011). 


Table A5.1:  g-Factors for breasts simulated with PMMA 

PMMA 
thickness 
(mm) 
Equivalent 
breast 
thickness 
(mm) 
Glandularity
of 
equivalent 
breast 
(%) 
g-factor (mGy/mGy) 
HVL (mm Al) 
0.30 0.35 0.40 0.45 0.50 0.55 0.60 0.65 0.70 0.75 0.80 
20 21 97 0.378 0.421 0.460 0.496 0.529 0.559 0.585 0.609 0.631 0.650 0.669 
30 32 67 0.261 0.294 0.326 0.357 0.388 0.419 0.448 0.473 0.495 0.516 0.536 
40 45 41 0.183 0.208 0.232 0.258 0.285 0.311 0.339 0.366 0.387 0.406 0.425 
45 53 29 0.155 0.177 0.198 0.220 0.245 0.272 0.295 0.317 0.336 0.354 0.372 
50 60 20 0.135 0.154 0.172 0.192 0.214 0.236 0.261 0.282 0.300 0.317 0.333 
60 75 9 0.106 0.121 0.136 0.152 0.166 0.189 0.210 0.228 0.243 0.257 0.272 
70 90 4 0.086 0.098 0.111 0.123 0.136 0.154 0.172 0.188 0.202 0.214 0.227 
80 103 3 0.074 0.085 0.096 0.106 0.117 0.133 0.149 0.163 0.176 0.187 0.199 

 
Table A5.2:  c-Factors for breasts simulated with PMMA 

PMMA 
thickness 
(mm) 
Equivalent 
breast 
thickness 
(mm) 
Glandularity 
of equivalent 
breast 
(%) 
c-factor* 
HVL (mm Al) 
0.30 0.35 0.40 0.45 0.50 0.55 0.60 0.65 0.70 0.75 0.80 
20 21 97 0.889 0.895 0.903 0.908 0.912 0.917 0.921 0.924 0.928 0.933 0.937 
30 32 67 0.940 0.943 0.945 0.946 0.949 0.952 0.953 0.956 0.959 0.961 0.964 
40 45 41 1.043 1.041 1.040 1.039 1.037 1.035 1.034 1.032 1.030 1.028 1.026 
45 53 29 1.109 1.105 1.102 1.099 1.096 1.091 1.088 1.082 1.078 1.073 1.068 
50 60 20 1.164 1.160 1.151 1.150 1.144 1.139 1.134 1.124 1.117 1.111 1.103 
60 75 9 1.254 1.245 1.235 1.231 1.225 1.217 1.207 1.196 1.186 1.175 1.164 
70 90 4 1.299 1.292 1.282 1.275 1.270 1.260 1.249 1.236 1.225 1.213 1.200 
80 103 3 1.307 1.299 1.292 1.287 1.283 1.273 1.262 1.249 1.238 1.226 1.213 
* for typical breasts for women in the age group 50–64 

Table A5.3:  Typical HVL measurements for different tube voltage (kV) and target/filter 
 combinations (data include the effect on measured HVL of attenuation by a 
 compression plate) 

 
HVL (mm Al) for target/filter combination 
kV Mo Mo Mo Rh Rh Rh W Rh W Ag W Al 
(0.5 mm) 
W Al 
(0.7 mm) 
25 0.32 r 0.02 0.38 r 0.02 0.37 r 0.02 0.50 r 0.03 0.51 r 0.03 0.34 r 0.03 0.42 r 0.03 
28 0.35 r 0.02 0.42 r 0.02 0.42 r 0.02 0.53 r 0.03 0.58 r 0.03 0.39 r 0.03 0.49 r 0.03 
31 0.38 r 0.02 0.45 r 0.02 0.45 r 0.02 0.56 r 0.03 0.61 r 0.03 0.44 r 0.03 0.55 r 0.03 
34 0.40 r 0.02 0.47 r 0.02 0.47 r 0.02 0.59 r 0.03 0.64 r 0.03 0.49 r 0.03 0.61 r 0.03 
37    0.62 r 0.03  0.67 r 0.03 0.53 r 0.03 0.66 r 0.03 
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Table A5.4a:  s-Factors for clinically used spectra (Dance et al., 2000) 

Target material 
Filter 
material 
Filter 
thickness 
(μm) 
s-factor 
Mo Mo 30 1.000 
Mo Rh 25 1.017 
Rh Rh 25 1.061 
W Rh 50–60 1.042 
W Ag 50–75 1.042 


Table A5.4b: s-Factors for a tungsten target filtered by 0.5 mm aluminium 

PMMA  
thickness  
(mm) 
Equiv. breast  
thickness 
(mm) 
s-factor 
20 21 1.075 
30 32 1.104 
40 45 1.134 
45 53 1.149 
50 60 1.160 
60 75 1.181 
70 90 1.198 
80 103 1.208 


Table A5.4c:  s-Factors for a tungsten target filtered by 0.7 mm aluminium. 
 
PMMA  
thickness  
(mm) 
Equiv. breast  
thickness 
(mm) 
s-factor 
20 21 1.052 
30 32 1.064 
40 45 1.082 
45 53 1.094 
50 60 1.105 
60 75 1.123 
70 90 1.136 
80 103 1.142 
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Table A5.4d:  s-Factors for a tungsten target filtered by 0.5 mm aluminium 
 
Breast 
thickness 
(mm) 
Glandularity 
range 
(%) 
Typical 
glandularity, 
age 50–64 
(%) 
Typical 
glandularity, 
age 40–49 
(%) 
kV range 
(kV) 
s-factor 
20 80–100 100 100 25–40 1.069 
30 62–82 72 82 29–40 1.104 
40 40–65 50 65 29–40 1.127 
50 23–49 33 49 30–40 1.139 
60 11–35 21 35 30–40 1.154 
70 2–24 12 24 30–40 1.180 
80 0.1–17 7 14 30–40 1.187 
90 0.1–14 4 8 30–40 1.198 
100 0.1–13 3 5 30–40 1.206 
110 0.1–13 3 5 30–40 1.212 


Table A5.4e:  s-Factors for a tungsten target filtered by 0.7 mm aluminium 
 
Breast 
thickness 
(mm) 
Glandularity 
range 
(%) 
Typical 
glandularity, 
age 50–64 
(%) 
Typical 
glandularity, 
age 40–49 
(%) 
kV range 
(kV) 
s-factor 
20 80–100 100 100 25–50 1.052 
30 62–82 72 82 25–50 1.060 
40 40–65 50 65 25–50 1.076 
50 23–49 33 49 25–50 1.087 
60 11–35 21 35 25–50 1.105 
70 2–24 12 24 28–50 1.121 
80 0.1–17 7 14 28–50 1.129 
90 0.1–14 4 8 28–50 1.136 
100 0.1–13 3 5 28–50 1.140 
110 0.1–13 3 5 28–50 1.144 
 
 
 


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Table A5.5:  Additional g-factors 

HVL Breast thickness (mm)               
(mm Al) 2 3 4 5 6 7 8 9 10 11 
0.30 3.90 2.74 2.07 1.64 1.35 1.14 0.98 0.859 0.763 0.687 
0.35 4.33 3.09 2.35 1.87 1.54 1.30 1.12 0.981 0.873 0.786 
0.40 4.73 3.42 2.61 2.09 1.72 1.45 1.26 1.106 0.986 0.887 
0.45 5.09 3.74 2.89 2.32 1.92 1.63 1.40 1.233 1.096 0.988 
0.50 5.43 4.06 3.18 2.58 2.14 1.77 1.54 1.357 1.207 1.088 
0.55 5.73 4.37 3.46 2.87 2.36 2.02 1.75 1.543 1.375 1.240 
0.60 5.87 4.66 3.74 3.10 2.61 2.24 1.95 1.723 1.540 1.385 
0.65 6.22 4.91 3.99 3.32 2.82 2.44 2.12 1.879 1.682 1.520 
0.70 6.44 5.14 4.21 3.52 3.00 2.59 2.27 2.017 1.809 1.638 
0.75 6.63 5.35 4.41 3.71 3.17 2.74 2.41 2.143 1.926 1.746 
0.80 6.82 5.55 4.60 3.89 3.33 2.89 2.54 2.270 2.044 1.856 
           
The table is in units of mGy/mGy.        
Additions to the table in Dance et al. (2000) are highlighted in grey. 

Table A5.6:  Additional c-factors for average breasts for women in the age group 50–64 

Breast                         
thickn. Gland. HVL (mm Al)           
(mm) (%) 0.30 0.35 0.40 0.45 0.50 0.55 0.60 0.65 0.70 0.75 0.80 
20 100 0.885 0.891 0.9 0.905 0.91 0.914 0.919 0.923 0.928 0.932 0.936 
30 72 0.925 0.929 0.931 0.933 0.937 0.94 0.941 0.947 0.950 0.953 0.956 
40 50 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 
50 33 1.086 1.082 1.081 1.078 1.075 1.071 1.069 1.064 1.060 1.057 1.053 
60 21 1.164 1.160 1.151 1.15 1.144 1.139 1.134 1.124 1.117 1.111 1.103 
70 12 1.232 1.225 1.214 1.208 1.204 1.196 1.188 1.176 1.167 1.157 1.147 
80 7 1.275 1.265 1.257 1.254 1.247 1.237 1.227 1.213 1.202 1.191 1.179 
90 4 1.299 1.292 1.282 1.275 1.27 1.26 1.249 1.236 1.225 1.213 1.200 
100 3 1.307 1.298 1.29 1.286 1.283 1.272 1.261 1.248 1.236 1.224 1.211 
110 3 1.306 1.301 1.294 1.291 1.283 1.274 1.266 1.251 1.240 1.228 1.215 
Additions to the table in Dance et al. (2000) are highlighted in grey.

Table A5.7:  Additional c-factors for average breasts for women in the age group 40–49 

Breast                         
thickn. Gland. HVL (mm Al)           
(mm) (%) 0.30 0.35 0.40 0.45 0.50 0.55 0.60 0.65 0.70 0.75 0.80 
20 100 0.885 0.891 0.9 0.905 0.91 0.914 0.919 0.923 0.928 0.932 0.936 
30 82 0.894 0.898 0.903 0.906 0.911 0.915 0.918 0.924 0.928 0.933 0.937 
40 65 0.940 0.943 0.945 0.947 0.948 0.952 0.955 0.956 0.959 0.961 0.964 
50 49 1.005 1.005 1.005 1.004 1.004 1.004 1.004 1.004 1.003 1.003 1.003 
60 35 1.080 1.078 1.074 1.074 1.071 1.068 1.066 1.061 1.058 1.055 1.051 
70 24 1.152 1.147 1.141 1.138 1.135 1.130 1.127 1.117 1.111 1.105 1.098 
80 14 1.220 1.213 1.206 1.205 1.199 1.190 1.183 1.172 1.163 1.154 1.145 
90 8 1.270 1.264 1.254 1.248 1.244 1.235 1.225 1.214 1.204 1.193 1.181 
100 5 1.295 1.287 1.279 1.275 1.272 1.262 1.251 1.238 1.227 1.215 1.203 
110 5 1.294 1.290 1.283 1.281 1.273 1.264 1.256 1.242 1.232 1.220 1.208 
Additions to the table in Dance et al. (2000) are highlighted in grey. 
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Appendix 7: Linear system theory metrics and a practical guide to 
their measurement (optional) 
A7.1 Modulation transfer function (MTF), noise power spectrum (NPS) and detective 
quantum efficiency (DQE) 
Linear system theory metrics offer reproducible, objective estimates of X-ray detector noise and 
resolution properties and are sensitive to changes in detector performance over time. The 
International Electrotechnical Commission (IEC) standard 62220-1-2 describes the measurement of 
these parameters (IEC, 2004). However, this document is intended for use by the manufacturers; they 
can remove the X-ray detector from the system and perform a separate bench test. This is not 
possible for detectors in clinical use and hence a pragmatic approach, suitable for routine QC 
conditions, is presented here. Measurement geometry is likely to vary between systems, resulting in a 
loss of generality, and hence caution must be exercised when using these metrics to compare across 
systems. However, measured with care, these parameters offer significant insight into the 
performance of an individual detector; they can isolate performance changes over time and are useful 
when troubleshooting the entire imaging chain. Definitions of the equations used to calculate these 
parameters are given in the recommended literature; a firm grasp of the theory underlying these 
parameters is required before performing these measurements. Given that many QC physicists will not 
have the time to develop the required software, validated/verified software can be used for the 
calculations. 
The IEC document prescribes standard measurements to be performed at ‘the detector surface’ 
(defined as ‘the accessible area which is closest to the image receptor plane’); for routine QC 
measurements, there will be additional non-removable parts (e.g. breast support table, antiscatter 
grid and/or detector covers) in the X-ray beam during the measurement. With this in mind, a 
consistent geometry should be used for a given system/model. When comparing quantitative 
measurements from different physics centres, the data acquisition conditions must be stated explicitly 
for the sake of transparency. These include the geometry (position of antiscatter grid and breast 
support table, use of collimation/field area), beam energy and detector air kerma, along with the data 
conditioning parameters used in the calculation of the MTF and NPS (ROI dimensions, de-trending 
used, sectioning, etc.). 
A7.2 Image type 
The first step is to identify/select ‘for processing’ images on the system. These are images that have a 
fixed gain between detector output signal and air kerma at the detector (no ‘autoranging’ of the 
signal) and have minimal additional processing. For example, DR systems will generally apply detector 
offset and gain corrections together with pixel corrections; this is acceptable. Processing such as edge 
enhancement or proprietary image processing that prepares images ‘for display’ etc. must be 
disabled/not used. These image types are sometimes listed as a specific ‘series’ and ‘study description’ 
by the manufacturer. 
A7.3 Collimation of X-ray field 
Collimation can be used to reduce the influence of scattered radiation on the measurements. The use 
of collimation represents good practice but may be time-consuming to set accurately during routine 
QC (depending on the collimation type available). If collimation is used, a field area of 100 mm × 
100 mm should be set at the beginning of the tests and kept in place for all the measurements (air 
kerma, detector response, NPS, MTF). Figure A7.1 shows suggested positioning of the collimation. 
 
(XURSHDQJXLGHOLQHVIRUqualityassuranceLQEUHDVWFDQFHUVFUHHQLQJDQGGLDJQRVLVFourtheditionSupplements38 
SUPPLEMENT 1 – DIGITAL MAMMOGRAPHY UPDATE – APPENDIX 7 
Figure A7.1:  Position of the collimation – if used, this should be in place for all the   
  measurements 
 


A7.4 Detector response function 
Quantitative analysis requires the measurement of the detector response function, relating air kerma 
at the detector input plane to pixel value (PV). This is used for linearization of the images from which 
the quantitative image quality metrics are calculated. Measurement of the detector response requires 
an estimate of the air kerma at the detector entrance plane. 
For this measurement, set the same X-ray spectrum as used for a standard image, and place 2 mm Al 
at the X-ray tube. Remove the compression plate from the X-ray beam, protect the X-ray detector and 
measure air kerma as a function of mAs. Sample low mAs settings more finely because mAs linearity 
can be worse at low mAs values; furthermore, it is likely that low mAs values will be used in images 
for NPS estimation, given the filter efficiency/transmission of 2 mm Al. Calculate air kerma at the 
detector (K), applying an inverse square law correction to obtain the values at the level of the 
detector, and apply a grid transmission factor (use a factor appropriate for the geometry) if the grid is 
not removed. Fit a first-order polynomial function and confirm linearity of K with mAs; carefully 
examine mAs linearity at low mAs settings. Use this equation to calculate the mAs values needed for a 
range of detector air kerma values, e.g. 12.5, 25, 50, 100, 200, 400 and 800 ǋ*\7KLVZLOOHQDEOH
testing of the detector at a fixed air kerma level for the lifetime of the detector and allow changes in 
performance to be tracked. Remove the grid, set the calculated mAs values (closest mAs station on 
the system) and acquire uniformly exposed (flood) images over the air kerma range. Measure PV and 
standard deviation at the standard position using the standard ROI size. Plot PV vs K, fit the 
appropriate curve for the system type (linear, logarithmic or power) and record the fit parameters. 
This function is used to linearize the PV data on a pixel-wise basis in the edge and flood images 
before calculating MTF and NPS. This must be done for all systems, even systems that produce linear 
‘for processing’ images. After this step, the linearized images will have unity gain and zero offset (the 
mean PV in this image should be equal to the air kerma used to acquire the image). 
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A7.5 Noise power spectrum (NPS) 
The NPS describes the variance of an image intensity (image PV) divided among its frequency 
components and is calculated from ROIs taken from a region of a uniformly exposed image. In 
practice, the NPS is calculated using: 
 
(A7.1) 
 
 
where an ROI dimension of 256 × 256 pixels has been used. Here, M LVWKHQXPEHURI52,VƩx is the 
pixel spacing in the x GLUHFWLRQƩy is the pixel spacing in the y direction, I(xi,yj) are the (linearized) 
pixel data, S(x,y) is a 2-dimensional polynomial function fitted to the entire extracted region used for 
NPS analysis (not to the individual ROIs). 
Select a flood image acquired at some reference detector air kerma, e.g. at 50 or 100 ǋ*\ and 
calculate the NPS for this region. Use an image acquired at the same air kerma throughout the life of 
the detector. Linearize the image using the detector response curve. IEC 62220-1 defines an area of 
50 mm × 50 mm for the NPS estimation, divided into ROIs of 256 × 256 pixels that overlap each 
other by 128 pixels. This strictly limits the physical region from which the NPS is calculated, reducing 
the effects of non-stationarity and large area non-uniformity on the NPS; however, several images are 
required to increase the number of spectra in the ensemble and hence reduce uncertainty of the 
spectral estimate. For QC purposes, a region of 100 mm × 100 mm can be used and ROIs of 256 × 
256 pixels taken from this area. To reduce statistical uncertainty, the spectra from several identically 
acquired images can be averaged. It is recommended that a 2-dimensional polynomial function be 
fitted to and subtracted from the 100 mm × 100 mm area before extraction of the ROIs of 256 × 256 
pixels. The final spectrum is sectioned from the ensemble. For systems with an isotropic NPS, this can 
be a radial average; for detectors with a non-isotropic NPS, the spectra sectioned from the 0° and 90° 
axes should be recorded separately. The axes (0° and 90° spatial frequency bins) contain information 
about the axial structured noise of the detector/image and should be included in the spectral 
estimate. The spectral ensemble (averaged over the number of individual spectra in the ensemble) is 
then normalized to give the normalized noise power spectrum (NNPS) by dividing by the mean PV of 
the linearized flood image used to calculate the spectral estimate, i.e. by dividing by the air kerma 
used to acquire the flood image. 
The IEC standard specifies the use of collimation of 100 mm × 100 mm when acquiring the flood and 
edge images, to control the quantity of the scattered radiation in the image. A higher quantity of 
scattered radiation effectively leads to a higher detector air kerma per image and hence an increased 
NPS. Whereas collimation is essential for laboratory detector measurements, the value of collimation 
in a QC setting is limited and it should be considered optional (the collimation is heavy, and exactly 
the same collimator dimension must be used across QC visits). 
The antiscatter grid can influence the measured NPS in several ways. First, the grid can introduce 
structured noise, predominantly of low spatial frequencies, which is often seen along the 0° and 90° 
NPS axes. Structured noise is multiplicative in nature and increases relative to other noise sources as 
detector air kerma is increased. The spatially periodic nature of the grid can also introduce spikes, 
indicating increased noise power at distinct spatial frequencies; this may indicate a grid motion 
problem. For example, a linear grid with 30 lines cm–1 will generate spikes at 3.0 mm–1 (and 
associated harmonics) in the NPS; these will be seen on the axis (0° or 90°) that is parallel to the 
direction of grid movement in the image. 
The presence of the antiscatter grid in the X-ray beam during detector calibration presents a further 
complication. Some systems may have flat-field corrections explicitly for the case of grid in and grid 
¦¦¦
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out of the X-ray beam, whereas others may have a single flat-field correction which presumes that the 
grid is present. For this latter system type, an ‘imprint’ of the flat-field correction will be applied to 
flood images that have been acquired with the grid removed, leading to a potential increase in the 
structured noise present in the image and hence in the NPS. 
Record the NPS at 0.5 mm–1 and 2.0 mm–1 (either a radial average or the 0° and 90° axis values 
separately). 
Limiting value ([SHFW ±15% change in NPS at 0.5 mm–1 and 2.0 mm–1 from previous QC 
 visit value and from baseline. 
Frequency Every 6 months. 
Equipment 2 mm Al filter (minimum 99% purity), calibrated dose meter, software for 
 calculating objective image quality parameters. 
A7.6 Pre-sampled modulation transfer function 
The MTF describes the spatial frequency response of a linear, spatially invariant imaging system and is 
typically determined using a slanted radio-opaque edge placed at the detector input plane, a robust 
technique suitable for routine QC. This method generates the detector pre-sampled MTF, a parameter 
that describes the blurring due to the detector pixel aperture and the X-ray converter layer. The pre-
sampled MTF is measured in two directions across the detector: the left-right and front-back (chest 
wall-nipple) directions. A stainless steel square of thickness 0.8 mm and dimensions 60 mm × 60 mm 
can be used; the provisos are that the edges must be sharp and straight and the edge must be radio-
opaque. If the edge is not radio-opaque, then scattered radiation can influence the edge spread 
function (ESF) and hence the MTF. Alternative materials can be used, such as niobium, tantalum, 
tungsten, lead, etc. However, the edge must be of sufficient thickness (radio-opaque) and the 
material should not generate large quantities of characteristic radiation that may influence the ESF. 
The pre-sampled MTF is calculated from a finely sampled (‘over-sampled’) ESF, generated by re-
binning or re-projecting the (linearized) PV data in some region containing the edge. The over-
sampled ESF is differentiated to generate the line spread function (LSF): 
 
                   (A7.2) 
 
 
The pre-sampled MTF is obtained from the LSF by using the fast Fourier transform (FFT) and 
calculating the magnitude: 
                    (A7.3) 
 
With regard to practical measurements, set the same beam quality as used to acquire the flood 
images and an mAs setting to produce an air kerma at the detector that is approximately 3× the 
typical K value for AEC images. There must be no saturation in the high-signal region of the ESF, and 
there must be no clipping or truncation to zero linearized PV in the low-signal region of the ESF. This 
is generally achieved by ensuring that the PVs in the edge image (before linearization) all lie within 
the range covered by the detector response function. Place the edge on the breast support table 
(‘detector surface’) with an approximate angle of 1° to 3° with respect to the pixel matrix. In a full 
evaluation, 4 edge images are acquired, positioned to measure the MTF at the lateral centre of the 
detector and at 6 cm from the chest wall edge (Figure A7.2). An MTF is calculated for each 
acquisition: the left-right direction (low to high signal and high to low signal changes for the ESF) and 
similarly for the chest wall-nipple direction. The final MTF is an average of the two edge orientations; 

LSF(x) =  ESF(x)
d
dx
MTF= |F[LSF(x)]| 
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e.g. the left-right MTF would be averaged from the 0° and 180° edge orientations in Figure A7.2. 
Extract a sufficiently large region containing the edge such that glare (low-frequency signal spread) 
within the detector is characterized. The actual ROI dimension will depend on the characteristic 
distance of the glare; however, an ROI of at least 40 mm × 40 mm should be used. Linearize the 
image PV data before calculating the MTF. Note the conditioning applied when obtaining the MTF 
result (smoothing, windowing, extrapolation of the LSF tails, etc.). 
Figure A7.2: Positions of the edge for MTF measurement (any additional collimation that 
 may be used is not shown) 
 
 
If a metal square with at least two sharp, straight edges is available, then the MTF can be calculated 
from a single image for the two detector directions, although in this case the MTF will be evaluated at 
different positions on the detector. This is acceptable for routine QC measurements. 
Corrections for non-uniformity in the MTF image can be applied to remove low-frequency trends using 
a uniformly exposed image (i.e. with the edge removed) acquired with exactly the same technique 
factors, although great care must be taken when making this kind of correction. As with the NPS, the 
X-ray beam can be collimated to 100 mm × 100 mm to reduce scattered radiation, although this is 
optional for QC measurements. 
Record the spatial frequencies at which the MTF reaches 50% (left-right and chest wall-nipple direc-
tions). 
Limiting value ([SHFW ±10% change in the spatial frequency for the 50% MTF point. 
Frequency Every 6 months. 
Equipment Radio-opaque edge of minimum dimensions 60 mm × 60 mm with sharp and 
 straight edges, 2 mm Al filter, calibrated dose meter, software for    
 calculating objective image quality parameters. 
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A7.7 Detective quantum efficiency (DQE) 
The DQE describes the degradation of the input SNR by the X-ray detector due to detection, 
conversion and amplification of the X-ray signal. DQE is defined as the square of the ratio of the 
detector output SNR to the SNR at the detector input. It is common to compare the detector against a 
perfect photon counting device, and hence the reference SNR at the detector input is the number of 
X-ray photons per unit area (mm–2). 
              (A7.4) 
 
 
This equation is given for the 1-dimensional case; MTF(u) is the pre-sampled MTF, NNPS(u) is the 
measured NNPS, Ka is the estimated air kerma at the detector surface and SNRin2 is the number of X-
ray photons μGy–1 mm–2 for the beam quality used. Hence, Ka × SNRin2 gives the total number of X-
ray photons mm–2 at the detector input. Table A7.1a gives SNRin2 for some typical spectra (with added 
2 mm Al at the X-ray tube) used by current X-ray systems, as provided also by IEC 62220-1. The data 
of Boone and colleagues (Boone et al., 1997) can be used to calculate SNRin2 for spectra that are not 
included in the IEC standard, using the formula: 
 
         (A7.5) 
 
ZKHUHĭ(E,V) is the photon fluence at energy E when a tube voltage V is applied. Table A7.1b gives 
SNRin2 values for some other spectra, calculated according to Boone et al. (1997). 
MTF and NPS are sensitive image quality parameters and are sufficient to track changes in detector 
performance for QC purposes. The DQE is an important image quality metric when comparing the 
absolute performance of detectors, either of a similar type or between manufacturers. However, 
calculation of the DQE requires an accurate estimate of the air kerma at the detector input plane and 
the true number of photons per unit air kerma for the photon spectrum used. Both of these can be 
difficult to achieve in practice. The DQE can be compared against manufacturer reference data. 
Limiting value None. 
Frequency Every 6 months. 
Equipment 2 mm Al filter, calibrated dose meter, software for calculating objective image 
 quality parameters, spectral modelling tool. 
 
Table A7.1a:  Number of photons μGy–1 mm–2 (SNRin2) for 2 mm Al according to IEC   
  standard 62220-1-2 
 
Tube 
potential (kV) 
Anode System filter SNRin2 
(μGy–1 mm–
2) 
28 Mo Mo (32 μm) 4981 
28 Mo Rh (25 μm) 5439 
28 Rh Rh (25 μm) 5944 
28 W Rh (50 μm) 5975 
28 W Al (500 μm) 6575 


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VESNR
a
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Table A7.1b:   Number of photons μGy–1 mm–2 (SNRin2) for 2 mm Al according to Boone 
et al. (1997) for some spectra not included in the IEC standard 
Tube 
potential (kV) 
Anode System filter SNRin2 
(μGy–1 mm–
2) 
29 Rh Rh (25 μm) 6248 
35 W Al (500 μm) 8823 
32 W Ag (50 μm) 7143 
 
 
Further reading 
The following publications are recommended for further reading: Cunningham (2000), Neitzel et al. 
(2004), Carton et al. (2005), Dobbins et al. (2006), Samei et al. (2006), Marshall (2007), Marshall 
(2009a), Marshall (2009b) and Mackenzie et al. (2010). 
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Appendix 8: Description of CDCOM version 1.6 
A8.1 The CDMAM phantom 
The CDMAM phantom was designed to derive contrast-detail visibility threshold information for 
mammography systems by conducting four alternative forced choice (4-AFC) experiments. It contains 
a grid marking of 205 cells, and each cell contains one gold disc at the centre and one disc in one of 
the corners (Figure A8.1). The corner in which a disc is located varies randomly between cells. The 
combination of disc diameter and thickness is unique to each cell. A total of 16 different diameters 
and 16 different thicknesses are present in the phantom (Bijkerk et al., 2001; Bijkerk et al., 2002). 
The CDMAM phantom is built up as an aluminium base on which the gold discs have been deposited 
by evaporation. The base is attached manually to a PMMA cover, which contains the grid lines and 
information about disc thickness and diameter (Figure A8.2). 
After imaging the CDMAM phantom, the 4-AFC experiment is conducted by asking observers to mark 
the corner of each individual cell containing a gold disc. Afterwards, the observer output is compared 
with the true disc locations. This produces a grid with ‘true’ and ‘false’ scores. To reduce the impact of 
isolated true or false scores in the matrix, a nearest neighbour correction scheme should be applied 
on this matrix before the detection threshold is derived for each diameter. 
Combining these detection thresholds for multiple readers and images for each disc diameter 
produces the contrast-detail threshold information (Figure A8.3). For more detailed information, see 
Young et al. (2006) and Young et al. (2008). 
Figure A8.1: The CDMAM phantom 
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Figure A8.2: The aluminium base contains the gold discs of the CDMAM phantom; the  
  PMMA cover contains the grid lines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A8.3: Example of human readout of the CDMAM phantom after nearest neighbour 
  correction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

A8.2 Disadvantages of human readout of the CDMAM phantom 
Human readout of the CDMAM phantom does have several disadvantages: 
x The reading of images is time-consuming. 
x Due to the long reading time, in practice only small numbers of images and readers are used, 
which decreases reliability. 
x Inter-reader variability, the variation in phantom image score from reader to reader. 
x Intra-reader variability, the variation in phantom image score by one reader. 
x There is a learning effect: readers may know the positions of the discs by heart. This influences 
their score. 
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x The nearest neighbour correction may not be the best scheme to obtain contrast-detail curves. 
To eliminate and reduce these disadvantages, computer readout of CDMAM phantom images has been 
introduced. 
A8.3 CDCOM 
CDCOM is a software tool developed to automate the tasks of reading CDMAM version 3.4 phantom 
images and generating score sheets. CDCOM does not read CDMAM version 3.2 images. CDCOM 
does not aim to predict human readout, however. Instead, it tries to use the information present in 
the image more optimally to conduct a 4-AFC experiment. The results of CDCOM can therefore not be 
used directly in combination with contrast-detail visibility limits set for human observers. In 
Section 2b.2.4.1 of this protocol, the procedure is given to predict results for human observers from 
CDCOM results. To download software for automated readout of CDMAM images, see Visser & 
Karssemeijer (2012). 
The automated image analysis by CDCOM can be separated into five phases: 
x Analysis of the DICOM header 
x Transformation to a standardized input 
x Grid detection 
x Phantom-specific and image-specific corrections 
x Individual disc detection. 
A8.4 Analysis of the DICOM header 
CDCOM needs the following elements in the DICOM header to correctly assess the image: 
x (0018,1164) Imager Pixel Spacing (used only as an initial estimator of image scale). If not 
present, use (0028,0030) Pixel Spacing. 
x (0028,0010) Rows 
x (0028,0011) Columns 
x (0028,0100) Bits Allocated 
x (0028,0101) Bits Stored 
x (0028,1041) Pixel Intensity Relationship Sign (used to facilitate grid detection; can be overruled 
by manual selection). If not present, use (0028,0004) Photometric Interpretation. 
x (7fe0,0010) Pixel Data. 
A8.5 Transformation to a standardized input 
The images of the CDMAM phantom are read by CDCOM and are transformed to a standardized form: 
(1) the image is cropped to the image of the phantom, (2) the image is rotated to the standardized 
orientation and (3) the image is scaled to a pixel size of 50 μm. This step is performed to eliminate 
differences in the detection of discs within the search area for images with different pixel size (see 
Section A8.8, Individual disc detection). 
A8.6 Grid detection 
As is the case for the human observer, the gridlines are used as a reference for global positioning. 
First, a linear Hough transform is performed at a reduced resolution of 400 μm per pixel, allowing the 
position of the gridlines to be detected as two sets of equidistant maxima in Euclidian space 
(Figure A8.4a). The cell corners can be calculated as the points where two gridlines intersect. Next, 
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
the locations of the corners of each cell are determined more accurately by applying template 
matching (Figure A8.4b) to the area around the approximate locations of each cell corner. In this 
procedure, the template of the line crossing at the estimated position is correlated with the image 
data within a small area (21 × 21 pixels) around the predicted crossing. The location with the highest 
cross-correlation is the optimal location of the crossing. This step prevents image deformations 
(geometrical distortion), e.g. caused by a concave bucky shape, from influencing the results. No 
special template for the (partial) crossing at the boundaries is used; hence, this procedure may 
occasionally fail. Therefore, the consistency of the final result must be checked. If an outlying 
boundary crossing is found, this is corrected by interpolation from surrounding points (Veldkamp et 
al., 2003). 
Figure A8.4a: Example of the result of a Hough transformation of a CDMAM image. The  
  grid can be recognized as two columns with equidistant local maxima 
 
 
 
 
 
 
 
 
 
 
 
Figure A8.4b: Template matching: in an area of 21 × 21 pixels around the predicted  
  crossing, the cross-correlation of the image with a template is determined 
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A8.7 Phantom-specific and image-specific corrections 
CDCOM performs a 4-AFC experiment with an ideal observer model. It is based on the assumption 
that for each disc (with known diameter) there are four possible positions (yellow circles in 
Figure A8.5), of which the possible locations are exactly known. In practical situations, however, there 
will always be some inaccuracy in the determination of these positions (through human and computed 
observations) caused by the production process of the phantom, the geometrical distortion of the 
phantom image and the limited resolution of the imaging system. Therefore, CDCOM needs to vary 
slightly by applying the model observer in a search region around each calculated (theoretical) 
position (purple circles in Figures A8.5 and A8.6). It is crucial to understand that increasing the size of 
the search region will increase the influence of the image noise at the disc detection step. Therefore, 
increasing the search region will result in deterioration of the detection results, especially for smaller 
diameters. To limit the influence of the noise specific to every individual image, the disc search region 
has to be kept as small as possible, while avoiding the possibility of missing (part of) the disc under 
investigation. 
Figure A8.5: Schematic illustration of the calculated disc positions (yellow inner circles) 
  and the disc search areas defined around them (purple outer circles) 

To avoid having to increase the search region, an estimate of the phantom-specific and image-specific 
translation, rotation and scaling is made by analysing the position of all easily detectable centre discs 
(large diameter and high contrast) using a UHODWLYHO\ ODUJHVHDUFKDUHDRIǋP2. A template with 
the correct positions of all discs is rotated, translated and scaled to match the easily detectable discs, 
DQG FDOFXODWHG SRVLWLRQV RI DOO GLVFV DUH REWDLQHG 8VLQJ D VHDUFK DUHD RI  ǋP2 around the 
calculated disc positions has proven to give reliable results (Visser et al., 2005). 
A8.8 Individual disc detection 
Due to the phantom-specific correction of the calculated disc positions, the disc search area for 
individual disc detection can be limited to 200 μm2 around the calculated positions. Within this search 
area, the location in which a disc of the specified size is most likely to be located is determined. 
This is done by finding the (by approximation) disc-shaped area that has the lowest or highest 
(depending on the image properties) total PV; see Figure A8.6a. In Figure A8.6b, the template is 
shown that is used to detect the circular discs on the phantom image. Due to the digital nature of the 
image, the shape of the circle is approximated by the template. This approximation would not be 
equal for different pixel sizes and would introduce differences in detection of the disc. Therefore, the 
CDMAM image is rescaled to a pixel size of 50 μm (see Section A8.5). 
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Figure A8.6:  Individual disc detection: (left) the disc search areas in each of the cell 
corners (purple outer circles) and the positions within each search area 
(blue inner circles) where the disc is most likely to be located (based on 
total pixel value); (right) close-up of the detection (blue inner circle) of a 
0.5 mm disc within a search area (purple outer circle) 
 
 

The average values of the pixels in the four locations are then compared to decide which corner is 
most likely to contain the gold disc by determining the corner with the highest (or lowest, in the case 
of pixel values decreasing with higher object density) pixel value. If the corner selected is the corner 
actually containing the disc, CDCOM has correctly detected the disc; otherwise, it failed to detect it. 
This process is repeated for the centre disc together with the 3 corners not containing a disc to obtain 
a second phantom image reading. 

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Appendix 9: Significance of test items 
The test items described in the digital section of the European protocol for the quality control of the 
physical and technical aspects of mammography screening in the fourth edition and in Part 1 of the 
supplement to the digital section can be divided into four categories: (1) essential test items, which 
must be measured; (2) desirable test items, which should be measured; (3) optional test items, which 
could be measured and (4) test items that have been omitted in the supplement. This last category 
consists of (a) test items that have been proven to be of low importance, (b) test items that are 
(indirectly) covered by other tests and (c) test items that are difficult to measure by individual 
physicists and are covered by the supplier/manufacturer when installing a system. 
Essential test items: 
2b.2.2.1.1 Response function/2b.2.2.1.2 Noise evaluation 
2b.2.1.3.3 AEC short-term reproducibility 
2b.2.1.3.4 AEC long-term reproducibility (weekly/daily QC) 
2b.2.1.3.5 AEC Breast thickness and composition compensation 
2b.2.2.3.1 Image receptor homogeneity  
2b.2.3  Dosimetry (requires 2b.2.1.2.2 Half value layer) 
2b.2.4.1 Threshold contrast visibility 
2b.2.4.5 Ghost image/erasure thoroughness 
 
Desirable test items: 
2b.2.1.2.1 Tube voltage 
2b.2.1.3.1 Exposure control steps (if applicable) 
2b.2.1.3.2 Back-up timer and security cut-off 
2b.2.1.3.6 Local dense area 
2b.2.1.4 Compression 
2b.2.2.2 Missed tissue at chest wall side 
2b.2.2.3.2 Detector element failure 
2b.2.2.4 Interplate sensitivity variations 
2b.2.4.3 Exposure time 
 
Optional test items: 
2b.2.1.1.3 Alignment of X-ray field/image area 
2b.2.1.1.5 Tube output 
2b.2.4.2 Modulation transfer function (MTF), noise power spectrum (NPS) and detective quantum 
efficiency (DQE) 
 
Omitted test items: 
2b.2.1.1.1 Focal spot size 
2b.2.1.1.2 Source-to-image distance 
2b.2.1.1.4 Radiation leakage 
2b.2.1.5.1 Grid system factor 
2b.2.1.5.2 Grid imaging 
2b.2.2.5 Influence of other sources of radiation 
2b.2.2.6 Fading of latent image 
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1 Introduction 
The protocol described in Part 2 of this supplement has been developed to test whether digital 
imaging systems of a given type or brand are fundamentally capable of fulfilling the acceptance 
criteria of the European protocol for the quality control of the physical and technical aspects of 
mammography screening (van Engen et al., 2006), which has been updated in Part 1 of this 
supplement (van Engen et al., 2013). The European type testing protocol takes into account the 
updates reported in Part 1 of this supplement and it provides guidelines for best practice in controlling 
dose and (clinical) image quality. Differences between the type testing protocol and the applicable 
standards and procedures for acceptance and constancy testing are also pointed out in this second 
part of the supplement. After a successful type test, individual mammography units of the same type 
or brand still need to undergo an acceptance test before clinical use. 
The European protocol for type testing is currently developed for digital mammography (DR and CR) 
systems. In the future, the protocol may be expanded to include type testing of image-processing 
algorithms, workstations and film digitizers. 
The authors welcome all comments and feedback on this document to improve the standards and 
protocols. Future updates of the current version will be made available on the web sites of the 
European Commission (http://ec.europa.eu/health/index_en.htm) and EUREF (www.euref.org). 
2 Type testing procedure 
2.1 Technical and clinical phases 
A type test encompasses two evaluation phases: technical evaluation and clinical evaluation. 
x Phase 1: Technical evaluation 
In the first phase, two full physico-technical evaluations are performed on different systems in dif-
ferent locations. The medical physics experts testing the equipment are appointed by the medical 
physics team of the unit conducting the type test. They must be highly experienced in physico-
technical quality control of mammography systems and in quality assurance of clinical aspects of 
breast cancer screening and diagnosis. The type test applicant (i.e. the manufacturer) must arrange in 
advance the locations and all logistic preparations with the unit conducting the type test. The systems 
must be available for the physico-technical evaluations for a period of at least 3 days. The physico-
technical tests are primarily based on the measurements specified in Chapter 2b of the fourth edition 
(van Engen et al., 2006) and the updates to that chapter (van Engen et al., 2013). However, some 
tests have been modified for type testing, and some additional tests that are described in Section 3.2 
must be performed. 
After all results of the technical evaluation are available, the medical physics team of the unit conduct-
ing the type test will meet to discuss the results and decide whether phase 2, the clinical evaluation, 
can be initiated. To prepare the decision, the results of the physico-technical evaluation are compiled 
in a report and comments on the findings in the report are requested from the applicant and from the 
medical physics team of the unit conducting the type test. The medical physics team will consider 
whether problems have been detected that would need to be solved in order to pass the test, and if 
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so, whether the applicant is likely to be able to respond effectively. If the team determines that a 
solution is unlikely, the type test may be aborted by either the medical physics team or the applicant. 
If the two physico-technical evaluations yield conflicting results, the medical physics team may decide 
that (some) tests must be repeated on a third system. 
For CR systems, the physico-technical tests must be performed on two X-ray units of different brands. 
The applicant should provide appropriate information on the set-up of the X-ray units for the appli-
cant’s CR system and ensure that the mammography units are set up correctly for the applicant’s CR 
plates at the sites of type testing. 
x Phase 2: Clinical evaluation 
After the technical evaluation phase is completed, the performance of the digital system is evaluated 
under clinical use for a period of at least 3 months at one of the sites at which the technical evaluation 
was performed. At this site, reading must be by soft copy and all workstations must pass the 
European protocol for viewing conditions. The site must also have sufficient workflow (i.e. similar to 
that used in European screening centres with an average of at least 50 clients or patients per system 
per day). The site is chosen by the applicant in cooperation with the unit conducting the type test. 
Before the clinical test is allowed to start, images of 50 patients must be sent to the unit conducting 
the test for pre-review to determine whether the configuration of the image processing requires opti-
mization. At the start of the clinical test, an application specialist of the manufacturer requesting the 
type test and a representative of the unit conducting the type test will be present at the clinical site 
for a period of at least 2 days to help start the clinical evaluation. 
During the first week of the clinical evaluation, experts of the unit conducting the evaluation perform 
an initial assessment of the images. If image quality is not satisfactory or if dose exceeds permissible 
levels, adjustments to the equipment must be made by the applicant. If image quality and/or dose 
levels remain unsatisfactory, the clinical evaluation may be aborted by the unit conducting the 
evaluation. Further adjustments during the period of clinical testing are only allowed after consultation 
with the unit conducting the evaluation. Some adjustments may require an additional technical 
evaluation. 
During the clinical evaluation period, a homogeneity image must be acquired every day in fully 
automatic mode to monitor the stability of the equipment. A record must be kept of all artefacts on 
clinical images and of all problems that occur with the equipment, by the radiographers/radiologists at 
the test site. At the end of the clinical evaluation period, a bad pixel map is obtained to determine the 
number of detector elements that became defective during the evaluation period. 
When problems occur, the medical physics group of the unit conducting the type test has the right to 
extend the clinical evaluation period as necessary or to abort the clinical evaluation. 
In addition to the stability test, a dose survey is conducted. For the dose survey, X-ray exposure data 
must be available, and the respective images must be available for verification. The mean glandular 
dose recorded in the DICOM header is compared with the values from the dose survey. 
At the end of the clinical testing period, a set of clinical images is evaluated by a team of experts 
consisting of two radiologists with substantial experience in digital mammography, who are invited by 
the unit conducting the type test, and one of the members of the unit’s medical physics team. The 
evaluated images consist of two groups: 50 patients or clients selected based on breast thickness, and 
20 cases randomly selected out of referred patients. If a system with more than one mode is 
evaluated, at least 30 images of each mode are required. 
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In the event that the evaluation team is unable to reach a firm conclusion about the adequacy of 
overall image quality using the above-mentioned clinical images, additional evaluation may be 
required, e.g. through insertion of simulated lesions in unprocessed images to assess image 
processing. 
2.2 Duration of a type test 
After the two technical evaluations are performed, the results of both systems will be discussed by the 
unit conducting the type test, and permission to start the clinical evaluation will be given, depending 
on the adequacy of the technical results. The duration of the clinical evaluation is at least 3 months. 
2.3 Final report 
After completion of the clinical evaluation, the unit conducting the type test prepares a final report; it 
includes the overall result of the type test and is sent to the applicant. If a system passes, the results 
will be published on the web site of the unit conducting the test. If a system fails, the results will not 
be published on the web site (see Section 2.5). 
2.4 Non-disclosure of confidential information 
Type tests might be performed on systems using techniques that are different from currently existing 
systems. For such systems, current methods of measurement might be unsuitable and adaptations 
may be necessary and new test items may need to be added that are not specified in the current 
version of the type testing protocol. The applicant must therefore provide the medical physics team of 
the unit conducting the type test with all relevant information on the system being tested. 
Relevant information includes: basic principles of the mammography system and particularly the 
image receptor, philosophy and operation of the AEC system, pre-exposure parameters, 
reconstruction technique of bad pixels, accepted number of bad pixels, etc. It is recommended that 
the unit conducting the type test consult the EUREF Physico-Technical Steering Group before initiating 
a type test, for advice on whether test items need to be adapted and/or new test items need to be 
added. If requested by the applicant, any relevant information provided can be regarded as 
confidential and a non-disclosure agreement can be signed with the parties involved. 
2.5 Publication of results 
The full report on the results of the type test will be made available to the applicant. If a system 
passes the type test, the results will be published on the web site of the unit conducting the type test. 
The applicant of the test will be able to comment on the report before publication on the web site. 
The unit conducting the type test will not use the information obtained from performing or reporting 
the results of the test in other publications without the consent of the test applicant. 
In consensus with the applicant, it may be mentioned on the web site of the unit performing the test 
whether a specific system is under (technical or clinical) evaluation. If a system fails, its name will be 
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removed from the list. It will not be mentioned on the web site that a specific system has failed the 
type test. 
3 Type testing protocol 
By definition, type testing is performed on new types of equipment. Therefore, type tests may be 
performed on systems that use techniques that are different from those of existing systems. For such 
systems, the current methods of measurement could be unsuitable and adaptations may be 
necessary. It is also possible that new, additional tests will be required. Therefore the medical physics 
team of the unit conducting the test must be provided by the system manufacturer with all relevant 
information on the system being type tested. If measurement techniques require adaptation, this 
must be communicated in advance to the applicant whenever possible by the unit conducting the test. 
If differences are noticed during type testing, adaptations of methods of measurement will be made 
on the spot and discussed afterwards. This discussion must take place before the second physico-
technical test is performed. 
It is recommended that the unit conducting the type test consult the EUREF Physico-Technical 
Steering Group before initiating a type test, for advice on whether test items need to be adapted 
and/or new test items need to be added. Prior contact also facilitates further communication in the 
event that ad hoc advice is requested during performance of measurements. 
Section 3.1 provides an overview of all technical tests performed in a European type test. Some 
additional clinical tests are described in Section 3.2. 
For CR systems, at least 4 cassettes of standard size (18 × 24 cm) and 4 cassettes of large size (24 × 
30 cm) should be available during the technical evaluation; at the site of the clinical evaluation, at 
least 8 cassettes should be available. If cassettes of large size are available, they may also be used at 
the clinical site. 
3.1 Technical evaluation protocol 
3.1.1 Relevant test items based on Chapter 2b of the fourth edition 
The following test items described in Chapter 2b of the fourth edition (van Engen et al., 2006) and in 
Part 1 of this supplement (van Engen et al., 2013) are measured in a European type test technical 
evaluation: 
2b.2.1.1.5 Tube output: Use the method described in Part 1 of this supplement. Do not use 
limiting values. 
2b.2.1.2 Tube voltage and beam quality 
2b.2.1.2.1 Tube voltage: Use the method described in Chapter 2b. 
2b.2.1.2.2 Half value layer: Use the method described in Part 1 of this supplement. 
2b.2.1.3 AEC system 
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2b.2.1.3.2 Back-up timer and security cut-off: Use the method and limiting values in 
Chapter 2b. 
2b.2.1.3.3 Short-term reproducibility: Use the method and limiting values in Part 1 of this 
supplement. 
2b.2.1.3.4 Long-term reproducibility: Use the method in Chapter 2b. Use the limiting values 
of Chapter 2b as action limits for further investigation. In the final report, present 
measurements on long-term stability from the clinical test period. 
2b.2.1.3.5 Breast thickness and composition compensation: Use the method and limiting 
values in Chapter 2b (see ‘Object thickness’) and in Part 1 of this supplement. 
2b.2.1.3.6 Local dense area: Use the method and limiting values in Part 1 of this supplement. 
2b.2.2 Image receptor 
2b.2.2.1 Image receptor response 
2b.2.2.1.1 Response function: Use the method and limiting values in Chapter 2b. 
2b.2.2.1.2 Noise evaluation: Use the method and limiting values in Part 1 of this supplement. 
2b.2.2.2 Missed tissue at chest wall side: Use the method and limiting values in Chapter 
2b. 
2b.2.2.3 Image receptor homogeneity and stability 
2b.2.2.3.1 Image receptor homogeneity: Use the method and limiting values in Chapter 2b 
and in Part 1 of this supplement. 
2b.2.2.3.2 Detector element failure (DR systems): Use the method and limiting values in 
Chapter 2b. The bad pixel map should be easily accessible for all users. If uncorrected 
bad pixels are visible on the images, this should be taken into account when evalu-
ating detector element failure. 
2b.2.2.3.3 Uncorrected defective detector elements (DR systems): Use the method and 
limiting values in Chapter 2b. 
2b.2.2.4 Interplate sensitivity variations (CR systems): Use the method and limiting 
values in Chapter 2b of the fourth edition and in Part 1 of this supplement. At least 4 
cassettes of each size should be present. 
2b.2.2.6 Fading of latent image (CR systems): Use the method in Chapter 2b. 
2b.2.3 Dosimetry: Use the method and limiting values in Chapter 2b and in Part 1 of this 
supplement. 
2b.2.4 Image quality 
2b.2.4.1 Threshold contrast visibility: Use the method and limiting values in Chapter 2b 
and in Part 1 of this supplement. 
Threshold contrast visibility is determined at several dose levels: the clinical glandular dose level and 
2–4 other dose levels, which will be chosen such that a large range of dose levels is covered (e.g. 
between ½ and 2 times the clinical dose level). 
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For details of 0.1, 0.25, 0.5 and 1.0 mm diameter, threshold contrast is plotted against glandular 
dose. The dose is calculated at which the minimum acceptable image quality standard, and the 
achievable image quality standard, is obtained for the 0.1, 0.25, 0.5 and 1.0 mm diameter objects on 
the contrast threshold visibility phantom. 
2b.2.4.2 Modulation transfer function (MTF), noise power spectrum (NPS) and 
detective quantum efficiency (DQE): Use the method described in Appendix 7 of 
Part 1 of this supplement. 
2b.2.4.3 Exposure time: Use the method and limiting values in Chapter 2b. 
2b.2.4.4 Geometrical distortion and artefact evaluation: Use the method and limiting 
values in Chapter 2b. 
2b.2.4.5 Ghost image/erasure thoroughness: Use the method and limiting values in 
Chapter 2b. 
3.1.2 Thickness indication 
European type testing includes a clinical evaluation (see Section 3.2). In the clinical evaluation, a dose 
survey is conducted that requires prior checking of the indicator of the height of the compression 
paddle. 
Two foam blocks with compressed thickness of about 20 mm and 40 mm are used for this 
measurement. A strip is cut out of the foam block to allow measurement of thickness during 
compression (see Figure 2.1). Thickness indication can be checked when the foam blocks (180 mm × 
240 mm) are placed on the bucky. Position the blocks such that half of the block is positioned on the 
bucky and half of the block is positioned over the edge of the bucky at the chest wall side (see 
Figure 2.1). Apply compression (approximately 100 N), record the thickness indication and measure 
thickness at the reference point with an appropriate device (e.g. a calliper). Perform this 
measurement for the two foam blocks separately and together (so that measurements can be done at 
about 20, 40 and 60 mm compressed thickness). 
Figure 2.1: Thickness indication check 
 
          foam block 
 
 
3.2 Clinical evaluation protocol 
3.2.1 Introduction 
The imaging chain consists of several components, beginning with a patient or client who is being X-
rayed and extending to the radiologist who is reading and reporting the images. During physico-
technical evaluation, each component is checked separately. The clinical part of the European type 
testing protocol is essentially a global test. The quality of clinical images is affected interdependently 
by all components, including the image processing, which is not evaluated technically. The clinical part 
of the protocol therefore cannot be conducted separately; it must be performed on a system that has 
passed the technical evaluation. 
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The clinical evaluation includes an assessment of the image quality by a team of experts including 
radiologists, a stability test and a clinical dose evaluation. The required duration of the clinical 
evaluation is 3 months, but if problems occur, the unit conducting the clinical evaluation may decide 
to extend the period accordingly or to abort the evaluation. 
The site at which the clinical images are obtained will be mutually decided by the unit conducting the 
clinical evaluation and the applicant. It must be one of the two sites at which the preceding technical 
evaluation was performed. It must have a sufficient workflow of 4 images per patient/client, and soft-
copy reading is required. The clinical images will be sent to and scored by the unit conducting the 
clinical evaluation. The workstations used to evaluate the images must pass the European guidelines 
quality criteria. If an applicant prefers that the images be scored on the applicant’s own workstation, 
the workstation must be provided to the unit conducting the evaluation. Before use, the applicant’s 
workstation will be checked to verify that it passes the European guidelines quality criteria. 
3.2.2 Procedure for acquiring the images 
The clinical evaluation will be performed for a minimum of 3 months. Before the evaluation can start, 
anonymized images of 50 patients must be sent to the unit conducting the clinical evaluation for pre-
review to determine whether the configuration of the image processing requires optimization. At the 
beginning of the clinical evaluation, a representative of the unit conducting the evaluation will be 
present at the clinical test site, together with a specialist of the applicant. The unit conducting the 
evaluation will install a hard disk onto which all images from the clinical test period will be copied. The 
DICOM headers of all images must be correctly filled in, but all patient or client data on the hard disk 
must be anonymized. Any image quality issues that may occur at the clinical test site, such as 
artefacts, must be recorded and reported to the unit conducting the evaluation. 
3.2.3 Procedure for scoring the images 
The images of 70 selected women will all be scored by a reading team consisting of radiologists and a 
physicist who have experience in digital mammography and in the assessment of image quality. These 
70 cases will be selected from the images collected during the clinical test period as follows. First, the 
information on the DICOM headers is used to calculate the doses of all women who received a 
mammogram during the clinical test period. The data are also used to plot the mean glandular dose 
as a function of compressed breast thickness. This permits both determination of the dose distribution 
of clinical images and systematic selection of the cases to be scored by the reading team (all 
thicknesses, all types of tissues). The images are divided into 5 classes based on compressed breast 
thickness. In each thickness class, patients are ranked as a function of their dose; 10 patients are 
then selected in ranked series from each of the 5 classes using the image at the 10th percentile of the 
dose distribution, the image at the 20th percentile, the image at the 30th percentile, etc. A total of 50 
cases are chosen in this manner. The other 20 cases are randomly selected from referred patients; 
the respective images must include opacities and microcalcifications. 
Reading for image scoring is performed simultaneously by two radiologists and a physicist. A third 
radiologist with substantial experience in digital mammography and evaluating image quality is 
appointed in case of image quality problems. This could be either a radiologist from the unit 
conducting the clinical evaluation or an external radiologist. 
3.2.4 The scoring form 
The scoring form is based on experience with type testing in the Belgian and Dutch breast screening 
programmes (Van Ongeval et al., 2005; Van Ongeval et al., 2008). The first part (13 questions) 
requires ‘yes’ or ‘no’ answers from the panel of experts; it includes questions about anatomical 
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structures, noise, and contrast in low and high pixel value areas. In the second part (4 questions), the 
panel of experts scores the contrast and sharpness of the images on a scale between –2 and +2. In 
the third part (3 questions), the panel of experts rates the images on a scale from 1 to 10 according 
to certain characteristics and their potential impact on the interpretation of the image. The scoring is 
performed at the workstation where the reading team views the images. 
3.2.5 Procedure for evaluating the data 
The unit conducting the type test should have software for data entry during evaluation and analysis, 
including comparison with results of previous testing of other types. Ideally, the program should 
display the images and the score could be entered directly for the respective image. The software can 
be used to generate the median score for each question and also the number of ‘yes’ or ‘no’ answers 
for each question. The results are compared with other systems; any significantly lower value on a 
question for a system will be investigated in detail in collaboration with the third radiologist. 
  Dose evaluation 3.2.5.1
A dose survey is conducted during the clinical evaluation period; this requires access to the relevant X-
ray exposure data and breast thickness data, which must be available in the image header. The mean 
glandular dose is compared with calculated values. When testing CR systems, the applicant should 
ensure that the mammography unit and reader are connected to fill in the DICOM header with the 
exposure values, breast thickness and dose indicator. 
  Stability test 3.2.5.2
During the clinical evaluation period, an image of a 45 mm homogeneous block of PMMA covering the 
whole image receptor must be acquired every day in fully automatic mode to monitor the stability of 
the equipment. A record must be kept of all artefacts on clinical images and of all problems that were 
noticed by the radiographers/radiologists at the test site. At the beginning and at the end of the 
clinical evaluation period, a bad pixel map may be obtained to determine the number of detector 
elements that became defective during this test period. These QC images and records will be sent to 
the unit conducting the type testing for evaluation. 
  Additional comments 3.2.5.3
Comments about potential special features, ergonomics and other relevant characteristics or 
conditions that may affect the results will be noted by the representative of the unit conducting the 
evaluation, who will be present at the start of the clinical evaluation period. In addition, comments 
may also be requested from the radiologists and radiographers at the clinical evaluation site. 
3.2.6 Requirements for the set-up at the clinical test site 
The software set-up at the clinical test sites is shown in Figure 2.2: 
1. All image data (both clinical and technical) are sent in parallel to the Picture Archiving and 
Communication System (PACS) normally used at the site and also to a local, dedicated DICOM 
Service Class Provider (SCP). To enable this, the vendor must configure a DICOM output node at 
the mammography unit. 
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2. A software package (e.g. Gladys) (Jacobs et al., 2006) is installed on a local computer. This is a 
DICOM SCP that can be scripted to perform specific actions based on the values of the DICOM 
headers. All data are stored on an external hard drive, provided by the unit conducting the 
evaluation. In the paragraphs below, the requirements for Gladys are used as an example. Other 
software packages with similar functionality are also allowed. The requirements for these other 
packages may differ. 
 
Requirements: 
a. A computer that is connected to the mammography unit via the network 
b. A free USB 2.0 port 
c. A fixed IP address 
d. An administrator access to this computer to install the software package as a Windows 
service. 
 
Figure 2.2:  Software set-up at clinical test site 
 
 
 
 
3. For the stability test, the homogeneous images (only ‘for processing’ images) are stored by Gladys 
on the external hard drive. The technical analysis is performed in a QC reference centre. To 
distinguish between patient data and the homogeneity data, the patient name (‘QCMAMMO’) is 
taken by convention and action is undertaken by Gladys based on this patient name. 
4. All clinical images (both ‘for presentation’ and ‘for processing’ images) are also sent to Gladys. 
Using a one-way hash algorithm, these image data are anonymized and stored on the external 
hard drive in a specific folder structure. The DICOM headers that need to be anonymized can be 
different at each clinical test site, and Gladys can therefore be configured. This action will be 
performed on all data with a patient name that is different from ‘QCMAMMO’. 
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5. For the collection of patient dosimetry data, a second copy of the anonymized patient data (only 
‘for presentation’ images) is stored without any image information. These DICOM files are used by 
the unit conducting the evaluation to simplify the patient dosimetry study. 
6. For the collection of the selected 20 referred cases, local radiologists are asked to note down the 
unique identifiers of at least 20 possible cases. They must include opacities and microcalcifica-
tions. To preserve confidentiality, the unique identifiers of the selected clinical cases must be 
anonymized at the clinical test site. For this purpose, the identifiers are saved as a text file in a 
format similar to that shown in Figure 2.3a. Gladys converts this text file using the same one-way 
hash algorithm as in (4). An example output file can be seen in Figure 2.3b. These steps assure 
that no client/patient-related information leaves the clinical test site. This procedure is performed 
by a representative of the unit conducting the evaluation. 
 
Figure 2.3a:  Example input format for selected patient cases 
 
 
 
 
 
 
Figure 2.3b: Example output format for selected patient cases 
 
 
 
3.2.7 Set-up at the reference site 
The set-up at the reference site of the unit conducting the evaluation is shown in Figure 2.4: 
1. All data are transferred from the clinical test site to the reference site using the external hard disk 
provided by the unit conducting the evaluation. 
2. The homogeneous acquisitions are evaluated for artefacts, and the stability over time of the 
mammography unit is monitored. 
3. The DICOM headers without the image data are scanned for dosimetry-related DICOM data. 
These header values are used to calculate the patient dose using the method of Dance (Dance, 
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1990; Dance et al., 2000; Dance et al., 2009; Dance et al., 2011). Calculated values are compared 
with the current European guidelines levels. 
4. The clinical image quality is evaluated using a dedicated software platform to perform observer 
studies by means of a visual grading analysis following the clinical evaluation form, which can be 
found at the end of this document (Section 3.2.8) (Jacobs et al., 2008). This task must be 
performed in a controlled environment using DICOM-calibrated viewing stations. If the applicant 
prefers to use a different workstation, that must be mutually agreed with a representative of the 
unit conducting the evaluation before the clinical evaluation period. 
 
 
Figure 2.4:  Software set-up at reference site 
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3.2.8 Clinical evaluation form for European type testing 
 
Client 
number 
 
 
 
Please answer the following questions with ‘yes’ or ‘no’ (or N/A): 
 
 Yes No N/A 
1 Is the skin line visualized well? 
   
2 Are the vascular structures visible through the dense parenchyma? 
   
3 Is the pectoral muscle visualized sharply? 
   
4 Are the Cooper’s ligaments and vascular structures in the subcutaneous and pre-pectoral area visualized well? 
   
5 Are the microcalcifications well visualized and well outlined? 
   
6 Is the contrast in the dark areas sufficient (e.g. no saturation of intensity of signals, no fully dark regions)? 
   
7 Is the contrast in the white areas sufficient (e.g. no fully white regions)? 
   
8 Is the glandular tissue sufficiently white? 
   
9 Is the background sufficiently dark? 
   
10 Do all images appear in the same way? (if not, please comment) 
   
11 Is there disturbing noise in the dark areas? 
   
12 Is there disturbing noise in the white areas? 
   
13 Are there any artefacts? 
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For the following questions, please grade the images with a number from –2 (bad) to +2 (good). 
Please use the whole range. 
 –2 –1 0 1 2 
1 Contrast in the white regions      
2 Contrast in the dark regions      
3 Overall contrast       
4 Sharpness       
 
For the following questions, please rate the images with a number from 1 (bad) to 10 (good). Please 
use the whole range. 
 1 2 3 4 5 6 7 8 9 10 
5 How satisfied are you with the representation of micro- calcifications?           
6 How satisfied are you with the representation of opacities?           
7 How satisfied are you with the representation of the image?           
 
Remarks: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you very much for providing this assessment. 
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1 Introduction 
The present supplement deals with several topics in the quality assurance of pathology in breast 
cancer screening and diagnosis in which problems and practical solutions as well as new techniques 
and other advances have emerged in recent years. The authors felt that these topics warranted 
urgent attention pending a full revision of the pathology chapter. They include the classification of 
early forms of neoplastic changes in the breast and the differential diagnosis of columnar cell lesions 
(CCLs), atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS). Other sections provide 
an update on the classification of invasive carcinoma and on the diagnosis and differential diagnosis of 
microinvasive carcinoma. Special attention is paid to the assessment of the axilla, and the updated 
guidance on axillary dissection and preoperative staging takes into account problems and pitfalls as 
well as the most recent revision of the TNM system (Sobin et al., 2009). The supplement also includes 
comprehensive practical recommendations on examination techniques and interpretation of sentinel 
node biopsy specimens. Best practice in the use of frozen sections, an update on vacuum-assisted 
needle core biopsy (VANCB) and recommendations on pathological reporting of post-chemotherapy 
specimens are also provided. 
The supplement has been prepared by the European Working Group on Breast Screening Pathology, 
which also prepared the chapter on pathology in the fourth edition (Wells et al., 2006) and in previous 
editions of the guidelines. The group consists of 38 breast pathologists in 23 EU Member States, 
Switzerland and Turkey and has been led by the editor of the chapter on pathology in the guidelines. 
The recommendations in the supplement have been drafted by selected members of the group and 
have been discussed and agreed upon at twice-yearly meetings held in Hungary, Switzerland, Italy, 
France, the Netherlands and Finland since the fourth edition was published. 
2 Columnar cell lesions and atypical ductal 
hyperplasia 
2.1 Background 
In recent years there has been a growing interest and awareness of epithelium having a columnar 
morphology within breast biopsies. One of the common accompaniments of this change is the 
presence of secretions within lumina, which are often distinctly eosinophilic and associated with micro-
calcifications (Fraser et al., 1998). These microcalcifications are detectable by mammography, and 
consequently more of these lesions are being detected with the introduction and expansion of breast 
screening programmes, especially since the implementation of digital mammography (Feeley & Quinn, 
2008; Verschuur-Maes et al., 2011a). 
Diverse terminology has been used for this epithelium, e.g. columnar cell lesions (CCLs) (Schnitt & 
Vincent-Salomon, 2003), flat epithelial atypia (FEA) (Tavassoli & Devilee, 2003), columnar cell 
alteration with apical snouts and secretions (CAPSS) (Fraser et al., 1998), enlarged lobular units with 
columnar alteration (McLaren et al., 2005), atypical cystic lobules (Oyama et al., 1999), ductal 
intraepithelial neoplasia flat type (Tavassoli, 1998), atypical cystic ducts (Kusama et al., 2000) and 
clinging carcinoma (Azzopardi et al., 1979). This diverse terminology, the increased detection of this 
lesion at screening and the uncertainties about its biology continue to cause concern among both 
diagnostic breast pathologists and their clinical colleagues in the breast care team. In this supplement, 
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we present a proposal for a simplified terminology for lesions with columnar epithelium and 
histological criteria for recognizing these (Walker et al., 2010). These proposals are not carved in 
stone and are likely to change as more knowledge is acquired about the pathobiology of these lesions 
and their natural course. 
2.2 Terminology 
In general, CCLs are characterised by enlarged terminal duct/lobular units (TDLUs) lined with 
“columnar” epithelium, meaning tall cells with eosinophilic cytoplasm and small cytoplasmic snouts 
protruding into the lumina. Intracytoplasmic vacuoles (like those in lobular neoplasia) are regularly 
seen. Usually, the nuclei are located basally within the cell, adjacent to the myoepithelium. Often, 
there is microcalcification in the lumina, and there may be extensive mucin production, which may 
even rupture into the stroma, producing a mucocoele-like lesion (Verschuur-Maes & Van Diest, 2011). 
Necrosis is extremely rare. 
These lesions comprise a spectrum from the earliest columnar changes in otherwise almost-normal 
acinar epithelium to low-grade ductal carcinoma in situ (DCIS). Further, there may be a cross-over to 
lobular neoplasia, usual ductal hyperplasia and apocrine lesions. 
Different classifications have been proposed for CCLs. The simplest classification and probably the 
most reproducible system for “pure” CCLs has been proposed by Schnitt et al. (Schnitt & Vincent-
Salomon, 2003). This system discerns 4 groups of CCLs: columnar cell change (CCC), columnar cell 
hyperplasia, CCC with atypia and columnar cell hyperplasia with atypia. The morphology of those with 
atypia corresponds to FEA, as detailed in the latest WHO classification, and corresponds to ductal 
intraepithelial neoplasia 1a (DIN1a) (Tavassoli & Devilee, 2003). Sometimes CCLs may co-exist with 
lobular neoplasia. 
2.3 Classification of columnar cell lesions (CCLs) 
2.3.1 Columnar cell change (CCC) 
Classic CCC consists of lobular acini, usually enlarged and lined by epithelial cells that are tall and 
snouted in a manner similar to that observed in tubular carcinoma. The cytoplasm is eosinophilic, and 
often there are luminal secretions and/or microcalcifications. There is morphological diversity within 
these groups. For example, the hyperchromasia of the nuclei can vary, as well as the nuclear shape 
and the “tallness” of the cells. In some cases, therefore, some cells are more cuboidal than columnar. 
The nuclei are regular and show no atypia and only small or no nucleoli. Mitoses are very rare, as is 
apoptosis. 
2.3.2 Columnar cell hyperplasia 
These lesions are like CCC, except that there is now a piling up of > 2 layers of epithelium, assuming 
that the stratification is real, as opposed to artefactual as a consequence of cross-cutting. This multi-
layered epithelium may be flat or “hilly”. There should be no complex cribriform architecture or 
micropapillary structures without stroma, as these favour a diagnosis of atypical ductal hyperplasia 
(ADH) or low-grade DCIS. 
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2.3.3 Columnar cell change with atypia 
These lesions are like CCC, except that there is now “atypia”. Atypia may manifest in different ways. 
There may be relatively uniform rounded, evenly spaced nuclei with a similar cytomorphology to that 
displayed by the cells of low-grade DCIS and some intermediate-grade DCIS with larger, more 
irregular nuclei and/or nuclei with clear nucleoli. Here, polarisation of the cells is usually lost and the 
nuclei are often more centrally placed. Alternatively, there may be disturbance of the regular nuclear 
arrangement and/or mild to moderate nuclear atypia as reflected by larger, more irregular nuclei 
and/or nuclei with clear nucleoli. Mitoses are still very rare. Marked nuclear atypia favours a diagnosis 
of high-grade DCIS (e.g. cancerisation of lobules). 
2.3.4 Columnar cell hyperplasia with atypia 
These lesions are like columnar cell hyperplasia without complex architecture, except that there is now 
“atypia”. As above, there may be relatively uniform rounded, evenly spaced nuclei with a similar 
cytomorphology to that displayed by the cells of low-grade DCIS and some intermediate-grade DCIS 
with larger, more irregular nuclei and/or nuclei with clear nucleoli. Polarisation of the cells is, again 
usually lost and the nuclei are often more centrally placed. Again, there may be disturbance of the 
regular nuclear arrangement and/or mild to moderate nuclear atypia with larger, more irregular nuclei 
and/or nuclei with clear nucleoli. Mitoses are still very rare. Marked nuclear atypia favours a diagnosis 
of high-grade DCIS (e.g. cancerisation of lobules). 
2.4 Differential diagnosis 
2.4.1 Atypical ductal hyperplasia/low-grade ductal carcinoma in situ (DCIS) 
By definition, CCLs do not have a complex architecture. If micropapillary or cribriform structures are 
seen, a diagnosis of ADH or low-grade DCIS should be considered, depending on the size of the lesion 
and how extensive the architectural complexity and regularity are. In practice, CCLs are often seen 
merging with the more elaborate architecture of ADH and DCIS, demonstrating the close relationship 
of atypical CCLs to these lesions. ADH and low-grade DCIS may well derive from CCLs. (See Table 1) 
2.4.2 Ductal carcinoma in situ (DCIS) 
Where flat proliferative epithelium within a TDLU has high cytonuclear grade nuclei (usually 
accompanied by more apoptosis and mitosis), the lesion should be categorised as high-grade DCIS. 
2.4.3 Apocrine change 
Apocrine epithelium shares with CCC the presence of apical snouts and, sometimes, associated 
secretions. However, the cytoplasm of apocrine cells is typically copious, granular and more pink than 
the eosinophilic appearance of CCLs. Further, unlike in most columnar cells, nucleoli are readily seen. 
Apocrine cells are usually androgen receptor (AR) positive but oestrogen receptor (ER) and 
progesterone receptor (PR) negative. 
2.4.4 Lactational change 
Another lesion that may be mistaken for atypical CCL is focal lactational change, which may appear 
both single-layered and mildly cytologically atypical with enlarged hyperchromatic nuclei. Typically, the 
epithelial cells are “hobnail”, or more cuboidal than tall, and the foamy appearance of the cytoplasm 
produced by finely divided lipid should alert the pathologist to this diagnosis. 
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2.5 Immunohistochemistry 
In CCLs, there is extensive, and uniform, positivity of the nuclei for ER and PR in all lesional cells 
(Oyama et al., 1999; Allred & Mohsin, 2000; Vincent-Salomon, 2003; Tremblay et al., 2005). Most 
cells stain positively for keratin 19 (Oyama et al., 1999) and osteoprotegerin (Van Poznak et al., 
2006), and a high proportion are positive with cyclin D1 (Oyama et al., 1999). CCLs do not express 
basal markers such as CK5/6 and CK14 (Otterbach et al., 2000) and are not uniformly positive for AR. 
p53 accumulation is lacking (Simpson et al., 2005). The utility of GCDFP15 (BRST2) to discriminate 
CCLs from apocrine change where it is extensively expressed has yet to be documented in the 
literature. High-grade DCIS with a flat morphology is positive for HER2, unlike CCC, which is uniformly 
negative for HER2 (Simpson et al., 2005). 
2.6 Genetic aberrations 
There is increasing evidence that there is progressive chromosomal damage in CCLs (with atypia) 
through to DCIS and invasive carcinoma, implying a molecular continuum from some lesions with a 
columnar morphology. This is not the case for ADH and carcinoma. Most importantly, in different 
studies a high concordance level of the genetic abnormalities was seen in CCLs with atypia as well as 
in the accompanying infiltrating and in situ components. With comparative genomic hybridisation, 
chromosomal abnormalities were identified with loss on 16q, 17p and X and gain on 15q, 16p and 19 
(Simpson et al., 2005). Recently, with use of loss of heterozygosity (LOH), allelic losses were identified 
in CCL with atypia, low-grade DCIS and tubular carcinoma on the long arm of chromosome 16, as well 
as at chromosomes 8p21, 3p14, 1p36 and 11q14 (Aulmann et al., 2009). In another study, LOH at 
chromosomal loci 11q21-23.2, 16q23.1-24.2 and 3p14.2 was present in 50%, 45% and 41% of cases, 
respectively (Moinfar et al., 2000). Dabbs et al. have similarly shown progressive accumulation of 
allelic damage at 9q, 10q, 17p and 17q with increasing severity of the lesion (Dabbs et al., 2006). 
This makes it very likely that CCLs are among the earliest forms of neoplastic change in the breast. 
Therefore, CCLs need to be seen as clonal and neoplastic proliferations, in which different 
chromosomes play a role, with loss on chromosome 16q seeming to be the most important. 
2.7 Significance of columnar cell lesions 
The overall biological significance of CCLs is not yet fully understood (Tremblay et al., 2005). There is 
supporting evidence for a precursor role within the spectrum of the low nuclear grade family of breast 
cancers (Abdel-Fatah et al., 2008). This includes an association with tubular carcinoma (Goldstein & 
O'Malley, 1997; Rosen, 1999; Aulmann et al., 2009) and the findings that these lesions are more 
commonly present in cancerous breasts than in non-cancerous breasts (Wellings et al., 1975), are 
often continuous with cancerous lesions (Kusama et al., 2000), commonly co-exist with lobular in situ 
neoplasia (Brogi et al., 2001) and share similar cytological characteristics and immunohistochemical 
profile and genetics with co-existent malignancies (Oyama et al., 1999; Moinfar et al., 2000; Tavassoli 
& Devilee, 2003; Simpson et al., 2005; Dabbs et al., 2006). 
Despite the above, the certainty and speed of progression of these lesions to malignancy is not well 
known. A follow-up study performed by Boulos et al. showed a relative risk of 1.47 of developing 
invasive carcinoma after a needle core biopsy showing CCL (with or without atypia) (Boulos et al., 
2008). The study had a follow-up interval of 17 years, and 1154 CCLs were included. Shaaban et al. 
described that 8 cases of CCL with atypia had a relative risk of 2.32 of developing subsequent invasive 
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carcinoma, compared with 11 controls with CCL without atypia, who did not develop cancer in the 
follow-up period (Shaaban et al., 2002). Verschuur-Maes et al. reported an 8-year progression risk for 
CCL with atypia and ADH emerging in CCL of about 20% (Verschuur-Maes et al., 2011b). However, 
other studies did not find evidence of the increased risk of breast cancer. Eusebi et al. discovered only 
1 recurrence of the 25 CCLs with atypia (in their study, called low-grade clinging carcinoma of flat 
type) after 3 years, with a follow-up interval of 19 years (Eusebi et al., 1994). Bijker et al. and De 
Mascarel et al. also found no invasive carcinoma or DCIS in 59 and 84 CCLs with atypia, respectively, 
with a mean follow-up of 5.4 and 13.3 years, respectively (Bijker et al., 2001; de Mascarel et al., 
2007). 
It is worth noting that McLaren et al. found that patients with ER negative CCLs were at increased risk 
of malignancy compared with those whose lesions were ER positive (McLaren et al., 2005), but as yet 
there are no confirmatory studies. 
Table 1: Characteristics of columnar cell lesions and ADH/DCIS 
 
   * If the cells display marked pleomorphism, then the lesion does not fall within the spectrum of CCLs but should 
be regarded as high-grade DCIS. 
 ** Also referred to as flat epithelial atypia (FEA). 
  
Diagnosis 
 
Feature Columnar cell 
change 
Columnar cell 
hyperplasia 
Columnar cell lesion 
with atypia ** 
ADH/DCIS 
Topography TDLU, acini may be 
mildly dilated or of 
normal size 
TDLU, acini may 
be mildly dilated or 
of normal size 
TDLU, often microcystically 
dilated acini 
TDLU +/– adjacent ducts 
Shape of acinar 
spaces 
Irregularly shaped 
luminal margin 
Irregularly shaped 
luminal margin 
Often rounded acinar 
spaces, with smooth inner 
margin 
Often rounded acini, but 
with complex structures 
extending into lumen (see 
Architecture, below) 
Architecture Flat Tufts and mounds Flat or tufted/mounds, not 
complex 
Complex with micropapillary 
or cribriform structures 
Stratification/ 
multi-layering 
Not present Present May be present May be present 
Luminal 
secretions often 
with micro-
calcifications 
Present Present Present May be present 
Nuclear size Small to medium Small to medium Small to medium Small to medium 
Nuclear shape Oval, elongated Oval, elongated Often, but not always, 
rounded 
Rounded 
Nuclear texture Bland Bland Speckled chromatin pattern 
may be present 
Speckled chromatin pattern 
is common 
Pleomorphism* Uniform Uniform Uniform to moderately 
pleomorphic 
Uniform 
Position of 
nuclei within cell 
Basally placed Basally placed Often central Central 
Nucleoli Not conspicuous Not conspicuous Evident May be evident 
Mitoses Generally absent Generally absent Generally scarce Generally scarce 
Extent May be focal or 
extensive 
May be focal or 
extensive 
May be a focal area within 
background of non-atypical 
CCL 
May be focal area within 
background of non-atypical 
CCL; by definition, ADH is 
small/microfocal 
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2.8 Reproducibility of current classification of columnar cell 
lesions 
The reproducibility of the diagnosis of CCLs varies in the published literature. One study looking at the 
assessment of images by a mixed group of assessors showed poor agreement (Tan et al., 2005). 
Another demonstrated “excellent agreement” for a specified task within the CCL group after a 
PowerPoint-directed training session undertaken by a group of pathologists with an interest in breast 
pathology (O'Malley et al., 2006). Agreement was slightly better for determining the absence of CCLs 
with atypia (in their study, called FEA) (92.8%; 95% CI, 84.1–97.4%) than for determining its 
presence (90.4%; 95% CI, 79.9–96.7%). O’Malley et al. concluded that the diagnosis of CCLs with 
atypia and its distinction from those without atypia was highly reproducible if the available diagnostic 
criteria were adhered to. This simplified classification in the study of O’Malley et al. forms the basis of 
the recommendations presented here. 
Issues of poor reproducibility can confound diagnosis and lead to inconsistent patient care. This is 
more likely when complex and diverse terminology with possible different interpretations exists. This is 
nowhere more apparent than in the case of lesions with columnar epithelial morphology and is the 
strongest argument for the simplified classification of these lesions presented here. 
2.9 Clinical management of columnar cell lesions in needle core 
biopsies 
Core biopsies bearing CCLs are typically sampled for the histological assessment of mammographic 
microcalcification. As with similar specimens, these should be examined at multiple (at least 3) levels. 
If CCC or columnar cell hyperplasia only is found, without atypia, the lesions should be regarded as 
benign, requiring only follow-up. Core biopsies with CCLs without atypia should be classified in the B2 
category. 
CCLs with atypia (whether CCC or columnar cell hyperplasia) should be regarded as of uncertain 
malignant potential, with a risk similar to ADH and atypical lobular hyperplasia. Atypical CCLs are 
associated with more advanced lesions in subsequent excisional biopsy more frequently than are 
those without atypia. (Guerra-Wallace et al., 2004; David et al., 2006; Kunju & Kleer, 2007; Martel et 
al., 2007; Chivukula et al., 2009; Senetta et al., 2009; Ingegnoli et al., 2010; Verschuur-Maes et al., 
2011a). As for all such screen-detected lesions, multidisciplinary discussion should be undertaken to 
correlate radiological, clinical and histopathological findings to decide on surgical excision biopsy, 
vacuum-assisted biopsy or a wait-and-see policy. A recent systematic review concluded that, on the 
basis of the (in situ) carcinoma underestimation rates of patients with a core diagnosis of CCL with 
atypia and ADH associated with CCL, surgical excision should be considered (Verschuur-Maes et al., 
2012). Core biopsies with CCLs with atypia should be classified in the B3 category. 
2.10 Columnar cell lesions in surgical excision specimens 
Thorough sampling and histological examination of surgical specimens bearing CCLs with atypia 
should be performed to search for more established neoplasia like ADH, DCIS, lobular neoplasia or 
even invasion. In association with some DCIS and/or invasive carcinoma, CCLs with atypia may be 
present and may be extensive and/or may extend to the margins of the specimen. This is particularly 
problematic for lesions that are well recognised to be associated with CCL with atypia, such as tubular 
carcinoma (Rosen, 1999). There is a very limited evidence base for guidance with regard to re-
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excision or radiotherapy, but at present it is recommended that whole tumour size (DCIS plus invasive 
carcinoma) and margin status should include only those areas regarded as established DCIS or 
invasive tumour using conventional criteria. It should be recognised that these lesions have a very low 
risk of development of life-threatening disease. 
2.11 Atypical ductal hyperplasia (ADH) 
The distinction between low-grade DCIS and ADH is based on evidence derived from many series, 
including studies by David Page and co-workers (Page & Dupont, 1993). These have been supported 
by other studies, such as the Nurses’ Health Study (Connolly & Schnitt, 1993; Marshall et al., 1997). 
The significance of the diagnosis of ADH lies in the increased risk of invasive breast carcinoma, which 
is about 4–5 times that of the general population (Page et al., 1985; Ma & Boyd, 1992; London et al., 
1992; Dupont et al., 1993; Page & Jensen, 1994) and may be even greater for pre-menopausal 
women (approaching 6 times increased risk) (London et al., 1992). This risk is further increased if the 
patient has a first-degree relative with breast cancer (10 times increased risk) (Page et al., 1985; 
Tavassoli & Norris, 1990; Page & Dupont, 1992). 
The diagnostic criteria used to define ADH are imperfect. ADH was described initially based on 
exclusion rather than positive criteria, i.e. the recognition of some but not all of the features of DCIS 
(as well as the lack of the characteristics of usual type epithelial hyperplasia) (Page et al., 1985). This 
definition of ADH has been updated and, while the diagnosis still rests on an absence of all the 
features of DCIS, additional supporting features have been described (Page & Rogers, 1992; National 
Coordinating Group for Breast Screening Pathology, 1995). Page’s view that the cellular changes of 
DCIS are present but occupy < 2 separate duct spaces is widely accepted. Others use a 2 mm cut-off; 
a lesion < 2 mm in maximum dimension is classified as ADH and a larger lesion as DCIS (Tavassoli, 
1992). Others mention the involvement of a single TDLU. These criteria recognise essentially the same 
lesions. In essence, ADH is usually small and focal, measuring < 2–3 mm in maximum dimension. 
Larger foci are accepted as ADH if associated with a radial scar/complex sclerosing lesion or a 
papilloma. 
There are three components to the diagnosis of ADH: the architectural pattern, cytology and disease 
extent. Because disease extent cannot be optimally assessed in core biopsy samples, the diagnosis of 
ADH cannot be made from core biopsy specimens, and the term “atypical intraepithelial proliferation 
of ductal type” is used in this setting (see the appropriate section in the fourth edition). ADH is formed 
from a uniform population of small or medium-sized round, cuboidal or polygonal hyperchromatic 
cells, which are regularly arranged. The nuclei are evenly distributed and may form a rosette-like 
pattern. Single small nucleoli only are present. Mitoses, particularly abnormal forms, are infrequently 
seen. Geometric spaces are noted and, in the cribriform type, the cells are arranged at right angles to 
the bridges formed. Micropapillary ADH is also recognised, and a solid pattern may very rarely be 
seen. Small foci of necrosis may rarely be identified in ADH and do not indicate that the process 
should be classified as DCIS. 
At present, it is recommended that the diagnosis of ADH should be restricted to lesions that show the 
features described by Page et al. (Page et al., 1985; Page & Rogers, 1992), to which the quantified 
risk of developing breast carcinoma is linked. Even then, the diagnosis of ADH should be made with 
caution and only if low-grade DCIS has been seriously considered in the differential diagnosis. Lesser 
changes for which the possible classification lies between florid usual type hyperplasia (UEH) and ADH 
are less relevant with regard to a risk of developing breast carcinoma and should not be classified as 
ADH. However, it should also always be borne in mind that a proliferation at the edge of a biopsy may 
represent the periphery of a more established lesion of DCIS and further excision of the adjacent 
tissue may be warranted. 
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3 Acceptable use of frozen sections 
3.1 Palpable breast tumours 
Frozen section for intraoperative assessment of palpable breast tumours was invented several decades 
ago and has been widely used since then. It is a reliable method for palpable lesions > 1 cm in 
diameter (Fessia et al., 1984; Niemann et al., 1996). Discrepancies between frozen section diagnosis 
and subsequent paraffin section diagnosis consist mainly of false-negative results, with a low 
frequency of 1–2%. False-positive frozen section diagnoses are very rare events, occurring in < 0.1% 
of cases. In some cases the definitive diagnosis in frozen section has to be deferred to paraffin 
section. Overall sensitivity of frozen section diagnosis is reported to be > 90% and specificity about 
97%. The main reasons for failure are due to macroscopic and microscopic sampling errors, 
histological interpretative errors, poor technical quality of frozen sections and lack of communication 
between pathologist and surgeon (Cserni, 1999; Laucirica, 2005). The introduction of preoperative 
diagnosis on core biopsies has led to a marked reduction in the use of frozen sections for assessment 
of breast lesions (Laucirica, 2005). Frozen section diagnosis may still be performed rarely, e.g. when 
core biopsy results are equivocal. Tumours < 1 cm in maximum diameter should not be subjected to 
frozen section diagnosis. In general, it would be expected that extensive preoperative interdisciplinary 
discussion between radiologists, surgeons and pathologists would decrease the need for frozen 
sections, which should be performed only where there is an immediate impact on surgical treatment. 
3.2 Margin assessment 
No consensus exists about the method of intraoperative margin assessment. Frozen sections are 
considered suitable for this application. The accuracy of frozen sections for margin assessment is 
described with a sensitivity and specificity of only 86% and 83%, respectively (Noguchi et al., 1995). 
This is mainly due to intraductal tumour components not included in frozen sections but detected on 
subsequent examination in paraffin sections. The fatty nature of the margins is often a technical 
hurdle for adequate frozen sections. However, frozen sections of margins for breast cancer may be 
unnecessary in cases where specimen radiology is performed and reported to an adequate standard. 
3.3 Sentinel lymph node biopsy 
Frozen sections for intraoperative assessment of sentinel lymph nodes (SLNs) should be performed 
only in cases with impact on immediate surgical treatment. The main purpose is to spare patients, 
with a positive SLN, 2-step surgery. Not all metastases will be identified in these lymph nodes in 
frozen sections due to the limited number of sections acceptable intraoperatively and freezing 
artefacts. The risk of false-negative results is reported to be between 9% and 52% (Cserni et al., 
2003). Rarely, false positivity may occur. Overall, the accuracy is reported to be between 79% and 
98%. In addition, during frozen sectioning, tissue loss may occur, which must be kept to a minimum 
(Cserni, 2006; Varga et al., 2008; Fritzsche et al., 2010). Imprint cytology is an acceptable alternative 
in centres with cytological expertise (Van Diest et al., 1999). 
The findings of the ACOSOG Z0011 trial, suggesting that SLN micrometastases do not adversely 
impact on prognosis and challenging the view that all patients with a positive SLN require complete 
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axillary lymph node clearance, has led to a reduction in the need for intraoperative SLN evaluation 
(Giuliano et al., 2011). 
3.4 Non-palpable breast tumours 
Frozen section diagnosis is not recommended for non-palpable breast tumours. They are usually 
screen-detected and < 1 cm in diameter. Because of their small size, significant amounts of tissue 
may be lost during frozen section preparation, and definitive diagnosis in paraffin sections may 
become impossible. 
3.5 Needle core biopsy and vacuum-assisted needle core biopsy 
Core biopsies are small-volume specimens and are often used for screen-detected breast lesions, 
which may be complex lesions detected only by microcalcification in many cases and requiring special 
expertise in breast pathology. Overdiagnosis and underdiagnosis in this type of specimen are well-
known phenomena, even in paraffin sections. For example, in cases of DCIS underdiagnosis is found 
in up to 20% of cases when compared with subsequent open biopsy (Verkooijen, 2002). Moreover, 
core biopsies are very small in volume and significant amounts of tissue may be lost during frozen 
sectioning, rendering paraffin section diagnosis impossible. Biomarkers, e.g. steroid hormone 
receptors, may need to be assessed on paraffin sections from carcinoma in core biopsies. If frozen 
sections are performed on core biopsies, reliable assessment cannot be guaranteed due to freeze and 
thaw artefacts. Therefore, frozen section examination of core biopsies is not appropriate under any 
circumstances. 
4 Classifying invasive carcinoma 
Typing invasive carcinomas has prognostic value and provides information on the pattern of 
metastatic spread and behaviour. Because (1) typing of breast carcinomas has been shown in external 
quality assurance EQA schemes to be relatively poorly reproducible, (2) the most frequent traditional 
type (ductal) can be correlated to prognosis only through additional grading and (3) important 
progress has been made in classifying breast cancers in a more molecular way that predicts response 
to current adjuvant therapeutics, the system has been revised to include current molecular insights. 
Caution should be exercised in typing carcinomas in poorly fixed specimens or in specimens that have 
been removed from patients who have been treated by primary chemotherapy, hormonal therapy or 
radiotherapy before surgery. 
4.1 Towards molecular classification of breast cancer 
Microarray gene expression studies have suggested that breast cancers cluster in 3 main groups: (1) 
luminal cancers, which mainly have properties of glandular cells of the breast, driven by high 
expression of steroid receptors; (2) HER2-driven cancers, with amplification and overexpression of 
HER2/neu but lacking steroid receptor expression and (3) basal cancers, which have properties of the 
stem cells of the breast (Sorlie et al., 2001). Because these expression profiles reflect carcinogenetic 
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pathways and correlate with response to therapy, incorporating this new way of molecular thinking 
into breast cancer classification is becoming increasingly important. Because microarray gene 
expression is not easily performed in routine practice and, for the time being, requires frozen material, 
attempts have been made to translate this molecular classification into an immunohistochemical 
classification based on the expression of established markers such as ER, PR, HER2, basal 
cytokeratins, epidermal growth factor receptor (EGFR), and proliferation rate. This surrogate 
molecular classification is still evolving, and no real consensus has been reached. We nevertheless 
think it important to follow this trend and to attempt for the first time to come to some form of 
integration between traditional and molecular (“histomolecular”) typing using our current state of 
knowledge (Weigelt & Reis-Filho, 2009). 
Luminal cancers show expression of ER and/or PR, the luminal A subtype without and the luminal B 
subtype with overexpression of HER2 and/or high Ki67 score. Most tubular, invasive cribriform, 
mucinous, invasive micropapillary and lobular cancers fall into this group, as do most grade 1 and 2 
ductal cancers. Luminal cancers especially metastasise to the bone, although luminal B cancers 
metastasise also to the brain with increased frequency. 
The HER2 group shows overexpression of HER2 and lacks expression of ER and PR. This group 
comprises mainly ductal and some apocrine cancers. Apocrine cancers usually show expression of AR. 
Basal cancers lack expression of ER, PR and HER2 (often denoted “triple negative”) and express basal 
cytokeratins like CK5/6 and/or CK14 or EGFR. Please note here that “triple negative” does not equal 
basal per se! Although basal cancers may also express other markers associated with stem cells, like 
p63 and vimentin, these markers are not routinely used. The group of basal cancers usually comprises 
well-circumscribed cancers with high-grade features (atypical nuclei, many mitoses, geographic 
necrosis), lack of tubule formation with larger solid and often interconnecting islands, and abundant 
lymphocytoplasmic infiltrate around the lesion. There is often a central fibrotic/necrotic area. This 
group comprises high-grade cancers such as most medullary cancers and metaplastic cancers, BRCA1 
germline mutation-associated cancers and many grade 3 ductal cancers. Low-grade basal cancers 
comprise the salivary gland-like cancers (e.g. adenoid cystic carcinoma) (Foschini & Krausz, 2010). 
Some triple negative cancers may express AR and are possibly apocrine-derived. 
In this supplement, we have attempted to relate the traditional histological types to this molecular 
classification to arrive at a synthesis of traditional morphological and new molecular typing (see Table 
2). Inherently, this means that traditional histological typing has lost some of its importance because 
clinically it may no longer always be useful to discern some of the traditional WHO types that clinically 
behave similarly and, in fact, always overlapped considerably (Weigelt et al., 2008; Reis-Filho & 
Lakhani, 2008). 
It should be realised, however, that invasive breast cancer forms a morphological and also a 
molecular spectrum, so not all established morphological types completely fall into one of the 
molecular groups, nor will all individual cancers be easily classifiable into one of the molecular types. 
4.2 Special type versus mixed type and “no special type” 
A special type cancer shows a classic morphology with all the hallmark histological features that will 
reproducibly be classified as such by different pathologists, requiring > 90% purity. 
Mixed morphological differentiation with < 90% purity is relatively common, as is the mere absence of 
specific differentiation patterns, which mostly leads to a classification as “ductal – no special type” 
(ductal-NST). ER, PR and HER2 usually do not vary clearly between the histologically different parts of 
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these tumours, so that assessing these receptors in these mixed cancers does not pose specific 
problems. Prognosis, however, is dictated by the “worst” (least differentiated) part of the tumour. 
Table 2: Molecular typing of breast cancer based on common immunohistochemical 
 markers (Abd El-Rehim et al., 2005; Goldhirsch et al., 2011) 
Molecular 
intrinsic subtype 
Clinico-
pathological 
definition 
ER PR HER2 Ki67 Basal markers* 
Luminal A  Luminal A + + or – – Low - 
Luminal B Luminal B 
(HER2 
negative) 
+ + or – – High - 
Luminal B Luminal B 
(HER2 
positive) 
+ + or – Overexpressed Low or 
high 
- 
HER2 HER2 positive 
(non-luminal) 
– – Overexpressed Usually 
high 
+/- 
Basal Triple 
negative 
(ductal) 
– – – Usually 
high 
+ 
       * CK5/6 or CK14 
4.3 Immunohistochemistry of breast cancer 
Besides the markers used for molecular classification, we describe more specific markers for the 
different morphological types. In general, breast cancers are positive for AE1/3 (and other broad-
spectrum keratins), CAM5.2, CK7 and EMA, and for BRST2 (GCDFP-15), which is usually focal (except 
in the case of apocrine differentiation). 
4.4 Assessing predictive and prognostic markers 
Proper assessment of prognostic and predictive factors requires adequate tissue processing in the first 
place. This includes freezing representative tissue when necessary (snap freezing in liquid nitrogen or 
isopentane, followed by storage in a –80° freezer) and adequate fixation of the rest in neutral 
buffered formaldehyde. Freezing or formaldehyde fixation must be done with as little delay as 
possible. To achieve adequate fixation, tissue must be sliced at 4–5 mm thickness, which should 
ensure full fixation in 24–48 hours. Longer fixation must be avoided to prevent false-negative or false-
positive results for prognostic or predictive tests. 
Prognostic features that are currently widely used include invasive tumour size (as measured in the 
fresh specimen, corrected when necessary on the microscopic sections), (sentinel) lymph node status, 
histological grade and proliferation rate (as measured by mitotic activity index or Ki67 labelling index). 
DNA microarrays are promising prognostic tools but are as yet insufficiently validated for routine 
clinical use as predictors of response to therapy. The cost of these tests is also worrisome. 
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Predictive tests for hormonal treatment are expression of ER and PR, whereas overexpression of HER2 
predicts response to anti-HER2 therapy. The negative predictive value of these tests is generally 
higher than their positive predictive value, e.g. ER (and PR) negative tumours are unresponsive to 
hormonal therapies, but ER positive tumours are not necessarily responsive. For HER2, gene 
amplification tests (like fluorescence chromogenic, or silver in situ hybridisation, or PCR-based tests) 
are increasingly important, especially for equivocal cases or on core biopsies. Participation in quality 
assessment programmes for different molecular and immunohistochemical tests is essential. 
Clearly, molecular assessments are the task of the pathologist within the regular framework of tumour 
workup. Pathologists should be and are ready to implement new molecular tests in their laboratory as 
soon as they are sufficiently clinically validated. 
4.5 Infiltrating lobular carcinoma 
Consideration of both the cytological appearance and the infiltration pattern leads to the diagnosis of 
lobular carcinoma and, in particular, to relevant subclassification. Typical cytology (small regular cells 
with clear boundaries, frequently having intracytoplasmic mucous vacuoles, and small nuclei with 
inconspicuous nucleoli) and a typical infiltration pattern (cells dissociated from each other or forming 
single files, often in targetoid patterns around uninvolved ducts) lead to the diagnosis of "classic type" 
lobular carcinoma. Mitotic rate is low. There are often satellite lesions around the dominant nodule, 
and infiltration is often multifocal. Several variants have been identified in addition to this classic form. 
At least 90% of the tumour should exhibit one or more of the classic or variant patterns to be 
classified as infiltrating lobular. 
The alveolar variant exhibits small round aggregates of 20 or more cells with typical lobular cytology, 
and is better demarcated than the classic type. 
The solid variant consists of more solid sheets of cells with little intervening stroma, often better 
demarcated than the classic type. Mitoses are usually also more frequent, and atypia may be more 
prominent. 
The tubulolobular type exhibits microtubular formation as part of the classic pattern, thereby forming 
a spectrum with tubular cancer, and probably lies closer to tubular cancer in both morphological and 
immunohistochemical aspects. Tumours that show mixtures of typical tubular and classic lobular 
carcinoma should be classified as mixed (see below). 
The pleomorphic variant is less common and exhibits the growth pattern of classic lobular carcinoma 
throughout, but the cells, although retaining lobular characteristics such as their discohesive character 
and intracytoplasmic vacuoles, have polygonal, eccentric pleomorphic nuclei. Mitoses are usually also 
more frequent, and expression of ER/PR is often less than in classic lobular carcinoma, reflected in a 
somewhat worse prognosis than classic lobular carcinoma (Eusebi et al., 1992; Weidner & Semple, 
1992). 
Lobular mixed type lesions consist of mixtures of the above subtypes of lobular carcinoma. 
Histiocytoid or myoid cellular differentiation may occur (Eusebi et al., 1995; Del Vecchio et al., 2005). 
It is currently insufficiently clear whether lymphoepithelioma-like cancer is a variant of lobular cancer. 
The pleomorphic variant can be associated with a prominent inflammatory infiltrate, a feature that 
may present a difficult differential diagnosis with lymphoepithelioma-like carcinoma (Dadmanesh et 
al., 2001). 
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These lesions are thought to derive especially from lobular neoplasia (atypical lobular hyper-
plasia/lobular carcinoma in situ [LCIS]) but may also be related to CCLs or low-grade DCIS (Abdel-
Fatah et al., 2008). 
Infiltrating lobular carcinoma is frequently non-palpable and/or mammographically occult. These 
lesions may also be difficult to visualise sonographically and are therefore over-represented in studies 
of interval cancer. Many of these are so-called “real” interval carcinomas without suspicious signs on 
the pre-diagnostic screening mammograms. For the same reasons, lobular carcinomas are also over-
represented in the group of occult carcinomas initially presenting with metastasis. 
Prognosis of lobular carcinoma as a group is intermediate, with a worse prognosis for pleomorphic and 
solid types, and there are often lymph node metastases that may require cytokeratin 
immunohistochemistry for recognition. Lobular cancers metastasise to the bone and gastrointestinal 
tract and other odd sites, like ovaries, bladder, orbit, serosal surfaces and meninges, in a higher 
frequency than other cancer types. Rare HER2-overexpressing lobular cancers may metastasise to the 
brain with increased frequency. 
Immunohistochemically, typically E-cadherin and p120 are reduced, either aberrant (cytoplasmic) or 
negative; ER/PR are positive; HER2 is negative; low-molecular-weight keratins 7, 8, 18 and 19 are 
positive and high-molecular-weight keratins CK5/6 and CK14 are negative, with the exception of 
34betaE12, which often shows positive staining. Most lobular cancers therefore fall into the luminal A 
molecular type, whereas a small minority will be luminal B when they overexpress HER2 or have high 
Ki67. Metastatic gastric cancer should be considered as a differential diagnosis in morphologically 
lobular cancers with no ER or PR expression. 
4.6 Tubular carcinoma 
Tubular carcinomas are composed of round, ovoid, teardrop-shaped or angulated single-layered 
tubules in an abundant cellular fibrous or fibro-elastotic stroma. The neoplastic cells are small and 
uniform and may show cytoplasmic apical snouting. Nuclei should not show a high degree of atypia. 
At least 90% of the tumour should exhibit the classic growth pattern to be classified as tubular. 
However, if the co-existent carcinoma is solely of invasive cribriform type then the tumour should be 
typed as tubular if the tubular pattern forms > 50% of the lesion. Some tubular differentiation may be 
seen in tubulolobular carcinomas (see above). Mitoses are rare. 
These lesions are thought to derive from low-grade DCIS and CCLs, and are rarely associated with 
lobular neoplasia (Abdel-Fatah et al., 2008). 
The clinical presentation is usually as a palpable, mammographically and sonographically visible lesion. 
The characteristic radiological appearance is that of a stellate abnormality, which can resemble a 
radial scar, or an asymmetric density. 
Prognosis is excellent, but lymph node metastases may occur. Rare metastases are found especially in 
bone. 
Immunohistochemically, typically E-cadherin is positive, ER is positive and PR usually so, HER2 is 
negative and CK5/6 and CK14 are negative. Almost all tubular cancers therefore fall into the luminal A 
molecular type. 
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4.7 Invasive cribriform carcinoma 
This tumour is composed of cribriform islands of small, uniform neoplastic cells, with cytoplasmic 
apical snouting. Nuclei should not show a high degree of atypia. More than 90% of the lesion should 
exhibit a cribriform appearance, except in cases where the only co-existent pattern is tubular 
carcinoma (see above), when > 50% must be of a cribriform appearance to be classified as of 
invasive cribriform type. There are usually very few mitoses. 
These lesions are thought to derive from low-grade DCIS and CCLs, and are rarely associated with 
lobular neoplasia (Abdel-Fatah et al., 2008). 
The clinical presentation is usually as a well-circumscribed, palpable and mammographically and 
sonographically visible lesion, generally not stellate as in tubular carcinoma. Prognosis is quite good, 
but lymph node metastases may occur. Rare metastases are found especially in bone. 
Immunohistochemically, typically E-cadherin is positive, ER/PR are positive, HER2 is negative and 
CK5/6 and CK14 are negative. Almost all invasive cribriform cancers therefore fall into the luminal A 
molecular type. 
4.8 Mucinous carcinoma 
This type has also been known as mucoid, gelatinous or colloid carcinoma. These lesions are relatively 
well circumscribed and show cribriform or papillary islands of uniform cells in lakes of extracellular 
mucin. The degree of nuclear atypia and mitotic activity may vary. At least 90% of the tumour must 
exhibit a mucinous appearance to be so classified. 
Mucinous cancers can be divided into two groups: mucinous A (or paucicellular) and mucinous B (or 
hypercellular). Mucinous B cancers display histological and genetic features that significantly overlap 
with those of endocrine carcinomas (Sapino et al., 2000) (see below). 
The precursor lesion is the mucinous form of DCIS (for both types A and B; for type B, there will 
usually be endocrine features) or the mucinous variant of CCLs (for type A). 
The clinical presentation is usually as a palpable and well-circumscribed lesion on mammography and 
sonography, which can simulate a benign lesion. 
Prognosis is good for pure (generally low-grade) lesions, but lymph node metastases may occur. Rare 
metastases are especially found in bone. 
Immunohistochemically, typically ER/PR are positive, HER2 is negative and CK5/6 and CK14 are 
negative. Almost all mucinous type (types A and B) cancers therefore fall into the luminal A molecular 
type. Rarely, type B mucinous cancers may be luminal B. 
4.9 Invasive micropapillary carcinoma 
This type shows an infiltrative growth pattern of small regular micropapillary groups, not showing 
further gland formation (Zekioglu et al., 2004; Chen et al., 2008). Due to fixation and expression of 
mucins on the outside of the groups, they tend to detach from the surrounding stroma and often form 
a “halo” around the groups. Microcalcification is common. Atypia and mitotic activity may vary. These 
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tumours often show prominent lymphovascular invasion, and there are in fact cases where tumour is 
only found in lymph vessels. 
The precursor lesion for this type of cancer is unclear. It is sometimes associated with micropapillary 
DCIS, but the common name does not imply a precursor relationship. 
The clinical presentation is usually as a palpable lesion visible on mammography and sonography. 
The degree of lymph node involvement is high. Prognosis is not essentially different from that of 
invasive ductal carcinomas of similar grade, but is therefore relatively poor because many are high-
grade. There is a high rate of local recurrence. 
Immunohistochemically, typically E-cadherin is positive, ER/PR are positive, HER2 is frequently 
positive and CK5/6 and CK14 are negative. These tumours can fall into the luminal A or luminal B 
molecular types, depending on the HER2 status and the Ki67 index. MUC1/EMA are present on the 
outer surface of the tumour islands (which can be stained by EMA), hence the original “inside-out” 
carcinoma designation. 
4.10 Neuroendocrine breast cancer 
Neuroendocrine breast cancers share the peculiar architecture of solid sheets of cells with a tendency 
to produce peripheral palisading or insular structures separated by a delicate fibro-vascular stroma 
common to most endocrine tumours in general. Even more specific are the cytological features: 
plasmacytoid, spindle or with signet ring appearance and with intracytoplasmic granules (in the apex 
of plasmacytoid cells or diffuse in the cytoplasm of mucous or spindle cells), which are particularly 
evident in Giemsa and Diff-Quik-stained smears. There is also a variant with true small-cell 
cytonuclear features like in other organs. The degree of nuclear atypia and mitotic activity varies, so 
that these cancers can be grade 1, 2 or 3. True small-cell neuroendocrine carcinomas should be 
regarded as grade 3 by definition. There may be some mucinous or apocrine differentiation in non-
small-cell types. 
The precursor lesion for this type of cancer is DCIS with similar morphological (sometimes mucinous) 
and neuroendocrine features. 
The clinical presentation is usually as a palpable lesion visible on mammography and sonography in 
older patients. Serum levels of (neuro)endocrine markers may be increased. 
Immunohistochemically, neuroendocrine breast carcinomas are exclusively those expressing chromo-
granin A, or chromogranin B, or synaptophysin in > 50% of their cells (Abd El-Rehim et al., 2005). 
Cancers that do not reach this threshold should be classified as “breast carcinomas with focal 
neuroendocrine differentiation”, which also do not show the typical morphology overall and have an 
older age range of patients. Expression of ER and PR is variable, and there is frequently expression of 
AR and GCDFP-15 (BRST2), pointing to apocrine differentiation. These tumours, therefore, can fall 
into any of the HER2 negative subtypes. 
Axillary lymph nodes may be involved. Prognosis is not essentially different from that of invasive 
ductal carcinomas of similar grade. Favourable prognostic features in these cancers are mucinous 
differentiation and expression of ER and PR. 
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4.11 Apocrine carcinoma 
These tumours are architecturally much like (high-grade) ductal cancers with variable morphology, but 
cytologically the cancer cells have abundant granular or homogeneously pink (“apocrine”) cytoplasm 
and big round nuclei with conspicuous nucleoli. Mitotic activity may vary. Apocrine differentiation may 
also be seen in endocrine cancers (see above). 
The precursor lesion of apocrine carcinoma is the apocrine variant of DCIS (which also may show 
variable architecture), and (atypical) apocrine hyperplasia may be the earliest precursor. To what 
extent (atypical) apocrine adenosis is a precursor is still unknown. 
The clinical presentation is usually as a palpable lesion visible on mammography and sonography. 
Prognosis and degree of lymph node involvement are not essentially different from those of invasive 
ductal carcinomas of similar grade. HER2 positive apocrine cancers metastasise to the brain with 
increased frequency. 
Immunohistochemically, typically E-cadherin is positive, usually ER/PR are negative, HER2 is most 
often positive, CK5/6 and CK14 are negative and CEA, BRST2 and AR are positive. Most apocrine 
cancers therefore fall into the HER2 molecular class, whereas some expressing ER/PR as well as HER2 
are classified as the luminal B molecular type. Occasional cases may be triple negative. It has been 
suggested that apocrine carcinoma may be a special molecular class driven by AR signalling (Weigelt 
et al., 2008). 
4.12 Medullary-like carcinoma 
Typical medullary carcinomas are well-circumscribed cancers composed of interconnecting solid 
epithelial islands, with a syncytial pattern and often with necrosis. The epithelium shows highly 
atypical nuclei and many mitoses, and there is abundant lymphoplasmocytic infiltrate in and around 
the lesion. Some squamous metaplasia may occur. 
Cancers showing many but not all of these features are classified as medullary-like, and because there 
are few differences in molecular make-up and clinical behaviour between typical medullary and 
medullary-like cancers, they are placed together in this histomolecular classification. There is clearly 
overlap here with metaplastic cancers as well. Also, many of the BRCA1 germline mutation-related 
cancers fall into this group, as well as cancers with sporadic inactivation of BRCA1 (e.g. due to 
promoter hypermethylation). 
These cancers are thought to derive from a similar type of DCIS expressing basal cytokeratins/EGFR, 
which are likely to originate from the stem cells of the breast. In typical medullary carcinoma, the 
presence of DCIS is, however, rare. 
The clinical presentation is usually as a rapidly growing palpable and well-circumscribed lesion on 
mammography and sonography, which can simulate a benign lesion, often at relatively young age. 
Prognosis is intermediate (not as bad as for usual basal cancers), and brain metastases occur 
commonly, but interestingly lymph node metastases are rare in typical medullary type cancers. 
Immunohistochemically, typically E-cadherin is positive, ER/PR/HER2 are negative and often CK5/6 
and/or CK14 are positive; most medullary-like cancers therefore qualify as (high-grade) basal cancers 
(Jacquemier et al., 2005). There is no consensus on the required level of CK5/6 and/or CK14 
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expression, but probably any expression of these basal keratins would suffice. Further, there is often 
expression of EGFR, c-kit, p63, vimentin, smooth muscle actin, p-cadherin and CD10, and 
accumulation of p53 (usually related to a p53 mutation). 
4.13 Metaplastic carcinoma 
Metaplastic carcinomas often have the features of medullary-like carcinomas, showing metaplasia of 
any kind. Squamous metaplasia is most often found, but undifferentiated mesenchymal areas, or 
areas showing (smooth or striated) muscle differentiation, cartilage or bone formation, or more rarely 
nerve type differentiation may also occur. The degree of metaplasia (especially that of mesenchymal 
metaplasia) may be so abundant that the primary epithelial nature of the cancer is morphologically no 
longer, or hardly, recognised and the diagnosis of carcinoma is primarily based on cytokeratin 
expression. Of these, especially the basal and high-molecular-weight cytokeratins may be useful. 
These usually high-grade cancers clearly overlap with the medullary-like cancers, and thereby include 
cancers in BRCA1 germline mutation carriers, as well as cancers with a sporadic inactivation of BRCA1 
(e.g. due to promoter hypermethylation). 
These cancers are thought to derive from a similar type of DCIS expressing basal cytokeratins/EGFR, 
which are likely to originate from the stem cells of the breast, and are thereby basal (Weigelt et al., 
2009). 
The clinical presentation is usually as a rapidly growing palpable and well-circumscribed lesion on 
mammography and sonography, which can simulate a benign lesion, often at relatively young age. 
Prognosis is among the worst, and lung and brain metastases occur commonly. 
Immunohistochemically, typically E-cadherin is positive, ER/PR/HER2 are negative and CK5/6 and/or 
CK14 are positive. Most metaplastic cancers therefore qualify as (high-grade) basal cancers. There is 
no consensus on the required level of CK5/6 and/or CK14 expression, but probably any expression of 
these basal keratins would suffice. Further, there is often expression of EGFR, c-kit, p63, vimentin, 
smooth muscle actin, p-cadherin and CD10, and accumulation of p53. 
4.14 Salivary gland-like cancers 
This group of low-grade cancers comprises salivary gland-like cancers such as adenoid cystic 
carcinomas and rarer forms like acinic cell and oncocytic carcinomas. They show infiltrative growth, 
are often multinodular, and morphology may vary. The typical adenoid cystic types grow in rounded-
off epithelial groups of varying size, with some showing a cribriform pattern. There are two types of 
lumina; the less abundant type is epithelial, whereas the lumina lined by myoepithelial cells contain 
greyish basement membrane substance. Apocrine snouts around the lumina are lacking, which helps 
to distinguish them from the lumina in tubular/cribriform carcinomas. Nuclear atypia is usually low, 
and mitoses are typically not frequent. Other cancers in this group may show morphologically 
prominent myoepithelial differentiation. Perineural invasion (which is prominent in this tumour type 
within salivary glands) is rare in the breast. 
In situ precursors of similar (low-grade) morphology can be found in these cancers. 
The clinical presentation is usually as a palpable lesion visible on mammography and sonography. 
Prognosis is very good, and lymph node metastases are rare. 
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Immunohistochemically, typically E-cadherin is positive, ER/PR/HER2 are negative, CK5/6 and/or CK14 
are positive and there is expression of vimentin and myoepithelial markers such as smooth muscle 
actin, p63, calponin and caldesmon. Most salivary gland-like cancers are therefore classified as (low-
grade) basal cancers (Foschini & Krausz, 2010). Most adenoid cystic carcinomas bear a t(6;9)(q22-
23;p23-24) translocation, which leads to the formation of the MYB-NFIB fusion gene (Wetterskog et 
al., 2012). 
4.15 Secretory carcinoma 
Secretory type cancers may be considered to be almost a genetic entity due to the high frequency of 
a ETV6-NTRK3 fusion gene, which encodes a chimeric tyrosine kinase that has an oncogenic effect 
(Reis-Filho & Lakhani, 2008). Pathologically, these lesions are less well defined. Grossly, they usually 
form a circumscribed mass, architecturally resembling ductal carcinomas but with microcysts and/or 
secretory cytology with bubbly cytoplasm, signet cells and low-grade nuclei. DCIS precursors with 
similar cytology have been described. 
The clinical presentation is usually as a palpable lesion visible on mammography and sonography at 
exceptionally young age and fairly often in males. Prognosis is very good, but lymph node metastases 
may occur. 
Immunohistochemically, typically ER/PR are negative and HER2 is negative, but CK5/6 or CK14 may 
be positive, so that secretory cancers partly fall into the basal cancer group but should not be 
regarded as high-grade (Lae et al., 2009). 
4.16 Ductal – no special type (ductal-NST)
This group contains infiltrating carcinomas that cannot be assigned to any other category or classified 
as any of the less common variants of infiltrating breast carcinoma. The tumour shows < 90% special 
type characteristics. Consequently, invasive ductal carcinomas exhibit great variation in appearance 
and are the most common carcinomas, accounting for up to 75% in published series. 
These lesions are thought to derive from DCIS or CCLs, rarely from lobular neoplasia. 
The clinical presentation is usually as a palpable, mammographically and sonographically visible lesion. 
Prognosis of ductal-NST carcinomas as a group is worse than that of most specific types, and is 
largely dependent on proliferation rate and grade. Lymph node metastases often occur. Systemic 
spread may occur to any site, with a preference for bone (especially ER positive/PR positive cases), 
liver, lung and, to a lesser extent, brain (especially HER2 positive cases). 
Immunohistochemically, E-cadherin is usually positive and there is variable expression of ER/PR, HER2 
and the basal cytokeratins CK5/6 and CK14. Molecularly, ductal cancers therefore spread over all 
molecular groups. Cases with ER and/or PR positivity and HER2 negativity are luminal A, cases with 
ER and/or PR positivity and HER2 positivity or high Ki67 are luminal B, cases with ER/PR negativity 
and HER2 positivity are HER2, and triple negative cases with CK5/6 and/or CK14 and/or EGFR 
expression are classified as basal. 
Many cancers in patients with BRCA2 mutations have “no special type” morphology, and most are 
molecularly classified as luminal A because they express ER and/or PR but usually lack HER2 
expression. 
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Also, lymphoepithelioma-like cancers are included here as they are as yet difficult to group into any of 
the above categories, and are too rare to form a useful separate entity. Lymphoepithelioma-like 
carcinoma is considered by some to be a variant of invasive lobular cancer. It is usually well 
demarcated, with scattered pale individual cells, sometimes also forming solid groups, with vesicular 
nuclei showing only slight/moderate atypia and a small single nucleolus, mixed within a very marked 
infiltrate of lymphocytes and plasma cells. This tumour type, therefore, resembles the undifferentiated 
form of nasopharyngeal carcinoma, and has to be differentiated from medullary carcinoma. Mitotic 
activity may vary. Immunohistochemically, there is also variable expression of E-cadherin and ER/PR, 
HER2 is mostly negative and CK5/6 and CK14 are negative. Epstein-Barr virus (EBV) has not been 
convincingly demonstrated. Lymph node metastases are rare. 
4.17 Other malignant tumours 
Non-epithelial tumours and secondary carcinomas are included in this category. For purposes of 
convenience, malignant phyllodes tumours and malignant adeno-myoepitheliomas should also be 
recorded here. 
4.18 Not assessable 
This category should be used only if an invasive carcinoma cannot be assigned to any of the previous 
groups for technical reasons, e.g. the specimen is too small or poorly preserved. 
5 Assessing the axilla 
Axillary nodal status remains the single most important prognostic factor in patients with breast 
cancer. For many years, axillary dissection has been the preferred method for obtaining information 
about nodal status, but it has significant morbidity and node negative patients are hence 
disadvantaged. Axillary status can be assessed by various methods: clinical, radiological, pathological 
and surgical techniques, the most accurate of which is histological examination of sentinel lymph 
nodes (SLNs) or axillary dissection. Although imaging techniques (ultrasonography [US], colour 
Doppler, scintimammography, high-resolution computed tomography, etc.) have improved, no 
individual patient can be managed based exclusively on these results. Physical examination is 
inaccurate because node metastases are present in 15–60% of patients with non-palpable nodes and 
absent in up to one third of patients with palpable nodes. 
5.1 Preoperative staging 
Preoperative staging of axillary lymph nodes (ALNs) should be performed to support specific 
therapeutic decisions. For example, in patients with axillary metastases, the surgeon can save the 
expense and time needed to perform SLN biopsy (Boughey et al., 2010); more extensive staging can 
be planned, and “tailored” neoadjuvant chemotherapy can be instituted. US-guided biopsy of 
suspicious ALNs can be performed by fine-needle aspiration (FNA) using a 25 gauge needle (Bonnema 
et al., 1997; Sapino et al., 2003; Bedrosian et al., 2003; van Rijk et al., 2006) and/or by core needle 
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biopsy (CNB) using a 14–18 gauge needle (Damera et al., 2003; Nori et al., 2005; Abe et al., 2007; 
Rao et al., 2009); the choice is mainly operator- and institution-dependent. Specificity for both 
methods is high (95.7–100%), and sensitivity varies for both, depending on the selection criteria and 
number of passes. According to some authors (Rao et al., 2009), as far as diagnosis is concerned 
there is no clear advantage for either technique. Given the necessary expertise, FNA may allow 
equivalent sensitivity at a lower cost. FNA is also preferred by many units due to the proximity of large 
vessels and nerves. US-guided ALN biopsy can detect up to 64% of node positive patients 
preoperatively (Damera et al., 2003; Rao et al., 2009). 
Image-guided and fine-needle aspiration cytology (FNAC) or CNB of suspicious nodes can improve the 
preoperative axillary staging of patients with breast cancer, avoiding a 2-stage axillary procedure and 
sparing as many as 1–26% of patients open lymph node biopsies (Krishnamurthy et al., 2002; Ciatto 
et al., 2007). 
Handling of FNA and CNB material should follow the procedures in Chapters 6a and 6b of the fourth 
edition (Wells et al., 2006a). 
Diagnosis is usually straightforward when representative material is available with good technical 
quality; most false-negative cases correspond to “small” metastases. 
All cases of primary invasive breast cancer with negative results for metastatic disease on FNA or CNB 
are candidates for a SLN biopsy or other axillary procedure for definitive staging. 
To validate the diagnosis of metastasis from breast cancer, the morphology of the neoplastic cells 
present in lymph node FNA or CNB material should be compared with that of the primary tumour by 
review of the preoperative FNA or CNB material of the primary breast carcinoma because metastases 
are usually similar to the primary tumour. 
5.2 Problems and pitfalls 
Although the aim of preoperative study is the search for metastases, caution should be taken to avoid 
overlooking other causes of axillary lumps. 
5.2.1 Epidermal cysts and skin appendage tumours 
Inflammatory processes can occur from skin appendages. In these cases, an inflammatory 
background and the presence of squamous epithelial cells should alert the pathologist to a benign 
lesion. Apocrine cells may also be included from neighbouring apocrine sweat glands and may cause 
some problems. Skin appendage tumours may also be a challenge because the morphology and 
immunohistochemical profile can be quite similar to those of breast tumours. The clinical setting 
combined with US should allow a correct diagnosis. Axillary breast tissue may also give rise to benign 
epithelial clusters in smears. 
5.2.2 Lymph node inclusions 
Benign epithelial or, rarely, mesothelial inclusions in lymph nodes can also occur in approximately 
0.3% of cases and may be difficult to recognise due to their cytokeratin positivity. Naevus cell 
inclusions also occur. 
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5.2.3 Granulomatous inflammatory processes 
Epithelioid macrophages can mimic carcinoma cells. They are associated with other inflammatory cells 
in the smear, and the presence of multinucleated macrophages should prevent a false-positive 
diagnosis. In case of doubt, cytokeratin immunocytochemistry may solve the differential diagnostic 
problem. Whenever necrosis is present, microbiological or serological studies must be done to rule out 
the possibility of a specific infection (tuberculosis, cat scratch disease, etc.). 
5.2.4 Dermatopathic lymphadenopathy 
Melanophages can mimic carcinoma cells if the load of melanin is low. Usually the smears are not very 
rich in these cells and they are isolated or aggregated to vascular stroma. In case of doubt, immuno-
staining (CD68, etc.) easily confirms the histiocytic origin of these cells. 
5.2.5 Lipoma 
Mature adipose tissue can originate from a lipoma or from an adipose lymph node; only the presence 
of lymphoid cells can indicate the origin of the lump. The absence of carcinoma cells does not rule out 
the possibility of metastases, although their occurrence in adipose lymph nodes is not frequent. 
5.2.6 Metastatic tumours 
Melanoma 
ALN metastasis of melanoma is a difficult differential diagnosis. An amelanotic melanoma can mimic 
breast cancer metastasis and this differential diagnosis can be particularly difficult in FNA. However, 
metastases from melanoma frequently contain mono-, bi- and multinucleated malignant cells. The 
cells also are polyhedric and/or fusiform with intranuclear pseudo-inclusions and prominent nucleoli. 
Before looking at an ALN sample, a review of the primary breast carcinoma is important because 
metastases are usually similar to the primary tumour. Although melanoma can be a mimicker, it can 
be recognised and even in the absence of a clinical history, immunostaining (HMB45, pS100, etc.) is 
diagnostic. 
Carcinoma (other than breast) 
When a peculiar pattern, unusual for breast cancer, is seen, another metastatic tumour should be 
considered. A careful clinical history complemented by image study will resolve most problems. 
Lymphoma 
Hodgkin cells may mimic carcinoma cells; however, the comparison with the primary tumour, the 
relative paucity of malignant cells and the presence of eosinophils may alert the pathologist to the 
diagnosis of Hodgkin lymphoma. 
Whenever a non-Hodgkin lymphoma, especially small-cell lymphocytic lymphoma or lymphomas with 
plasmacytoid differentiation, is considered, haematological assessment, immunophenotyping and/or 
open tissue biopsy is indicated. 
5.3 Examination and interpretation of sentinel lymph node 
biopsy specimens 
Since the publication of the fourth edition (Wells et al., 2006a), new problems and techniques have 
emerged in relation to nodal staging, reflected in the TNM classification, which is now in its seventh 
edition (Sobin et al., 2009). Although the basic principles have not changed, it was considered 
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necessary to update the pathology chapter (Chapter 6) with a supplement addressing some of the 
difficulties experienced since the fourth edition was published. 
5.3.1 Isolated tumour cells (ITCs) 
The aim of pathological nodal staging is to make a statement about the status of the lymph nodes, 
either node negative or node positive. The nodes are usually axillary, but very occasionally from other 
locations. On the basis of the SLN theory, the SLNs are the first nodes draining lymph from the 
tumour site and are therefore the most likely site of nodal metastasis. With selective removal of these 
lymph nodes, there is an opportunity for more detailed pathological work-up of these, and indeed the 
SLNs are subjected to more intensive investigations. However, the techniques used vary from 
institution to institution, and this heterogeneity is partly responsible for discrepancies in the rates of 
node positive breast cancer reported by different centres. 
The pTNM is the staging system generally used. In its sixth edition, this classification introduced the 
concept of a type of nodal involvement (termed isolated tumour cells; ITCs) that should not be 
considered a metastasis from the point of view of staging and treatment. ITCs may be identified either 
by morphological methods [pN0(i+)] or by molecular studies [pN0(mol+)]. Whenever the lymph 
nodes are investigated for such lesions but the results are negative, the pN0(i-) and pN0(mol-) 
symbols are recommended by the TNM definitions. Although it is clear that pN0(i+) may reflect both 
ITCs detected by the standard haematoxylin and eosin (H&E) staining and those detected by 
immunohistochemistry (IHC), the seventh edition of the TNM classification (Edge et al., 2009; Sobin et 
al., 2009) clarifies that pN0(i-) should be used only for negative IHC findings. 
It was found to be common practice to evaluate SLNs at multiple levels. Gross slicing of the SLNs 
(and, in some recommendations, any lymph node) larger than 5–6 mm and H&E staining of one level 
per such slice is recommended in nearly all protocols. When this investigation or step sections by H&E 
staining disclose no nodal involvement of any type, the pN0 category without any qualifiers should be 
used, and pN0(i-) should be reserved for negative investigations beyond this limit, i.e. negative 
findings by IHC. Because this still allows several levels of precision in staging, it is considered optimal 
to report the method of SLN investigation. 
The definition of ITCs and their distinction from micrometastases was suboptimal and did not allow a 
reproducible segregation of low-volume nodal involvement into these two pTNM categories (Cserni et 
al., 2005; Cserni et al., 2006; de Mascarel et al., 2008). Although the classification of metastatic cells 
into the ITC category on the basis of the largest cluster not exceeding 0.2 mm in maximum diameter 
may have resulted in better reproducibility (Turner et al., 2008), this sometimes included rather large 
volume lesions, which were found to be associated with metastases beyond the SLNs more commonly 
than ITCs interpreted with a more restrictive approach (Cserni et al., 2008; Turner et al., 2008; 
Cserni, 2009; van Deurzen et al., 2010). The seventh edition of the TNM classification has introduced 
an alternative upper limit of 200 cells for ITCs (Edge et al., 2009; Sobin et al., 2009), and this should 
reduce the diagnostic discrepancies between different centres and also help to eliminate the 
unacceptable practice of labelling relatively extensive metastatic involvement of a lymph node as 
pN0(i+). Any lymph node involvement > 0.2 mm but < 2 mm in any of the 3 dimensions is 
categorised as a micrometastasis. According to the current TNM classification (Edge et al., 2009), the 
0.2 mm size cut-off relates to the maximum diameter of the largest tumour cell cluster. There may be 
instances of nodal involvement with the largest cluster measuring < 0.2 mm in diameter but 
containing > 200 cells, and vice versa, clusters > 0.2 mm in diameter with < 200 cells. Size should be 
considered first, and the cell count only if the largest cluster is < 0.2 mm (Cserni et al., 2011). 
5.3.2 Methods of nodal assessment 
One of the aims of the European guidelines is to decrease heterogeneity in staging. These should, 
therefore, concentrate on the reliability and accuracy of determining a node negative status. 
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The guidelines state that the minimum aim of SLN investigation is to find all metastases greater than 
2 mm in diameter (hereafter referred to as macrometastasis). It therefore follows that any SLNs 
reported to be pN0 or pN0(i-) should be interpreted that the SLN contains no metastasis greater than 
2 mm in diameter (but may still contain micrometastasis or ITCs). Therefore, by devising a protocol to 
detect all macrometastases, the aim is to promote optimal accuracy for identifying node negative 
status related to macrometastases as near to 100% as possible (100% negative predictive value). 
Similarly, when the guidelines state that the optimum aim in staging is to find (nearly) all 
micrometastases in the SLNs, they are also designed to identify a pN0 or pN0(i-) node negative status 
as near to a 100% predictive value for the lack of micrometastases as possible. 
The identification of ITCs in the initial levels mandates a search for a larger metastasis in the same 
SLN, and levels should be cut to exclude the possibility of the ITC cluster being a smaller tangentially 
cut part of a larger metastasis. This would confirm the initial staging correctly as pN0(i+). 
The pN0 or pN0(i-) category reflects that no ITCs were identified by the histological protocol used, 
although they may be present, just as occult metastases of other size may be present, depending on 
the sampling of the lymph node. This is why a systematic search is recommended and the method 
used should be reported, as stated previously. Optimally, the accuracy of staging should also be 
mentioned, at least in unit protocols (e.g. pN0(i-) with the examination of levels separated by 500 μm 
devised to identify metastases not smaller than 500 μm in greatest dimension; or pN0 with the 
examination of 4 levels separated by 250 μm from each slice approximately 2 mm in thickness, 
devised to identify metastases not smaller than 1 mm in greatest dimension). 
No reasonable histological method can aim to identify ITCs with 100% accuracy in the SLNs, but some 
reports have suggested that ITCs identified incidentally with protocols devised to identify larger 
metastases also have some impact on prognosis (Colleoni et al., 2005; de Boer et al., 2009). 
5.3.3 Intraoperative assessment 
The sensitivity and positive predictive value of the intraoperative assessment of SLNs can be improved 
by specific techniques such as rapid immunohistochemistry and molecular testing of the lymph nodes. 
Immunohistochemistry is most useful in cases of lobular carcinomas with micrometastatic involvement 
of the SLN, but can also help to identify larger metastases, and facilitate later paraffin section 
evaluation (Nahrig et al., 2003; Leikola et al., 2005; Choi et al., 2006). 
Molecular (RT-PCR-based) assays may detect ITCs in greater proportion than histological methods, 
but cannot be optimally validated against the gold standard method of histology because of sampling 
biases. Validation can partially be made against other validated molecular assays. 
The first group of RT-PCR-based nodal staging tests looked purely at the presence or absence of 
mammary epithelial (e.g. CK19, MUC-1, mammaglobin) or tumour cell markers (e.g. carcinoembryonic 
antigen, MAGE-3) and were confounded by many technical biases. Such tests should not be used for 
routine purposes (Cserni et al., 2003). 
The second generation of tests are based on quantitative real-time or other mRNA amplification 
assays, and these, with a well-chosen cut-off value, may exclude false-positive cases with reasonable 
accuracy (Visser et al., 2008; Viale et al., 2008; Julian et al., 2008; Mansel et al., 2009; Castellano et 
al., 2012). Such assays, by means of being quantitative, can also be calibrated in a way to exclude the 
histological category of ITC (i.e. the pN0(i+) category) and have been successfully used in the 
intraoperative setting. They also allow more tissue to be sampled (and homogenised). The main 
problem remains that of sampling (Daniele et al., 2009). If the tissue is used intraoperatively for a 
molecular assay, it can no longer be used for histology, and vice versa. While the staging categories 
remain defined by size, this should be measured and therefore histology will remain the gold standard 
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unless equivalence between a metastasis measuring a given size and a given amount of mRNA can be 
established in the future. 
It must be noted that a validated quantitative molecular assay is designed to detect nodal involvement 
greater than ITCs but the pN0(mol+) category recommended by both the sixth and seventh editions 
of the TNM classification does not take this into account. We therefore recommend that such cases be 
reported as “node positive (pN1) with ... (named) molecular assay”. Validation studies for some of the 
quantitative molecular assays have already been published (Cserni, 2012). 
When testing SLNs in the intraoperative setting, a compromise should be made between the use of 
practically the whole lymph node for the molecular assay (aiming at the highest accuracy in staging) 
and the use of a part of the SLN for histology and using the residuum for the molecular assay (aiming 
at increasing the accuracy of staging, but also facilitating a more complex histological evaluation of 
the lymph node). Many pathologists would agree that no molecular assay should be carried out 
without a morphological examination of the nodal tissue because the molecular staging assay is simply 
a test for the presence or absence of metastases, whereas histology is a more complex diagnostic 
method capable of identifying other nodal disorders too. Thus, should the first approach of using the 
whole SLN for molecular assay be favoured, it is recommended that at least a frozen section or a 
(touch or scrape) cytology specimen be taken, examined and archived by pathologists for microscopic 
evaluation of the SLN tissue. 
In the non-intraoperative setting, histology is the method of choice for SLN assessment (Khaddage et 
al., 2011; Cserni, 2012; Castellano et al., 2012). 
The findings of the ACOSOG Z0011 trial, suggesting that SLN micrometastases do not adversely 
impact on prognosis and challenging the view that all patients with a positive SLN require complete 
ALN clearance, has led to a reduction in the need for intraoperative SLN evaluation (Giuliano et al., 
2011). 
6 Microinvasive carcinoma 
A frequently encountered problem in the histological examination of in situ carcinoma is identifying 
the smallest focus or foci of invasive carcinoma (Boecker et al., 2006), so-called microinvasive 
carcinoma (MIC). 
Although microinvasion is virtually almost exclusively associated with high nuclear grade comedo 
DCIS, it may also be associated with other types of DCIS and with LCIS. Microinvasion is reported to 
be related to the size/extension of associated in situ carcinoma. The incidence rate of MIC ranges 
from 0.68% to 2.4%. 
The current prevailing view is that MIC appears to have an excellent prognosis with a low risk of 
associated ALN metastasis, but the reported incidence of ALN metastasis ranges from 0% to 20% 
(Bianchi & Vezzosi, 2008). 
By general agreement, SLN biopsy is the standard procedure in the treatment of patients with this 
type of lesion due to the possibility of ALN metastasis in MIC. Because most MICs with a positive SLN 
have low-volume metastases and consequently a low risk of additional metastases in ALNs, the role of 
complete ALN dissection is still debated. 
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From a practical point of view, as mammographically detected microcalcifications considered to be 
associated with in situ breast carcinoma are preoperatively assessed by percutaneous core biopsy 
(NCB) or vacuum-assisted needle core biopsy (VANCB), an accurate histological diagnosis identifying 
microinvasion on core biopsy enables a SLN biopsy and excision of the primary tumour to be 
performed in a single surgical session (Bianchi & Vezzosi, 2008). 
6.1 Definition 
MIC is defined as a tumour in which the dominant lesion is in situ carcinoma (usually extensive high 
nuclear grade DCIS, but rarely other types of DCIS or LCIS) in which there are one or more clearly 
separate foci of infiltration, usually into non-specialised interlobular (Tavassoli & Eusebi, 2009) or 
interductal fibrous or adipose tissue, none measuring > 1 mm (about 2 high-power fields) in 
maximum diameter. When there are multiple foci of MIC, only the size of the largest focus is used to 
classify the microinvasion; the presence of multiple foci of microinvasion should, however, be noted 
and/or quantified. This definition is very restrictive, and tumours fulfilling the criteria are consequently 
rare (Sloane, 1991). 
A focus of invasive carcinoma 1 mm or smaller without associated in situ carcinoma is not MIC but 
should be classified as invasive carcinoma and the maximum diameter measured, in contrast to the 
statement in the seventh edition of the AJCC Cancer Staging Manual/Handbook (Edge et al., 2009). 
The AJCC include small invasive tumours not exceeding 1 mm without in situ carcinoma in the 
microinvasive category. 
The fifth edition of the TNM Classification of Malignant Tumours, published in 1997 (Sobin & 
Wittekind, 1997), was the first one that recognised a specific T substage for MIC, defined as “the 
extension of cancer cells beyond the basement membrane into the adjacent tissues with no focus 
more than 0.1 cm in greatest dimension” and formally reported it as pT1mic. 
In the 2003 edition of WHO Classification of Tumours, Pathology and Genetics of Tumours of the 
Breast and Female Genital Organs (Sobin & Wittekind, 1997; Tavassoli & Devilee, 2003), it is 
reported, in spite of the pT1mic category officially being recognised by the fifth edition of the TNM 
Classification of Malignant Tumours (Sobin & Wittekind, 1997), that there is no generally accepted 
agreement on the definition of MIC, particularly about the maximum diameter compatible with a 
diagnosis of microinvasion. On this basis, MIC is still considered an evolving concept that has not 
reached the status of a WHO-endorsed disease entity. In the seventh edition of the TNM classification, 
this is referred to as pT1mi. 
6.2 Pathological diagnosis 
The tumour focus/foci must usually invade into non-specialised interlobular or interductal stroma. The 
cells deemed to be invasive should be distributed in a non-organoid pattern that does not represent 
tangential sectioning of a duct or lobular structure involved by in situ carcinoma. Tangentially 
sectioned foci of in situ carcinoma that simulate microinvasion are within the specialised intralobular 
and periductal stroma and usually occur as compact groups of tumour cells that have a smooth border 
surrounded by a circumferential layer of myoepithelial cells and stroma or a thickened basement 
membrane (Rosen, 2009). 
At the sites of microinvasive foci, tumour cells are distributed singly or as small groups that have 
irregular shapes reminiscent of conventional invasive carcinoma with no particular orientation (Rosen, 
2009). 
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The absence of basement membrane material around nests of tumour cells defines the process as 
being invasive. IHC for basement membrane components (laminin and type IV collagen) is helpful in 
demonstrating the presence or absence of basement membrane (Schnitt, 1998) even though IHC for 
laminin and type IV collagen is reported to be technically problematic in formalin-fixed, paraffin-
embedded tissue (Schnitt, 1998). Unfortunately, cells of invasive cancer can still synthesise some 
components of basement membrane around invasive nests; therefore, the use of basement 
membrane markers for the detection of stromal invasion is not formally recommended and, when 
performed, should be interpreted with caution (Yaziji et al., 2000). 
The presence of myoepithelial cells around nests of carcinoma cells defines the process as being in 
situ. IHC for myoepithelial cells has been used to help to determine whether a process represents in 
situ carcinoma or stromal invasion (Schnitt, 1998). A variety of markers have been used to detect 
myoepithelial cells. At present, the most commonly used antibodies are smooth-muscle myosin heavy 
chain (SMM-HC) and calponin; these are more specific for myoepithelial cells than actin antibodies 
(such as 1A4 and HHF-35 clones) and react less commonly with myofibroblasts. SMM-HC is not a 
perfect marker of myoepithelial cells because it manifests slightly lower sensitivity than calponin. 
Therefore, the optimal sensitivity and specificity of myoepithelial cell markers can be achieved when 
the SMM-HC marker is used in conjunction with the more sensitive but less specific marker calponin 
(Yaziji et al., 2000). 
In a more recent study (Werling et al., 2003), antibodies to p63, a member of the p53 gene family, 
have been reported to offer excellent sensitivity and increased specificity for myoepithelial cells 
relative to antibodies to calponin and SMM-HC. p63 antibodies have the following diagnostic 
limitations: (1) they occasionally demonstrate an apparently discontinuous myoepithelial layer around 
nests of in situ lesions and (2) they react with a small but significant subset of breast carcinoma 
tumour cells, especially in tumours with a basal phenotype; however, this aberrant reactivity rarely 
causes diagnostic difficulty. p63 can complement or replace SMM-HC and/or calponin in the analysis of 
microinvasion because of its near-perfect sensitivity and near-absolute specificity in distinguishing 
myoepithelial cells from myofibroblasts. Detecting microinvasion can be difficult when there is marked 
periductal fibrosis or inflammation; in these cases, IHC for cytokeratin may be useful to confirm the 
presence of separate foci of neoplastic cells embedded in periductal fibrosis or inflammation. 
The diagnosis of microinvasion still remains problematic, even with the use of ancillary techniques. If 
there is sufficient doubt about the presence of microinvasion (i.e. in cases with marked fibrosis or 
inflammation), the case should be classified as in situ carcinoma with possible microinvasion. 
The diagnosis of MIC depends principally on the tissue sampling. MIC cannot be reliably excluded 
unless all tumour tissue is completely embedded and submitted for histological examination. This 
method is now recommended in clinical guidelines (Olivotto & Levine, 2001) as well as in breast 
screening programmes (National Coordinating Group for Breast Screening Pathology, 2005). However, 
it is well known that even with a large number of paraffin blocks, only a part of the tissue is examined 
microscopically and pathologists can never be absolutely certain that microinvasion is really absent. 
Serial sections supported by IHC usually provide the best evidence of microinvasion. Care should be 
taken to perform IHC early in the evaluation of suspected microinvasion, before the blocks have been 
sectioned excessively (Rosen, 2009), first to confirm microinvasion and second to exclude the 
possibility of larger invasive foci. 
6.3 Differential diagnosis 
Microinvasion is one of the most commonly overdiagnosed events (if not the most commonly 
overdiagnosed event) in the pathology of breast carcinoma. 
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A variety of patterns in DCIS and, more rarely, in LCIS may be misinterpreted as stromal invasion. 
Schnitt has summarised lesions and artefacts commonly mistaken for microinvasion (Schnitt, 1998): 
x DCIS involving lobules (“lobular cancerisation”); 
x chronic inflammatory reaction present in association with, and obscuring, involved ducts and acini; 
x branching of ducts; 
x distortion or entrapment of involved ducts or acini by fibrosis (due to a prior needling procedure); 
x crush artefacts; 
x cautery effects; 
x artefactual displacement of DCIS or LCIS cells into the surrounding stroma or adipose tissue due to 
tissue manipulation or a prior needling procedure. In cases with a history of a prior needling 
procedure (FNA, NCB or VANCB), the diagnosis of MIC should be made with caution because 
artefactual disruption of the epithelial-stromal junction of glandular structures involved by in situ 
carcinoma is not infrequently encountered in the subsequent excision biopsy or therapeutic 
specimen. Granulation tissue, old or recent haemorrhage (iron-laden macrophages, cholesterol 
crystals), tissue tears and a degenerative appearance of the dislodged tumour cells can help in 
distinguishing pseudo-invasion from true invasion (Tavassoli, 1999); 
x DCIS or LCIS involving benign complex sclerosing lesions such as radial scars, sclerosing adenosis, 
sclerosing papilloma, ductal adenoma. 
7 Pathological reporting of post-
chemotherapy specimens 
Pathological assessment of resections after primary or neoadjuvant chemotherapy can be difficult if 
there has been a complete response, if there is insufficient information about the site of the original 
tumour and whether the lesion is uni- or multi-focal. When neoadjuvant chemotherapy is contem-
plated, the clinician who performs the core biopsy may insert a permanent marking device such as a 
metallic marker or tattoo (Dash et al., 1999), which can be identified in the specimen (see below). 
The pathologist should also have access to radiological information such that, where a marker may 
not have been placed, the original quadrant and site of the tumour can be assessed to accurately 
identify any residual tumour. In this respect, MRI findings are generally preferred because these are 
often more detailed than US or mammographic examination (Londero et al., 2004). It is, however, 
recommended that all cases undergoing preoperative chemotherapy should have some form of marker 
inserted to avoid problems with the subsequent localisation of the tumour. This is particularly 
important in cases with complete response having wide local excision because it can be impossible to 
be certain that the site of the tumour nidus has been removed with a conservation procedure. To 
ensure that the tumour site is completely removed, some units tattoo the skin with 4 tattoos to 
delineate the maximum tumour size. It is recommended that some form of marking of the extent of 
the tumour pre-chemotherapy be performed either by this method or an equivalent system. The pre-
chemotherapy core biopsy should always be reviewed in parallel to assess response. Some units give 
an assessment of the number of cores involved. 
Specimens from cases after primary or neoadjuvant chemotherapy should be orientated and sent to 
the laboratory in a similar way to the specimen delivery of other specimens and as described in the 
fourth edition (Wells et al., 2006b). Adequate prompt fixation is as important here as in any other 
breast specimen. 
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7.1 Macroscopic examination 
Macroscopic examination of post-chemotherapy specimens should be performed in a similar manner 
to wide local excision or mastectomy specimens as recommended in the fourth edition (Wells et al., 
2006a) and the margins painted according to the standard local protocol in place. Post-chemotherapy 
tumours may be obvious if there has been little response, and these specimens are really no different 
to handle from any primary resection specimen. In this case, reference to the protocol in the fourth 
edition (Wells et al., 2006a) or a local protocol based on these will suffice. If there has been a good 
response, however, the tumour may be soft, pale and/or ill-defined and identification and sizing of the 
residuum may be impossible. Often, an oedematous area of fibrosis may be all that can be seen or if 
there is associated calcification, radiographic examination of the specimen and/or radiography of the 
subsequent slices may be helpful (Pinder et al., 2007). If a clip or wire coil has been used, this can 
also be identified by specimen radiography and attention directed to this area. The clip or coil should 
be macroscopically visible and should be removed before taking blocks of the area. If a tattoo method 
has been used to identify the site of the tumour then this area should be easily identified 
macroscopically. If there has been no pre-chemotherapy marking and there has been a good 
response, it may be very difficult to identify the tumour. In this case, the original site of the tumour 
should be identified based on the MRI or radiology as above, and this area should be extensively 
sampled. 
Post-chemotherapy specimens should be sliced at regular intervals (not more than 1 cm for 
mastectomy and 0.5 cm for wide local excision specimens) such that reconstruction of the residual 
tumour size can be performed accurately in the third dimension by multiplying the number of slices in 
which tumour is seen by the thickness of the slices (Apple & Suthar, 2006). Any multicentricity should 
be sought by reference to the radiology and by careful macroscopic examination. Large blocks may 
also be useful in this regard. 
Lymph nodes should be blocked in the routine manner recommended in the fourth edition, depending 
on the procedure (see Section 6b.3 in the fourth edition). Often preoperative nodal staging will have 
been attempted, sometimes by preoperative US-guided FNA or biopsy or by a pre-treatment SLN 
procedure. The latter may make the axillary assessment more difficult due to fibrosis. There is a 
suggestion that a decreased yield of nodes may be found (Baslaim et al., 2002). 
7.2 Microscopic examination 
If residual tumour is identified then there is no problem, but if there has been a complete response, 
there may be difficulty in confirming the original tumour site. As noted above, this can be critical to 
ensure that the nidus has been removed in those tumours being treated by wide local excision. 
Microscopy of the original tumour site often shows a scarred area with distortion of the normal 
architecture. Normal breast structures are effaced in this area, and there is often a macrophage and 
chronic inflammatory response, with the macrophages often containing iron pigment, haemosiderin 
and debris. Oedema or necrosis may be present, and the stroma is also frequently altered from 
normal breast stroma (Pinder et al., 2007). It is also important to assess both the cellularity and 
extent of the residual tumour. An indication of the extent can be assessed by documenting the 
number of involved blocks or slices per total number examined from the abnormal area. 
Preoperative chemotherapy can extensively alter tumours such that identifying isolated residual 
tumour cells can be difficult. Immunocytochemical staining with a broad-spectrum cytokeratin such as 
AE1/AE3 can be helpful in this respect. 
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Chemotherapy may effectively sterilise the invasive tumour but may leave in situ changes or lymphatic 
vessel emboli relatively unchanged (Honkoop et al., 1997). It should be also noted that normal lobules 
may show apocrine changes and severe nuclear atypia post-chemotherapy. 
7.3 Reporting of prognostic and predictive factors 
Tumour size, grade, typing and predictive factors (ER, PR and HER2) are extensively altered by 
chemotherapy, and in general the pre-treatment core biopsy is recommended for assessment of these 
prognostic factors. One should, however, realise that IHC for HER2 may yield both false-negative and 
false-positive results on core biopsy and that grading is a little less reliable on core biopsy alone 
(Harris et al., 2003; Rakha & Ellis, 2007). Chemotherapy should not be given without a representative 
core biopsy of the tumour before treatment, and trial or research protocols also recognise this (e.g. 
NEOTANGO). Although grading may retain prognostic value, in general these prognostic factors are 
best assessed on the preoperative core biopsy until large amounts of data become available from 
neoadjuvant trials to contradict this advice. As regards ER, PR and HER2 status, there are conflicting 
results in the literature and because of this and the possibility of complete response, it is 
recommended to assess these parameters on the pre-treatment core biopsy. 
7.4 Microscopic reporting of lymph nodes 
Assessment of lymph nodes should take into account the number of nodes containing residual tumour, 
the number showing fibrosis with other associated features of tumour regression, such as 
haemosiderin-containing macrophages, and alteration of nodal architecture. All nodes identified 
macroscopically should be submitted for histology, and a careful search for occasional residual cells in 
fibrotic nodes should be undertaken, including the use of IHC for broad-spectrum cytokeratins, e.g 
AE1/AE3 or MNF116, where necessary. There is some evidence that patients with evidence of 
response of nodal metastases and regression of metastases have better disease-free survival than 
those with persistent metastases (Newman et al., 2003). Because of this, the number of nodes 
assessed to have evidence of tumour regression should also be recorded. 
7.5 Reporting of tumour response 
There are several histopathological classifications of response to chemotherapy, but there is no 
current consensus favouring any particular system. This hampers the comparison of response 
between different studies. Systems evaluating both the response of the primary tumour and the 
response in nodes are conceptually most likely to be more accurate in predicting the outcome, but 
hard evidence for this is lacking. Most systems acknowledge that complete histopathological response 
is an excellent prognostic sign, and this was the basis for Feldman’s classification in 1986 (Feldman et 
al., 1986). This has been largely superseded by classifications such as those of Chevallier et al. 
(Chevallier et al., 1993) and Sataloff et al. (Sataloff et al., 1995). In some countries, the Miller-Payne 
system is used (Ogston et al., 2001). 
Pinder et al. (Pinder et al., 2007) proposed a classification of response along the lines of that 
proposed by Sataloff et al. (Sataloff et al., 1995) (see Table 3). An approach such as this is logical and 
includes both nodal and tumour response. This would seem to be sensible especially in cases where 
there is total or almost total tumour response in the breast but little effect on nodal disease. Where 
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there is a mixture of categories, e.g. one node with a metastasis showing no response and one node 
showing fibrosis, the worst category should be used (e.g. category 4). 
 
 
Table 3: Recommended classification of response to chemotherapy 
Tumour response 
1.  Complete pathological response, either (i) no residual carcinoma or (ii) no residual invasive 
tumour but DCIS present. 
2.  Partial response to therapy, either (i) minimal residual disease/near total effect (e.g. < 10% 
of tumour remaining) or (ii) evidence of response to therapy but with 10–50% of tumour 
remaining or (iii) > 50% of tumour cellularity remains evident, when compared with the 
previous core biopsy sample, although some features of response to therapy present. Points 
(ii) and (iii) are somewhat subjective, especially when the core biopsy cannot be reviewed. 
3.  No evidence of response to therapy. 
 
Nodal response 
1.  No evidence of metastatic disease and no evidence of changes in the lymph nodes. 
2.  Metastatic tumour not detected but evidence of response/down-staging, e.g. fibrosis. 
3.  Metastatic disease present but also evidence of response, such as nodal fibrosis. 
4.  Metastatic disease present with no evidence of response to therapy. 
 
In summary, it is recommended that pathologists report the following factors in post-chemotherapy 
specimens: 
x Presence or absence of invasive and/or in situ carcinoma 
x Histological type of residual invasive tumour (as in the fourth edition) 
x Residual tumour size and size of fibrotic nidus where possible 
x Margin status 
x Extent of nodal involvement (number of nodes, number of involved nodes and number of nodes 
with evidence of tumour regression) 
x Percentage of fibrosis, necrosis and inflammatory response 
x Presence or absence of multi-focality 
x Presence or absence of chemotherapy effect on both invasive and in situ carcinoma 
x Reporting of response to chemotherapy by an accepted system. The Working Group recommends 
the use of the system in Table 3 
x ypTNM. 
Features that should be reported on the original core biopsy: 
x Type 
x Grade 
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x Presence of vascular invasion 
x Presence of in situ disease 
x ER, PR and HER2 status. 
Ki-67 may be requested and used to inform therapy by some oncologists. IHC may be repeated after 
neoadjuvant treatment, and also in all relapses or metastases, because some changes in IHC 
expression may be found. 
A formula for the estimation of residual cancer burden has recently been published (Symmans et al., 
2007). This uses an algorithm that can be found online on the MD Anderson Cancer Center website 
(www.mdanderson.org/breastcancer_rcb). 
8 Vacuum-assisted needle core biopsy 
(VANCB) 
For certain types of mammographic abnormality, particularly microcalcification with a moderate or 
low-level suspicion of malignancy, a larger volume of tissue is required for accurate diagnosis (Meyer 
et al., 1997). This is possible with VANCB. The biopsy probe incorporates a vacuum channel, which 
applies negative pressure to the biopsy port and thereby sucks the adjacent breast tissue into the port 
for sampling. The biopsy probe is introduced into the breast and positioned using image guidance. 
The vacuum is activated and sucks breast tissue into the biopsy port; a cutting cylinder then passes 
down within the probe and separates the biopsy material from the surrounding tissue. The biopsy 
specimen is then delivered by applying negative pressure and while the main probe remains within the 
breast. Multiple specimens are obtained by rotating the biopsy probe within the breast so that the 
biopsy port is applied to different areas of breast tissue. 
The potential advantages of this system are the ability to obtain a larger volume of tissue for 
histological examination and the rapid evacuation of any haematoma that collects at the site of 
biopsy. This ensures that the specimens obtained are of good quality and are not compromised by the 
presence of haematoma (Liberman et al., 1998a). 
Under local anaesthetic, after a cutaneous incision of 5 mm, VANCB allows the radiologist to obtain 5–
25 cores with needles usually 8–11 gauge. In cases where the whole lesion or a high proportion of the 
lesion has been removed, a small metal marker should be introduced through the biopsy probe and 
deployed at the biopsy site (Liberman et al., 1998b; Kettritz et al., 2004). 
In cases of microcalcification, the cores obtained must undergo specimen radiography to identify 
those that contain representative microcalcifications. Afterwards, they should be put into a separate 
container with a fixative and labelled “with microcalcification”. The other cores should be put into 
another container with fixative and labelled “without microcalcification”. The cores should be 
embedded in separate cassettes (those with microcalcification separate from those without 
microcalcification), the number of cassettes depending on the number of samples. In each cassette 
the cores should be put in parallel and embedded in the same way. If significant calcification is not 
identified in the initial levels, the paraffin blocks can be X-rayed and the microcalcification identified. 
More levels of the block or blocks containing calcifications should be made until the calcified lesion is 
identified. The pathologist should identify the microcalcification biopsied by the radiologist in the 
respective slides and compare the microscopic morphology with the X-ray pattern. The 
multidisciplinary meeting is an ideal forum to correlate this. Specimen radiography using a dedicated 
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microfocus device with magnification at low kilovoltage (14–16 kV) improves the accuracy of specimen 
radiography. 
In the histological report, B categories should be used and it should be clearly stated whether or not 
microcalcification is present (Heywang-Kobrunner et al., 2003; Kettritz et al., 2005). 
As in US-guided core biopsies, cases where significant microcalcification is not identified in histological 
slides after several levels should be discussed by a multidisciplinary team (radiologist, pathologist and 
surgeon) (Heywang-Kobrunner et al., 2003; Kettritz et al., 2005; Tot, 2005; Tot & Gere, 2008). 
Consumables are expensive, and this technique is often reserved for non-palpable lesions, in particular 
for microcalcification. It is usually performed under stereotaxis, on digital dedicated tables, but it can 
also be US-guided (Liberman et al., 1998a). 
Published results on VANCB have demonstrated a lower equivocal sample rate and increased accuracy 
in the detection of small invasive tumours associated with an area of DCIS. The accuracy of 
histological diagnosis is 3% higher with 10 gauge needles than with 14 gauge needles (Salem et al., 
2009). Consideration of the likely underlying histological nature of the lesion from the imaging 
features should therefore be taken into account when deciding on the sampling method to be used 
(Tot, 2005). 
8.1 Multidisciplinary correlation 
A simple imaging classification should be used to indicate the radiologist's degree of suspicion (see 
Section 4.4.2 in the fourth edition). This is useful for multidisciplinary management and audit 
purposes. The indication and the preferred method for non-operative biopsy can be decided according 
to the degree of suspicion and the nature of the lesion.  
To optimise treatment planning, non-operative histological diagnosis should be the goal, replacing 
diagnostic open surgical biopsy. Management decisions for excision biopsy after needle biopsy (CNB or 
VANCB) should made based on radiological-pathological correlation, the presence of a detectable 
residual lesion in imaging after NB and the character of the lesion. 
When dealing with radiological-pathological correlation in the multidisciplinary conference, B3 results 
other than atypical epithelial proliferations of ductal type are not always an indication for an excision 
biopsy. Reliable decisions on regular follow-up without further diagnostic intervention include: (a) 
findings of lobular neoplasia (except the pleomorphic type or those with necrosis, categorised as B5a) 
or (b) flat epithelial atypia, but only if they are associated with a benign histological lesion that 
correlates with the biopsy target (e.g. fibroadenoma, etc.), (c) papillary lesions without atypical 
findings that were completely removed by the diagnostic intervention and (d) radial scars detected as 
an additional microscopic finding to a benign lesion considered to be the biopsy target, provided no 
additional architectural distortion is present. The implementation of vacuum-assisted biopsy devices 
generally used for the assessment of calcification increases the chance that small lesions are removed 
completely. Consequently, the number of B3 lesions for which no further surgical procedure is 
necessary increases and therefore the positive predictive value for malignancy on surgical excision 
improves. 
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Stockholm statement on 
successful implementation of 
population-based 
cancer screening programmes 
 
A multidisciplinary group of scientists and professionals experienced in implementation and quality 
assurance of cancer screening programmes and in development of scientific advice on health policy 
met at a pan-European workshop in Stockholm from 7 to 9 February 2011. The workshop was 
organized by the European Science Advisory Network for Health (EuSANH, www.EuSANH.eu). The list 
of experts attending the workshop is provided in this annex. The experts reviewed the available 
evidence on implementation and quality assurance of cancer screening programmes with a focus on 
organization and reduction of barriers to participation. After comprehensive discussion, the experts 
reached the following, mutually agreed conclusions:1 
Any policy decision in Europe to implement a cancer screening programme should take into account 
European Union (EU) recommendations and guidelines based on the available evidence and the 
experience in Europe in implementing population-based cancer screening programmes. Key references 
in this regard are the Council Recommendation of 2 December 2003 on cancer screening of the 
Council of the European Union [1], the European guidelines for quality assurance in breast, cervical 
and colorectal cancer screening [2–4] and recent reports dealing with the implementation of cancer 
screening programmes in the EU [5–7]. These references recognize that societal values in addition to 
professional, technical and scientific standards are of prime importance in any decision to implement 
cancer screening programmes. Furthermore, there is no doubt that the population-based approach to 
programme implementation as recommended by the Council of the EU and the European guidelines is 
more equitable, more effective and more cost-effective than an opportunistic approach. The latter 
usually leads to overuse of health resources by a portion of the target population with lower cancer 
risk, and underuse by less advantaged groups with higher cancer risk. 
The experience in Europe shows that successful implementation of population-based cancer screening 
programmes requires long-term political commitment, a comprehensive quality management 
programme and sustainable resources. In a fully established programme, the proportion of the 
expenditure devoted to quality assurance should be no less than 10–20%, depending on the scale of 
the programme. In the initial years, this proportion may be substantially higher due to the low volume 
of screening examinations compared with the situation after complete rollout of a nationwide 
programme. This investment is cost-effective and will save lives. 
Once the political decision has been taken to establish a population-based cancer screening pro-
gramme, a competent programme coordinator should receive the mandate to manage the entire 
process of programme implementation, beginning with a planning phase and followed by feasibility 
testing, piloting and, depending on the interim results, subsequent gradual rollout of a programme 
fulfilling the principles and standards recommended in the Council Recommendation [1] and the 
European guidelines [2–4] and relevant national standards and guidelines. The coordinator should be 
provided with sufficient organizational and financial resources to effectively manage the screening 
programme and take further decisions as necessary. These decisions should enable the coordinator 
1 The present statement summarizes key results of the workshop. A more detailed report has been published 
elsewhere [8] and is reproduced with permission of Elsevier in the second part of this annex. 
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and the coordination team to establish the screening programme in the respective health services 
context, taking into account the need for the professional and organizational management to control 
the quality of the entire screening process, including informing and inviting the target population, 
performance of the screening test, diagnosis, therapy and subsequent care. The existing expertise in 
Europe in implementation of population-based cancer screening programmes should be available for 
exchange of information and experience, such as through the European cancer screening networks 
and the European guidelines development activities coordinated by the International Agency for 
Research on Cancer (IARC, www.iarc.fr), and related initiatives such as the European Partnership for 
Action Against Cancer (EPAAC, www.epaac.eu). 
Additional tools, including computerized information systems and accessible registries, are necessary 
for the management of effective and efficient screening services (e.g. for call and re-call systems and 
fail-safe procedures in follow-up of participants with abnormal test results). They are also needed to 
monitor and evaluate the performance and the outcome of the screening programme, e.g. through 
linkage of individual data on cancer occurrence and morbidity, screening history, diagnosis and 
treatment. 
Furthermore, key performance and quality indicators of the screening process must be recorded and 
monitored and the results must be analysed and used for quality management processes. Monitoring 
and evaluation reports must be published regularly to inform the public and decision makers and to 
permit timely modification of programme policy, if necessary. The experience of EuSANH in developing 
advice for health policy making, taking into account not only scientific and professional but also 
societal aspects, could play an important role in this regard in the future. 
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